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ABSTRACT 
MUC1 is overexpressed in many adenocarcinomas, which makes it a potential target for 
immunotherapy. A large number of MUC1-specific, monoclonal antibodies have been 
produced but the stability, solubility and the size of the antibody determines their 
effectiveness in cancer therapy. Smaller antibody fragments are advantageous over full-size 
antibodies, since small antigen binding molecules can efficiently penetrate solid tumors. As a 
first step towards the design of a clinically desirable antibody fragment, the crystallization of 
a human VH fragment has been achieved. The fragment was derived from the human single 
chain antibody scFvM12, which recognizes the cancer-specific hypoglycosylated MUC1. 
The human M12-VH domain has been crystallized through limited in-vitro proteolysis of 
scFvM12 antibody fragment. Crystals of M12-VH domain grew in approximately 12 months 
up to a size of 180x60x60µm in 100mM MES, pH 6.5, 5mM zinc sulphate, 25 % v/v 
polyethylene glycol 550 monomethylether in the presence of low concentration of subtilisin 
Carlsberg. The protease addition results in complete degradation of M12-VL domain, linker 
and purification tags. The crystal belongs to space group C2 with unit cell dimension a = 
71.34Å, b = 37.97Å, c = 37.19Å and α = γ = 90°, β = 109.674°.  The solvent content of the 
crystal was calculated as 35.94%. The structure was solved up to 1.5Å resolution with an 
Rcryst factor of 15.8%, an Rfree of 19.7% and possesses a good stereochemistry. Dihedral 
angle values comparison of first and second complementarity-determining region (CDR) of 
M12-VH domain with an average value, for these two hypervariable regions, shows a 
significant deviation and therefore, it can be speculated that the M12-VH either suggests the 
existence of new canonical subclass or a link among the subclasses of canonical main-chain 
conformation in VH3 family.  
The natural existence of the stabilizing mutations Glu-H6, Arg-H66 and Ser-H52 
confers the intrinsic stability to M12-VH domain under reducing conditions and therefore, the 
framework of this antibody domain can be used for incorporation of other specificities. This 
result would be helpful in structure based single domain antibody designing for 
biotechnological and pharmaceutical applications especially against MUC1 related cancer.  
The isolated VH domain undergoes aggregation due to the exposure of the 
hydrophobic surface involved in VH/VL interface. The camelization of the position H44, H45 
and H47 can increase the hydrophilicity of the VH domain. Native and camelized M12-VH 
domain cloned in cytoplasmic expression vector would be helpful in assessing the 
immunogenic effects of camelizing the human VH domain. 
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I INTRODUCTION 
Mucin-1 (MUC1) is a transmembrane glycoprotein, protecting the epithelia from infection, 
dehydration, physical or chemical injury, which is also involved in cell-cell interactions, 
signaling, and metastasis (Parry et al., 2001). MUC1 is polymorphic in nature due to the 
occurrence of variable number of repeating amino acid segments called tandem repeats 
(Hinoda et al., 1994). The tandem repeats of MUC1 consists of 20 amino acids 
‘APDTRPAPGSTAPPAHGVTSA’. It has been observed that MUC1 expression is 
frequently elevated or altered in cancer and therefore, has a potential as a tumor marker 
(Hilkens et al., 1989). The determination of MUC1 antigen concentration in blood has been 
exploited as a measure of tumor burden and changing levels are used to monitor the response 
to therapeutic interventions (Berruti et al., 1994).  
 Although, the ‘APDTRP’ sequence of MUC1 is immunogenic, the observed cellular 
immunity was found to be very weak (Karanikas et al., 1997). Until now, the vaccine 
production by using either natural or synthetic MUC1 antigen did not proved to be 
successful. Therefore, an antibody-based therapy might be an alternative in the management 
of MUC1 related cancers. 
Despite the availability of a large number of antibodies for passive immunization 
against the MUC1 antigen, potential problems remains in their use as a therapeutic agent. 
These include immunogenicity of murine antibodies and poor tumor–penetration as a result 
of their large size. The former is a particular limitation in therapies where multiple 
administrations are required. These problems can be circumvented by the use of fully human 
antibody fragments like scFv’s and diabodies (McCafferty et al., 1990). Single domain 
antibodies such as VH or VL domains alone are advantageous due to their even smaller size 
and their efficient penetration of avascular cancerous tissues (Mayer et al., 1999). 
Furthermore, they have reduced immunogenicity due to the absence of the Fc region of the 
full size antibody. 
I.1 Antibodies 
 
I.1.1 Overview 
 
All vertebrates have an immune system that provides a protection against invading 
organisms and any toxic substance produced by them. Because these immune reactions can 
be detrimental, it is essential that they must be triggered in response to the foreign organisms 
or molecules that are not host-specific. This ability to distinguish foreign molecules from 
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self-molecules is a fundamental feature of the immune system. Any substance that is capable 
of eliciting an immune response is called an immunogen or antigen. The immune system can 
even distinguish between very similar immunogens such as the two optical isomers of the 
same molecule. The cell mediated and the humoral antibody mediated immune responses are 
the two main arms of the immune response. The cellular immune response involves the 
development and proliferation of specialized cells directed against the foreign antigens. The 
humoral antibody response involves the production of antibodies; these polypeptides are also 
called immunoglobulins (Ig). Antibodies circulate in the blood stream, permeate other body 
fluids and bind specifically to foreign antigens. The portion of the antigen recognized by 
specific antibodies is called the epitope. Antibodies are synthesized exclusively by plasma 
cells and produced in different forms with a variety of antigen binding sites and different 
amino acid sequence. Antibody or immunoglobulin (Ig) molecules are responsible for two 
major biological functions: (1) a binding function for the recognition of foreign antigens 
such as toxins, viruses, exposed molecules on the surface of pathogenic organisms and 
differentiated cells; and (2) an effector function which results in the elimination or 
inactivation of the foreign antigen or the cell marked by the presence of that antigen (Roitt et 
al., 1993). This ability to differentiate between antigens has made antibodies an 
indispensable tool in diagnostic medicine and as therapeutic agents of high potential. 
Figure I-1 Schematic representation of an IgG molecule. Green: Light chains, Gray: 
Heavy chains. 
 
The IgG antibody molecule (150kDa) consists of four polypeptide chains (Figure I-1). Two 
identical light chains with a mass of around 25kDa and two identical heavy chains with a 
mass of around 50kDa. In higher vertebrates there are five classes of antibodies namely IgA, 
IgD, IgE, IgG, and IgM, each with its own class of heavy chain - α, δ, ε, γ, and µ 
respectively. In addition, there are a number of subclasses of IgG and IgA immunoglobulins; 
for example, there are four human IgG subclasses (IgG1, IgG2, IgG3, and IgG4) having γ1, γ 
2, γ 3, and γ4 heavy chains respectively. The various heavy chains impart a distinctive 
conformation to the hinge and tail regions of antibodies and provide each class (and 
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subclass) the characteristic properties. In addition to the five classes of heavy chains, higher 
vertebrates have two types of light chains, κ and λ, either of which may be associated with 
any of the heavy chains. The IgG molecule has one variable (V) and constant (C) domain for 
each light chain and one variable (V) and at least three constant (C) domains for each heavy 
chain. Disulfide bridges connect the light chain to the heavy chain and one heavy chain to 
the other heavy chain. Areas of variability and conserved structure are divided into segments 
of 110 amino acid residues. The heavy-chain V unit shows similarity to the V part of the 
light chain, while the three heavy chain C region units show strong homology to each other 
and to the C region of the light chain. Each domain has a characteristic tertiary structure 
consisting of two β-pleated sheet structures. The sandwich-like structural domain possesses a 
hydrophobic interior. Sheets are covalently linked by disulfide-bridge near the center of the 
domain. The N-terminal variable parts of both heavy (VH) and light chain (VL) together 
constitute the antigen-binding region. Comparison of amino acid sequences of the VH and the 
VL domains revealed the occurrence of three regions of high variability in each chain. These 
hyper-variable regions are often referred as complementarity determining regions (CDR’s) 
(Wu et al., 1970). Their amino acid residues define the size and shape of the antigen binding 
regions. An individual antibody molecule always consists of identical light chains and 
identical heavy chains; therefore, its two antigen-binding sites are always identical. 
A classical method used in the size reduction of antibody molecules is the digestion of 
immunoglobulins with proteases (Figure I-2). Papain digestion of the antibody produces two 
Fab fragments (Fragment antigen binding) and one Fc fragment  (Fragment crystallizable) 
(Figure down). Fab fragments (50 kDa) consist of the entire light chain and a part of the 
heavy chain (VH and CH1 portion). Fab fragments contain one antigen-binding site and are  
 
 
 
 
 
 
 
Figure I-2 Fragmentation of IgG with papain and pepsin enzyme. L: Light chain, H: Heavy 
chain, Green: variable region, Fab: Fragment antigen binding, Fc: Fragment crystallizable. 
 
therefore monovalent. The Fc fragment (50 kDa) does not bind to the antigen. Pepsin 
digestion of the antibody produces one large bivalent fragment (100 kDa) called F (ab’)2 and 
degrades the remainder of the heavy chains into small pieces. When the large fragment i.e. F 
NH2 COOH
PepsinPapain
Low Molecular
weight Fragments
F(ab’)2
Fab
Fab
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(ab’)2 is treated with reducing agents, the disulfide bridges are disrupted, giving two Fab-like 
fragments, Fab’. Each of the Fab’ fragments is made up of the entire light chain and a 
slightly longer part of the heavy chain (Roitt et al., 1993). 
Intact antibodies also demonstrate segmental flexibility, which means that the two Fab 
portions can move relative to one another on antigen binding. The angle varies from 60 to 
180 degrees. This flexible region, where the arms meet the stem of the Y is called the hinge 
region and is located between the CH1 and the CH2 domains. Only IgG, IgA, and IgD 
antibody molecules have hinge regions. The heavy chains of IgM, IgA, and IgD antibody 
molecules possess additional amino acid residues on the carboxyl-terminus of the last CH 
domain. These areas, called tailpieces, permit IgM and IgA to interact with like antibodies 
and form multimeric molecules. Multimeric IgA also have a polypeptide called the joining 
(J) chain, which is disulfide-linked to the tailpieces and stabilizes the multimeric structure. 
Antibodies also contain carbohydrates; the percentage and location of the carbohydrate 
molecules differ according to the class of antibody. 
I.1.2 Antibody engineering 
 
Most natural antigens have multiple epitopes, the exposure of the animal to the antigen 
results in the generation of B-cells producing antibodies against different epitopes of the 
antigen. A mixture of antibodies that recognize different epitopes on the same antigen are 
said to be polyclonal. For many types of studies involving antibodies, monoclonal antibodies 
are preferable to polyclonal antibodies. However, the biochemical purification of 
monoclonal antibodies from the serum is not feasible, in part because the concentration of 
any given antibody is quite low. For this reason, a methodology was developed to 
immortalize the plasma cells in order to obtain usable quantities of monoclonal antibody. 
Because primary cultures of normal B-lymphocytes do not grow indefinitely, such cultures 
have limited use for the large-scale production of the monoclonal antibodies. This limitation 
can be avoided by fusing normal B-lymphocytes with immortal transformed lymphocytes 
called myeloma cells. 
In 1975, Köhler and Milstein developed the ‘hybridoma technology’, which allows 
the isolation and production of monoclonal antibodies having specificity for a single antigen 
epitope such as a protein, a carbohydrate, and nucleic acids. Besides the importance as 
research tools, the availability of murine monoclonal antibodies opened the way to the 
development of diagnostics and human therapeutics. Monoclonal antibodies constitute the 
most important tools for assay methods such as radiolabelled immunosorbant assay (RIA), 
flow cytometry, enzyme-linked immounosorbant assay (ELISA) and immunocytopathology.  
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However, the monoclonal antibodies possess a number of technical limitations and 
drawbacks such as: 
(1) expensive production method based on a mammalian expression system;  
(2) inability to optimize the antibody using genetic engineering techniques;  
(3) the elicitation of immunogenic reaction against mouse antibodies called human anti-
mouse antibody (HAMA) response after repetitive human administration (Kuus-
Reichel et al., 1994). 
Furthermore, the hybridoma technology relies on animal immunization, which are strictly 
controlled under new regulations. Although the hybridoma technology immortalizes the 
antibody producing B-cell, the advent of recombinant DNA technology provides a mean to 
immortalize the antibody gene (Plückthun, A., 1994). The technological advances in the 
recombinant DNA technology on one hand can help to solve the immunogenicity problem 
while on the other hand it allows us to tailor the antibodies to a desired size and specificity. 
Furthermore, it allows us to produce them in different expression systems.   
The technique of monoclonal antibody production and recombinant DNA technology 
were combined to try to resolve the problems that had arisen in the application of murine 
antibodies for human therapy. Thus the field of antibody engineering was initiated. To 
circumvent the problems associated with murine monoclonal antibodies, several strategies to 
bring the antibody format closer to the human one have been started. The humanization 
process and the requirement of the smaller antibody units in diagnostics and therapeutics 
lead to the development of functional forms of antibodies in different size format. The 
different forms (Figure I-3) are as follows: 
A. Chimeric antibodies (page 6) are made by joining the variable domains of a 
murine monoclonal antibody to the constant domains of a human antibody thus 
reducing the immunogenicity and ensuring the efficient recruitment of human 
effector function (Boulianne et al., 1984). Chimeric antibodies have a longer 
plasma half-life than the murine monoclonal antibodies (Billetta et al., 1992). 
However, the chimeric antibodies can elicit the human anti-chimeric antibody 
immune response (HACA) as a result of the murine variable domains. 
B. The immunogenicity of chimeric antibodies can be reduced by grafting 
complementarity-determining regions (CDR) of mouse antibodies on human 
framework region. The resulting antibodies are called as ‘humanized or reshaped 
antibodies’ (Riechmann et al., 1988). The resulting humanized antibodies are 
approximately 90% human. In this approach, the six CDR regions of the murine 
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light and heavy chain are grafted on to the human immunoglobulin framework 
region (Jones et al., 1986). This method takes the advantage of conserving the 
structure of the antibody variable domains, while using the human framework 
residues as a scaffold to support the CDR loops which will determine antigen 
specificity. Although this approach can be successful for some antibodies, it has 
been shown that the reconstitution of key contacts between loop and framework 
residues is necessary for other antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I-3 Different forms of antibodies. Monoclonal antibodies from hybridomas are of 
murine origin. Recombinant chimeric antibodies comprise murine variable (V) regions 
attached to human constant (C) regions, whereas in humanized (or reshaped) antibodies, 
only the antigen-binding complementarity-determining region (CDR) loops derive from rodent 
antibodies. Fully human antibodies can be constructed from human V regions (isolated by 
phage technology) and human C regions. Fv and scFv fragments, and diabodies comprise 
only V regions and can be cloned from hybridomas or isolated from phage libraries. 
 
C. Veneered antibodies are the non-human antibody fragments in which the exposed 
residues in the framework regions are replaced to match the human residues at the 
respective positions (Padlan et al., 1991). 
D. The antibodies derived from the humans directly are called as fully human 
antibodies. 
E. Although natural effector functions are powerful, antibodies can also be engineered 
so that the antigen-binding sites have dual specificity for a target cell and another 
molecule like a toxin. Such antibodies are described as ‘bispecific antibodies’. In 
these molecules, each of the two halves is derived from two parental antibodies of 
different specificities and the molecule therefore carries two different antigen-
binding sites. 
VH
VL
CL
CH1
CH2
CH3
Monoclonal 
antibody
Chimeric antibody Humanized or 
reshaped antibody
Human
antibody
Bispecific antibody
Fab scFv Bispecific
diabody
Fv
Antibody fragments
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F. Intact antibodies are large molecules (150 kDa) with limitations for many 
therapeutic applications; therefore, smaller functional antibody fragments are 
prepared. The smaller antibody fragments can be generated either classically 
through protease treatment (I.1.1) or though recombinant DNA technology. The 
repertoire of smaller antibody fragments is constituted by Fab’s (50kDa), variable 
fragments (Fv, 25kDa, the non-covalently combined variable light chain and heavy 
chain), single chain variable fragment (scFv, 27kDa, combination of variable light 
chain and heavy chain joined covalently through a linker), diabodies (50kDa, 
noncovalent combination of two scFv’s having shorter linker), minibodies (80kDa, 
scFv joined with CH3 domain) and variable heavy (VH) or variable light (VL) chain 
domains alone.  
Making human monoclonal antibodies poses difficulties using the classic hybridoma 
technology. The use of mouse myeloma as a fusion partner for human cells leads to the 
preferential loss of human chromosomes, and intolerable instability of the hybrids. As an 
alternative to fusion, immortalization of human cells by Epstein-Barr virus does lead to lines 
which are low producers of antibody and unstable (Winter and Milstein, 1991). Further, due 
to ethical reasons, human can rarely be hyper-immunized to order, especially with noxious 
chemicals, pathogenic viruses or cancer cells to obtain antigen specific human antibodies. 
Over the past decade, molecular display technologies enabled us to easily create fully human 
antibodies. In molecular display techniques, the genes encoding the desired protein are 
selected for the desired binding function. In 1990, McCarfferty et al., showed that antibody 
fragments could be displayed on the surface of filamentous phage particles by fusion of the 
antibody variable genes to one of the phage coat proteins like p8 or p3. Multiple rounds of 
affinity selection could subsequently enrich antigen-specific phage antibodies, because the 
phage particle carries the gene encoding the displayed antibody. In the early 1990’s Winter 
et al., showed for the first time that the phage display technology could be used to select 
antigen-specific antibodies derived from spleen B-cells of immunized mice. Fully human 
antibodies can also be obtained through phage display technologies (Clackson et al., 1991), 
thereby, bypassing the requirement to immortalize antigen-specific B-cells. Similarly, 
libraries were made from human B-cells taken from individuals immunized with antigen, 
exposed to infectious agents, suffering from a autoimmune diseases or cancer. Cloning Ig 
genes from the heterogeneous cell populations has the advantage that all the immune cells 
can be processed simultaneously for the amplification of the VH and VL genes but the 
associated disadvantage is that the original VH and VL pairing is lost upon pairing for high 
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affinity. A combinatorial library with only 1000 each of different VH and VL gene elements 
would necessitate the screening of 106 to 5x106 clones to recover most of the original 
pairing. Thus the chances of recovering original pairs of V genes from a large random 
combinatorial library from an immunized animal is very low and even more remote for the 
highest affinity antibodies of hyperimmune animals. Those pairs of VH and VL domains that 
are found to be capable of binding antigen are likely to do so at lower affinity or with lower 
specificity than those selected by antigen (Hudson et al., 1987). Another drawback of this 
strategy is that the immune libraries have to be built for each antigen and the library can be 
biased against self-antibodies and above all, the antigen must be immunogenic in nature. The 
alternative to this approach is the enrichment of phage antibodies from non-immunized 
healthy individuals called as ‘naïve library’ (Marks, et al., 1991) or by making libraries of 
synthetic antibodies with variable genes consisting of germline segments artificially 
diversified by oligonucleotide based cloning (Barbas, et al., 1992). One of the advantages of 
selecting antibodies from phage libraries is that antigens can be used that are difficult for 
eliciting an immune response e.g. instable antigens or autoantigens or toxins. 
Fully human antibodies can also be obtained by immunizing ‘Xeno-mice’ that carry 
the selected human immunoglobulin germline gene segments (Duchosal et al., 1992), 
resulting directly in the formation of human antibody producing B-cells. 
I.1.3 Therapeutic potential of antibodies 
 
Recombinant antibody technology made it relatively easy to select, to humanize and to 
produce antibodies in bulk and allows the design of antibody-based reagents of any 
specificity for a wide variety of applications. The therapeutic potential of antibodies can be 
traced back more than a century. Currently, recombinant antibodies represent over 30% of 
the biopharmaceuticals in clinical trials. Till now, the US Food and Drug Administration 
(FDA) has approved 15 antibodies to treat cancer, transplant rejection and to combat 
autoimmune diseases (Table I-1). 
At least 200 other monoclonal antibodies are worldwide in clinical trials including 
many fully human antibodies (Table I-2). As the development of new therapeutic agents into 
commercial products takes about 10 years, the FDA approved antibodies in end stage of 
clinical trails are mainly chimeric or humanized antibodies, since they were developed with 
early antibody engineering technologies. 
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Table I-1 FDA approved therapeutic antibodies (Hudson et al., 2003). *Tradenames are 
registered trademarks. 
 
  Trade name* Target   Product type Indication          Month of approval  
  Orthoclone OKT3  CD3  Mouse Transplant rejection June 1986 
  ReoPro GpIIb/gpIIa Chimeric Fab Cardiovascular disease  December 1994 
  Rituxan CD20  Chimeric Non-Hodgkin lymphoma November 1997 
  Zenapax CD25  Humanized Transplant rejection  December 1997 
  Remicade TNF-α  Chimeric Crohn’s disease  August 1998 
  Simulect CD25  Chimeric Transplant rejection  May 1998 
  Synagis RSV  Humanized Respiratory syncytial virus June 1998 
  Herceptin Her-2  Humanized Metastatic breast cancer September 1998 
  Mylotarg CD33  Humanized Acute myeloid leukemia  May 2000 
  Nabi-HB HBsAg  Human Ig Acute hepatitis B   October 2000 
virus infection  
  Campath CD52  Humanized Chronic lymphocytic leukemia May 2001 
  DigiFab  Digoxin  OvineFab Digoxin toxicity   August 2001 
  Zevalin CD20   Mouse  Non-Hodgkin lymphoma February 2002 
  Humira TNF  Human  Rheumatoid Arthritis  December 2002 
  Bexxar CD20  Mouse  Non-Hodgkin's lymphoma June, 2003 
 
Table I-2 Therapeutic antibodies undergoing various phases of clinical trials (Brekke et 
al., 2003). *Trade names are registered trademarks. 
 
   Tradename*  Molecule type Phase  Indication(s) 
   ABX-EGF   Human (anti-EGF-R) Phase II Non-small-cell lung cancer 
   ABX-IL8  Human (anti-IL-8) Phase II Chronic obstructive bronchitis 
   Eculizumab  Humanized (anti-C5) Phase IIb Rheumatoid arthritis 
   D2E7  Human (anti-TGF-α) PhaseIII Rheumatoid arthritis 
   CAT-152  Human (anti-TGF-β2) Phase II/III Scarring following Glaucoma 
   Antegren  Humanized  Phase III Crohn’s disease,  
(anti- α-4 integrin)    Multiple sclerosis 
   Avastin  Humanized  Phase III Metastatic breast cancer 
(anti-VEGF)  
   IDEC-151  Primatized (anti-CD4) Phase II Rheumatoid arthritis 
   MEDI-507  Humanized   Phase II Suppresses NK and T-cell  
(anti-CD2 Receptor)    function 
   XTL001  Human (anti-HBV)  Phase I/II  Hepatitis B virus neutralization 
   Hu1D10  Humanized   Phase II  Non-Hodgkin’s Lymphoma 
                                  (anti-MHC classII)  
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I.1.4 Recombinant small antibody fragments 
 
The smallest portion of the entire antibody that retains affinity towards antigen is constituted 
by the variable light (VL) and heavy chain (VH) segment (Bedzyk et al., 1990). These Fv 
molecules are often unstable due to the non-covalent interactions between the VH and VL 
fragments. Only occasionally stable Fv’s are obtained (Givol, 1991). Fv’s can be stabilized 
by chemical cross-linking of VH and VL using glutaraldehyde or by introducing disulfide 
bridges between VH and VL domains (Glockshuber et al., 1990). Another approach is to link 
the VH and VL domain with a flexible peptide linker, allowing the orientation of the CDR’s 
in a similar fashion as in natural antibodies and stabilizing the recombinant version of the Fv 
fragment. Such covalently linked Fv fragment is referred to as a single chain Fv (scFv) (Bird 
et al., 1988). Although the antibody fragments such as Fv and scFv’s can be vitally used but 
they may require further engineering to eliminate undesirable properties such as dissociation, 
and aggregation. An attractive alternative to overcome these problems can be isolated single 
antibody domains such as VH or VL.  
Other observations indicated that some heavy chains could bind antigens in the 
absence of the light chain (Winter et al., 1991 and Haber et al., 1966). Also VH domains with 
high affinities were detected in expression libraries of mouse VH genes (Ward et al., 1989). 
In contrast to the VL domains, such VH domains often retain the antigen-specificity of the 
parental antibody, since their CDR-H3 is often the major contributor to antigen binding. 
However, removing the VL domain from an Fv exposes the large interdomain hydrophobic 
surface of the VH to the solvent (the former interaction site with the VL), so that the isolated 
VH molecules becomes generally ‘sticky’ and are, therefore, difficult to produce in a soluble 
form.  
In contrast to this, a considerable fraction (up to 75%) of functional antibodies in 
Camelidae (camels, dromedaries and llamas) is constituted by variable heavy chains (15kDa) 
only. These antibody fragments lack the light chain (VL) and are referred to as heavy-chain 
antibodies (HCAb’s) (Hamers-Casterman et al., 1993) or variable heavy chain antibody, 
VHH (Renisio et al., 2002). VHH’s have also been documented in the spotted ratfish (Cos5-
Abs) and nurse shark (NAR) (Nguyen et al., 2002). The characteristic structural features of 
VHH can be mimicked to reduce the hydrophobic surface of VH domain at the VL domain. 
It has been observed that the VH domain affinity drops by one to three orders of 
magnitude compared to the scFv (Borrebaeck et al., 1992). The affinity of VH domains can 
be improved after site-specific secondary randomizations in CDR-H1 and CDR-H2, phage 
display and antigen selection (Davies et al., 1996). 
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I.1.5 Importance of antibody fragments 
 
Reducing the size of the antibody molecule to the size of the Fv, or even smaller, would be 
beneficial in immunoaffinity and biosensor applications (Welling et al., 1990-91). Smaller 
molecules are also shown to have a better tissue penetration and faster blood clearance in in-
vivo applications (George, 1994) and therefore better biodistribution. Such antibody 
fragments do not contain the Fc region of the antibody molecule, which is responsible for the 
effector functions of the immunoglobulin (Ig) molecule such as complement fixation, 
allergic responses and killer T-cell activation. They can be used for a variety of in-vivo 
applications such as enzyme inhibitors (Riechmann, L., 1999), as molecular building blocks 
to construct more complex molecules (bispecific or bivalent constructs), for in-vivo tumor 
targeting (Carter et al., 1997 and Cortez-Retamozo et al., 2002) and for immunoassays. 
I.2 The human VH family 
 
Antibodies are encoded by a limited number of germline gene segments that undergo 
somatic diversification through rearrangement and mutation. In humans, the immunoglobulin 
heavy-chain variable locus mapped to band q32.33 of chromosome 14 and constituted by 
individual variable (V), diversity (D), joining (J) and constant (CH) region segments linked in 
separate regions. The VH genes in the human haploid genome are classified according to 
sequence homologies of 80% or above into seven families. They differ in size and contain 
pseudogenes, form an interspersed cluster, exhibit homologies with mouse genes and have 
phylogenetically developed from a single primordial gene (Lukowsky et al., 1990). The 
different subgroups are designated as VH1 to VH7. The VH3 subgroup is the dominant 
subgroup followed by VH4, VH1, and VH5. The remaining subgroups represented only small 
contributions. The subgroup classification is based on DNA analysis and mRNA analysis  
 
 
 
 
 
Figure I-4 Schematic representation of IgG heavy chain unarranged gene and mRNA. L: 
Leader segment, V: Variable segment, D: Diversity segment, J: Joining segment, C: Constant 
segment, CH1, CH2 and CH3 are different constant segments, H: Hinge region. 
 
from B-cells (Cook et al., 1994). The number of VH gene segments per individual has most 
recently been estimated as about 76 (24 VH1 segments, 5 VH2 segments, 28 VH3 segments, 
14 VH4 segments, 3 VH5 segments, 1 VH6 segments, 1 VH7 segments) although these figures 
are likely to be underestimated (Walter et al., 1990). Some human VH gene segments are 
L V D J C
L V D J CH1 H CH2CH3
Unarranged DNA
mRNAAAAAH1 H2 H3
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remarkably stable such as human VH gene segments from the VH1, VH3 and VH4 gene 
families (Sanz et al., 1989). 
The human VH3 family is most homologous to mouse VH3 segments, suggesting that 
members of the VH3 family may be conserved by some functional constraint. The 5'-flanking 
region of each family has a family-specific structure (Haino et al., 1994). Amino acid 
sequence data indicate that human VH3 genes correspond to only a small subset of mouse 
VH3 genes. Human VH3 genes contain a shorter intron and are two codons shorter than most 
mouse VH3 genes. Both contain approximately 50% silent substitution (Rechavi et al., 1982). 
During somatic development, coding segments flanked by characteristic short recombination 
signal sequences, separated by intervening sequence regions that may exceed 2000kb, are 
recombined. Combinatorial joining of different segments as well as imprecision in this 
process contribute to the diversity of the primary antibody response; subsequent mutation 
further alters functionally rearranged genes (Hinds et al., 1986). Each variable heavy chain 
gene segment (V) encodes a 5’ hydrophobic leader peptide and between 95 and 101 amino 
acid residues of the mature domain flanked at 3’ end by two recombination signals 
consisting of a highly conserved heptamer (5’-CACAGTG-3’), a 23-base-pair spacer and a 
less-conserved nonamer (Figure I-4). 
I.2.1 Variable heavy chain domain 
 
I.2.1.1 General structure 
 
Variable domains are formed by two beta-sheets, packed face to face, and the inter-strand 
turns. Comparison of the different known structures shows that they have a core of 76 
residues, which has the same main-chain conformation in all structures. This common core 
contains almost all of the beta-sheet structure and three inter-strand turns. The regions that 
differ in conformation are the three hyper-variable regions, three other inter-strand turns and 
a few adjacent residues. Around the deep structure there are buried hydrophobic residues 
that, in different variable domains, can differ greatly in volume. These differences in volume 
are accommodated by conformational changes in turn regions that are outside the common 
core. On the surface they have strongly conserved hydrophilic or neutral residues (Chothia et 
al., 1998). 
I.2.1.2 Diversity of the VH domain 
 
The structural variability of the antibodies is the result of combinatorial genetic diversity. 
For the VH domain, the variability generated by the assembly of the variable (V), Diversity 
(D) and Joining (J) gene segments. Two of the CDR’s (1&2) are encoded by the variable (V) 
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gene segment while CDR-H3 is formed by the 3’end of the V gene segment, the D gene 
segment and the 5’end of the J gene segment (refer to I.1.5). With nucleotide addition (N-
region diversity at the V-D and D-J joins), the use of different reading frames in the D 
segment, and the combination of different rearranged heavy and light chains, results in huge 
diversity of the primary libraries (Tonegawa et al., 1983). During an immune response, the 
antibody variable regions are further diversified by somatic hypermutation, leading to higher 
affinity towards the antigen (Berek et al., 1988). The VH fragment has evolved by unequal 
crossing-over, conversion, duplication and deletion (Wysocki et al., 1989). 
I.2.1.3 Conformations of the hypervariable loops 
 
In antibodies, the six antigen-binding loops CDR-H1 to -H3 and CDR-L1 to -L3 can be 
defined by structural variability (Al-Lazikani et al., 1997) or sequence hypervariability (Wu 
et al., 1970). Sequence hyervariability can also be used to identify CDR’s for antigen 
binding by the correlation of loop residues that have a higher relative variability than others 
with residues that are known from crystal structures of antibody complexes to be important 
in antigen binding (Padlan et al., 1995). In human and mouse, the first two antigen-binding 
loops of a VH domain, CDR1 and CDR2, can be assigned to a limited number of possible 
conformations referred to as canonical structures (Chothia et al., 1987). The conformation of 
these loops depends both on their length and on the presence of specific residues at key 
positions. H3 plays the most important role in antigen binding (Padlan et al., 1994). High 
degree of sequence variations within the hypervariable loops or complementarity-
determining regions (CDR) is responsible for the specificity and affinity of the antibodies. 
Different CDR structures form according to the antigen structure. These CDR structures can 
create flat, extended binding surfaces for protein antigens, a specific groove for a peptide, 
DNA or carbohydrate, or deep-binding cavities for small molecules called haptens. It has 
been pointed out that the distribution of amino acids in variable domains seems to be biased, 
and certain residues (Tyr, Trp and Asn) seem to have a propensity for being in the CDR’s 
and for participating in antigen recognition. It seems that the aromatic side-chains (Tyr, Trp) 
are more exposed to the solvent than in usual water-soluble proteins, and they are frequently 
found to be involved in the interaction with the antigen. This is explained by their large size 
(hydrophobic interaction), large polarizability (van der Waals interaction), ability to form 
hydrogen bonds, and rigidity (reduced loss of conformational entropy upon complexation). 
Thus, the concentration of aromatic rings would give certain ‘stickiness’ to the CDR’s and 
give diverse specificity to antibodies. Specificity for a particular antigen therefore arises 
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from the complementarity of the shapes of the interacting surfaces created by the proper 
positioning of the aromatic rings and the correct location of polar and/or charged groups. 
Analysis of human and mouse immunoglobulins has shown that five of the six 
hypervariable loops that form the antigen binding site have a small repertoire of main chain 
conformations called canonical structures. The residue patterns in the VH segments imply 
that the first hyper-variable region (CDR-H1, H26-H32) adopts one of three described 
canonical structures and that the second hyper-variable regions (CDR-H2, H52-H56) adopt 
one of the five described canonical structures (Al-Lazikani et al., 1997). The specificity of 
the loops is produced by (1) sequence differences in their surface residues, particularly at 
sites near the combining site, and (2) sequence differences in the hypervariable and 
framework regions that modulate the relative positions of the loops (Chothia et al., 1992). 
The prediction of the third hypervariable loop (CDR-H3) structure of VH has been a 
bottleneck for a long time, although much progress was made in recent years (Al-Lazikani et 
al., 1997; Morea et al., 1998 and Shirai et al., 1996). The third hypervariable region of the 
heavy chain is far more variable in length, sequence and structure than the others, and 
therefore, it is difficult to classify them into canonical-structures.  
 
 
                
      
 
 
 
 
                A                        B 
Figure I-5 Typical bulged (A) and non-bulged (B) CDR-H3 torso region (Morea et al., 
1998). The choice of bulged versus non-bulged torso conformation is dictated primarily by the 
sequence, through the formation of a salt bridge between the side-chains of an Arg or Lys at 
position 94 and an Asp at position 101. Thus the torso region appears to have a limited 
repertoire of conformations, as in the canonical structure model of other antigen-binding 
loops. The heads or apices of the loops have a very wide variety of conformations. In shorter 
CDR-H3 regions, and in those containing the non-bulged torso conformation, the heads follow 
the rules relating sequence to structure in short hairpins (Chothia et al., 1998). 
 
The CDR-H3 region comprising the residues between Cys-H92 and Gly-H104 can be divided 
into a torso region (comprising residues proximal to the framework, four residues from the N 
terminus and six residues from the C terminus), and a head/apex region. Two distinct types of 
torso regions (Figure I-5 A&B) have been observed for the CDR-H3 loop having more than 
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ten residues: (1) the conformation of the torso has a beta-bulge at residue 101, and (2) the 
torso does not contain a bulge, but continues the regular hydrogen-bonding pattern of the β-
sheet hairpin. 
I.2.1.4 VH domain stability 
 
The folding of immunoglobulin domains almost invariably requires the formation of a 
conserved structural disulfide bond between Cys22 and Cys92 in the VH domain; their 
soluble expression in the reducing cellular cytoplasm has failed in general (Glockshuber et 
al., 1992). Few exceptions have been reported, notably scFv's against HIV proteins 
(Maciejewski et al., 1995 and Wu et al., 1996), but low stability, low expression rates, and 
unpredictable behavior currently limit these perspectives (Gargano & Cattaneo, 1997). 
Elegant screening methods and random mutagenesis have been employed in few cases, but it 
is not clear how these approaches can be generalized, because they have either depended on 
a specific immunoglobulin framework, naturally lacking a disulfide bridge, or a 
metabolically selectable ligand binding activity. The following mutations Lys03Glu, 
Pro07Ser, Ala16Gly, Arg43Glu, Ile58Thr, Lys66Arg, Pro74Ser and X52Ser were reported to 
have stabilizing effect on the cytoplasmic soluble expression of the VH fragment (Wirtz et 
al., 1999, Wörne, 1998 and Proba et al., 1998). X refers to any amino acid. 
I.2.2 Comparison between human VH and camelids 
VHH domains 
 
In Camelidae, the major portion (up to 75%) of the functional antibodies is constituted by 
the variable “heavy chain antibodies” (VHH). The heavy chain antibodies are homodimers, 
with each chain consisting of an unpaired variable domain (VHH) immediately followed by a 
hinge region, CH2 and CH3 domain. The cDNA sequence analysis illustrated that the 
equivalent of the conventional IgG’s CH1 domain is clearly missing. Nevertheless, VHH 
domains possess some remarkable properties, which clearly distinguish them from the 
variable domain (VH) of conventional antibodies. 
I.2.2.1 Sequence differences 
 
The comparison between the human VH3 gene family and camelid VHH gene family shows a 
high degree of sequence homology. The sequences were obtained from cDNA libraries and 
RT-PCR clones. It is unlikely that dromedaries possess other VHH gene families, as a 
representative database of germline VHH sequences revealed the presence of some 40 
different VHH genes that all evolved within the VH subgroup 3 (Nguyen et al., 2000). 
However, it was noted that the VHH’s carry a number of remarkable amino acid substitutions 
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in the framework-2 region (FR2). In conventional antibodies, the VH residues in FR2 region 
normally interact with the VL domain and are well conserved throughout the evolution 
(Kabat et al., 1991). The amino acid substitutions Val37Phe or Val37Tyr, Gly44Gln, 
Leu45Arg and Trp47Gly (Figure I-6) in VHH render the VH/VL interface more hydrophilic 
and an overall enhanced solubility in comparison to VH fragment is observed (Muyldermans 
et al., 1994 and Vu et al., 1997). Another noteworthy substitution is the Leu11Ser. This 
amino acid normally interacts with the CH1 domain, a domain missing in the camel heavy 
chain immuno-globulins (VHH). 
I.2.2.2 Structural differences 
 
The crystallographic structure of four VHH (Desmyter et al., 1996; Decanniere et al., 1999 
and Spinelli et al., 1996) and the NMR structure of the camelized human VH (Riechmann, 
1996) have been reported. All these structures confirm that the identical scaffold architecture 
of the VH and the VHH domain i.e. consisting of two anti-parallel beta-sheets organized in a 
beta-barrel (Renisio et al., 2002). The root mean square deviation of the framework-Cα 
atoms between a VHH and a human VH domain is approximately 0.75Å (Decanniere et al., 
2000). However, due to the presence of amino acid substitutions in the FR2 region of VHH, 
the surface formed by the FR2 residues is rendered much more hydrophilic.  
 
                                                
Figure I-6 Illustration of the differences between human VH and camelid VHH based on 
the sequence comparison (Mulysdermans & Lauwereys, 1999). The relative position of 
the antigen binding loops of heavy chain (CDR1, 2 and 3) and framework region (FR; blue 
segments) have been shown. Green: The possible extra disulfide bridge between CDR-H1 
and CDR-H3 along with the framework amino acid substitutes in VHH. 
 
Three hypervariable regions can be clearly distinguished in the VHH sequences (Figure I-6). 
The CDR-H1 and CDR-H2 loops adopt new structures that fall outside the canonical 
structures described for human or mouse VH loops (Decanniere et al., 2000). Furthermore, 
CDR-H1 loop of VHH fragments may begin closer to the N-terminus in comparison to 
human or mouse CDR's (Harmsen et al., 2000). The high incidence of amino acid insertions 
or deletions in, or adjacent to the first and second antigen-binding loops of VHH will 
undoubtedly diversify the possible antigen-binding loop conformations (Nguyen et al., 
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2000). The CDR-H3 loop of VHH fragments is on an average longer (17 residues) than the 
human (12 residues) or mouse (9 residues) CDR-H3 loop. To stabilize the long CDR-H3 
loop, the VHH domains often contain a second intra-domain disulfide bond, which connects 
the CDR-H3 with the end of the CDR-H1 or with a core residue between CDR-H1 and 
CDR-H2 loop (Muyldermans et al., 1994). The CDR-H3 loop in VHH lacks the salt bridge 
between Arg94 and Asp101. The VHH with known structure have a tendency to turn their 
CDR-H3 loop outwards from the beta-barrel, towards the region that would interact with the 
VL in an Fv structure. Therefore, the location of the long CDR-H3 within the VHH is 
incompatible with the association of a VL. In summary, the structural analyses provide 
evidence that the antigen-binding loops of VHH exhibit a much larger structural repertoire 
than the one observed for the VH’s. It is possible that the absence of the VL domain generates 
the additional freedom that makes these changes possible and necessary. 
I.2.3 Camelization of the VH domain 
 
Single domain antibodies are an attractive alternative to scFv’s because of their much 
smaller size and their comparable affinities (Spinelli et al., 1996). However, low levels of 
soluble expression and solubility problems have hampered the development of such 
molecules (Muyldermans et al., 2001). The discovery of soluble and functional camelid 
heavy chain antibodies ‘VHH’ (Hamers-Casterman et al., 1993) opened up new opportunities 
for the development of single domain antibodies. The VHH possess distinct sequential and 
structural features responsible for their greater solubility in comparison to conventional VH 
domains (refer to I.1.7.1 & I.1.7.2). The process of incorporating features of VHH domains 
into human VH frameworks is called camelization of VH domains. In 1994, Davies & 
Riechmann observed that isolated human VH domains undergo aggregation at protein 
concentrations above 1 mg/ml. The aggregation behavior of human VH’s after introducing 
the mutations G44E, L45R, W47G (to mimic the theoretical VH/VL interface of VHH), was 
significantly reduced. It might therefore be possible to create a human single VH domain that 
behaves well in solution by mutating a very limited number of residues involved in the 
‘former’ VL interaction to mimic those residues present in VHH (Davies et al., 1996). 
Camelization of human VH’s is a promising technology for the generation of small antigen-
binding fragments that should be useful for therapeutic purposes in humans. 
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I.3 Mucin 
I.3.1 Overview 
 
Mucins (Greek: slimy) are secreted or transmembrane heterogeneous glycoproteins of high 
molecular weight (>200kDa) that apically protects the epithelia from infection, dehydration, 
physical or chemical injury and are also involved in cell-cell interactions, signaling, and 
metastasis (Parry et al., 2001 and Hilgers et al., 1989). In addition, mucins can inhibit or 
block the cytotoxic activity of neutrophils, natural killer (NK) cells, and cytotoxic T cells 
(Hayers et al., 1990). Mucins also have antiadhesive properties (Lightenberg et al., 1992).   
The human mucin family is constituted by six membrane-bound or tethered mucins (MUC1, 
MUC3, MUC4, MUC11, MUC12, MUC13) and five secreted (MUC2, MUC5AC, MUC5B 
MUC7, MUC9) mucins (Perez-Villar et al., 1999). Genes encoding these mucins are found 
on different chromosomes except MUC2, MUC5 and MUC6, which are linked on 
chromosome 11. The mucin genes are highly polymorphic (Swallow et al., 1987). The 
structure of the cDNA’s and the protein core of different mucins is similar in exhibiting 
regions encoding N-terminal protein sequences followed by sequences containing a variable 
number of tandem repeats (VNTR). Following this is the transmembrane region and the 
cytoplasmic tail (Figure general MUC1 structure). Variation of this general pattern, caused 
by exon splicing, leads to the secreted and truncated forms of mucins (Apostolopoulos et al., 
1994). 
The tandem repeat region of each mucin consists of a different number and composition of 
amino acids: 20 amino acids (MUC1), 26 amino acids (MUC2), 17 amino acids (MUC3), 16 
amino acids (MUC4), 8 amino acids (MUC5), 169 amino acids (MUC6), and 23 amino acids 
(MUC7). In addition, the number of repeats gives many different alleles; for example, for 
MUC1 there can be between 40 to 80 repeats in different individuals (Apostolopoulos et al., 
1994). Therefore, the repeat units of the different mucins show no similarity to each other 
either in respect to their sequence or the number of amino acids (Table I-3). 
Table I-3 Comparison of the human tandem repeat amino acid sequences encoded by 
the seven-mucin genes. 
    Mucin  Amino acid residues 
    MUC 1  SAPDTRPAPGSTAPPAHGVT 
    MUC 2  PTTTPISTTTMVTPTPTPTPTGTTQT 
    MUC 3  HSTPSFTSSITTTETTS 
    MUC 4  TSSASTGHATPLPVTD 
    MUC 5  PTTSTTSA 
    MUC 6  169 amino acid repeat unit 
    MUC 7  TTAAPPTPSATTPAPPSSSAPPE 
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The VNTR and the whole protein are rich in O-linked glycosylation sites (have a high 
content of serine, threonine and proline residues). The 50% of the mucins molecular weight 
derives from the O-linked carbohydrate residues (Strouss et al, 1992). The average number 
of O-glycans added to each tandem repeat is around 2.5 (Muller et al., 1997). There is a great 
variety in the structure of the carbohydrate side chains, which may be composed of only one 
type of disaccharide or may be complex containing several sugars and branched chains. 
I.3.2 Human mucin-1 
 
Mucin-1 (MUC1) is also known, among many other denominations, as human milk fat 
globule (HMFG) antigen, DF3 antigen, epithelial membrane antigen (EMA), H23, PAS-0 
(positive staining for carbohydrate with periodic and acid-schiff’s reagents), epitectin, 
polymorphic epithelial mucin (PEM), peanut-reactive urinary mucin (PUM) and episialin 
(epithelial glycoprotein of high sialic acid content). MUC1 mucin is membrane bound and is 
not a secretory or gel-forming mucin (Van Klinken et al., 1995).  
The MUC1 gene (Ligtenberg et al., 1990) is located on chromosome 1q21-24 
(Swallow et al., 1987). The human MUC1 gene is unusually compact, spanning 
approximately 4 to 7kb of genomic DNA and contains seven exons, the second of which  
 
 
 
 
Figure I-7 Schematic representation of a full-length human MUC1 cDNA. SS: Signal 
sequence, TM: Transmembrane, CYT: Cytoplasmic tail, TAG: Stop codon, 3' UTR, 3' 
untranslated region, Green box: Hydrophobic signal sequence, Gray Box: Transmembrane 
domain, Striped box: Tandem repeat domain, Arrows: Area predicted for proteolytic cleavage, 
Asterisk: Cysteine residues. 
 
contains the entire tandem repeat sequence (Lancaster et al., 1990) (Figure I-7). The 
genomic sequence is unusual in composition. The overall genomic sequence is 65% G+C 
rich, whereas, the tandem repeat region is 82% G+C, which is in marked contrast to the 40% 
G+C composition usually observed in mammalian genomic DNA.  
The number of repeats varies from 20 to 125 per allele and results in an extensive 
genetic polymorphism, which is observed in the DNA, RNA and protein products. The 
regulation of MUC1 expression and the genetic mechanisms responsible for its increased 
expression in tumors is largely unknown.  
The cDNA encodes a protein with a very large extracellular domain (1000 to 2200 
amino acids) made up largely of 20 amino acid tandem repeats (TR’s). The extracellular 
domain was found to made up of 20-125 tandem repeats of 20 amino acids with the highly 
SS Repetitive domain                                    TM  CYT   3’UTR
TAG
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conserved sequence ‘HGVTSAPDTRPAPGSTAPPA’. The high degree of polymorphism 
observed in the protein was based on differing numbers of tandem repeats present in the core 
protein (Gendler et al., 1987). Although many of the repeats were identical, variant 
sequences have been observed in cancer cell lines (MCF-7, T47D and HPAF) and in normal 
human mammary gland cells from milk (Hanisch et al., 2000). Signal peptide, a hydrophobic 
transmembrane domain and a phosphorylated cytoplasmic tail of 72 amino acids, containing 
signalling motifs (Figure I-8). 
 
 
 
 
 
 
                                         Figure I-8 General MUC1 structure. 
 
MUC1 exists in alternatively spliced forms. MUC1/SEC is a secreted form and lacks 
the hydrophobic transmembrane and cytoplasmic domains required for anchorage to the cell 
membrane and the MUC1/Y lacks the tandem repeat domains (Zrihan-Licht et al., 1994). 
MUC1/Y is preferentially expressed in breast carcinomas. An additional alternative splice 
form lacking the TR domain called MUC1/X or MUC1/Z has been described. The 
significance of different splice forms is unknown. Different types of epithelia in different 
                                  
Figure I-9 The single tandem repeat peptide showing in hatched circles the residues to 
which O-linked glycans can become attached and in gray circles the epitopic sequence 
against which the majority of murine MUC1 monoclonal antibodies are directed. The 
circles enclose, in numerical order of frequency, the epitopic sequences against which natural 
human MUC1 antibodies are directed (von Mensdorff-Pouilly et al., 2000). 
 
Transmembrane form
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(104aa)
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physiologic states heterogeneously express MUC1. Glycosylation levels vary from about 
50% in the normal mammary gland to 80% in colon carcinoma cells or pancreas, resulting in 
MUC1 proteins ranging in size from approximately 500 to >1000 kDa (Baeckstrom et al., 
1991). With in each tandem repeat, two serines and three threonines represent five potential 
O-glycosylation sites (Figure I-9). The carbohydrate chain may be comprised of up to 16 or 
more monosaccharide units. At the termini, these may be fucosylated or sialylated (Hanisch 
et al., 1989).  
The determination of hydrophilicity profiles and secondary structures of the MUC1 
repeated VNTR sequence indicate that the protein core is dominated by a hydrophilic region 
extending through residues ‘PDTRPAP’ and bound by two S and T potential glycosylation 
site (Chou et al., 1978). Initially, the MUC1 mucin tandem repeat protein core was believed 
to exist in random-coil conformation, attaining the secondary structure solely by the addition 
of carbohydrates to serine and threonine residues. In 1993, Fontenot et al. showed that the 
MUC1 protein core is not in a random-coil secondary structure but adopts a polyproline β-
turn helix conformation extending 200 to 500 nm above the plasma membrane (Hilkens et 
al., 1992).  The immunodominant region of MUC1 is the ‘PDTRP’ sequence, which forms 
the tip of a protruding “knob” exposed to solvents forming a stable type II ß-turn. Extended 
spacer regions connect the knobs whereas only multiple tandem repeats can enhance their 
stability and presentation (Fontenot et al., 1995). The crystal structure of the SM3 Fab 
antibody fragment in complex with the peptide epitope ‘PDTRP’ has shown that the MUC1 
peptide is bound in an extended conformation in an elongated groove in the antibody-
combining site, with no discernible secondary structure (Dokurno et al., 1998). Therefore, 
the correct MUC1 structure determination needs further structural studies of the native 
protein. 
I.3.3 MUC1 and cancer 
 
In cancer, MUC1 is overexpressed on cells and has increased circulation levels (Zotter et al., 
1988). Its distribution is no longer restricted to the apical surfaces of ducts and glands but is 
rather found throughout the tumor mass and on the entire surface of tumor cells. There is a 
correlation between MUC1 overexpression and the high metastatic potential of the cancer as 
well as the outcome (Takao et al., 1999). In fact, statistics show that cancers expressing 
MUC1 accounted for about 72% of new cases and for 66% of death rate (Greenlee et al., 
2000). Therefore, it can be concluded that the most immunogenic molecule of carcinomas 
appears to be the MUC1 mucin (Burchell et al., 1989). 
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Tumour-associated MUC1 has aberrated carbohydrate side chains (Figure I-10) (Hull 
et al., 1989) resulting in unmasking of the peptide core to allow binding of the antibodies 
(such as SM3 and DF-3P), which have been valuable in detecting the aberrant presentation 
of the MUC1 protein in carcinomas (Burchell et al., 1987). On one hand, the overexpression 
of MUC1 in cancer cells interferes with cell adhesion, favouring metastasis (Hilkens et al., 
1995) and also shield the tumour cells from immune recognition; on the other hand, MUC1, 
in essence a self-antigen, is displaced and altered in malignancy and induces immune 
responses. In carcinomas, mucin molecules shed into the circulation (Hilkens et al., 1985). 
The variations in the levels of circulating MUC1 are used to monitor therapy and allow an 
early detection of reemergence of the tumors (Graves et al., 1998). 
        
Figure I-10 Two tandem repeat peptides schematically displaying the differences in 
glycosylation between normal and tumor-associated mucin. MUC1 that is expressed on 
cancer cells has shorter glycans attached to the peptide core, which leads to the exposure of 
peptide core epitopes. The shorter glycan chains present novel carbohydrate epitopes. 
 
The exposed protein core of MUC1, resulting of aberrant glycosylation, offers a unique 
opportunity to act as an immunotherapeutic target for the specific tumors (Barratt-Boyes et 
al., 1996). 
I.3.4 Antibodies against MUC1 
 
Immunization with MUC1 peptides or fusion proteins generally induces an antibody response 
rather than a CTL response in mice and humans (Karanikas et al., 1997). Natural antibodies 
against MUC1 are found in patients with malignant tumors. Circulating MUC1 IgM 
antibodies are present in breast, colon and pancreatic cancer patients (Kotera et al., 1994) and 
in women with benign and malignant ovarian tumors (Richards et al., 1998). MUC1 IgG 
antibodies have been detected in colorectal cancer patients (Nakamura et al., 1998). A 
recently described assay for free IgG and IgM antibodies directed against the MUC1 tandem 
repeat showed that high levels of free antibodies might inhibit natural metastasis (von 
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Mensdorff-Pouilly et al., 1998). It seems that humoral immunity is the only possible way to 
treat, reduce or eradicate MUC1 induced malignancies. 
Numerous mucin specific antibodies have been derived following immunization of 
animals with normal or malignant epithelial cells. The majority of the antibodies recognize 
the tumour associated MUC1 molecule. The monoclonal antibodies against MUC1 have 
been available since the early 1980s and are used in clinic for diagnostic purposes e.g. 
HMFG1 antibody used mainly for ovarian cancer (Maraveyas et al., 1994). Recent epitope 
mapping has established that many of these monoclonal antibodies react with the tandem 
repeat core, in particular with epitopes contained within the amino-acid sequence APDTRPA 
(Burchell et al. 1989).  
In particular, large number of murine monoclonal antibodies (~58) against MUC1 
have been raised and studied (Price et al., 1998). The repetitive use of these monoclonal 
antibodies in cancer therapy initiates a human anti-mouse antibody (HAMA) response in 
humans. Therefore, there is an urgent need either to humanize or to generate human 
antibodies against MUC1. Human antibodies of low affinity have been detected in serum 
after immunizing the patients with intact or fragmented MUC1 antigens. Unfortunately, very 
few recombinant human antibodies specific for the MUC1 have been developed (Andersson 
et al., 1999; Henderikx et al., 1998; Söderlind et al., 2000; Wong et al., 2001 and Jirholt et 
al., 2002) and several of these have been shown to be of low affinity and to display a rapid 
dissociation rate constant, probably making them less suiTable for tumor therapy or 
diagnosis. Furthermore, no attempt has been made to reduce the size of the antibodies 
needed to achieve a better drug distribution. The use of small recognition units in cancer 
therapy demands for their improved affinity towards the antigen and their increased stability. 
These requirements can be met by rational protein design based on the knowledge of the 
molecular basis of the antibody and its interaction with the antigen. 
I.4 Research objectives 
 
Numerous murine monoclonal antibodies have been generated against the MUC1 antigen, 
but the repetitive dosage of these antibodies can elicits the human anti-murine antibody 
(HAMA) response in humans. Humanized or human antibodies provide an effective 
alternative. The fully human scFvM12 antibody has reactivity against adenocarcinoma-
associated mucin MUC1 (Wong et al. 2001). The scFvM12 antibody fragment recognizes 
the hydrophilic epitope ‘PDTRP’ of the MUC1 core protein, considered as an 
immunodominant region.  
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Over the last decades, large numbers of peptide-antibody Fab structures have been 
reported (Wilson & Stanfileld, 1994). A number of uncomplexed tumor specific antibodies 
against the same antigen have been analyzed (Banfield et al., 1996). But only few structures 
of either murine or humanized Fab antibody fragments directed against MUC1 have been 
solved (Dokurno et al., 1998; Banfield et al., 1997).  The specificity of the scFvM12 
antibody towards the MUC1 antigen makes it a potential and useful tool in the diagnosis and 
treatment of MUC1 associated adenocarcinomas. It is therefore of significant interest to 
understand at the molecular level, the specificity of the mucin/antibody interaction, which 
might allow higher affinity antibodies to be obtained through the use of rational antibody 
engineering (Rees et al., 1994). The structure would be useful in the generation of antibody 
with improved functionality and physico-chemical properties such as improved stability, 
reduced immunogenicity, better tissue distribution and faster blood clearance when used in 
vivo. 
Single domain antibodies are more efficient in solid tumor penetration (Mayer et al., 
1999). Although, single domain antibodies have faster clearance rate, simultaneously in 
comparison to Fab or scFv’s, they achieve better biodistribution in avascular tissues. The 
crystallisation and structure determination of isolated VH and VL domains of the scFvM12 
antibody would provide the basis for developing stable small antigen recognizing units. In 
scFvM12, the VH and the VL domains are derived from two different human libraries (Sheets 
et al., 1998). The structural study of isolated domains and the conformational changes, which 
may occur upon their association in the scFv format, can be used to derive the rational of the 
VH/VL interaction occurring between two unrelated partners.  
In 1996, Riechmann reported that the camelization of the VH/VL interface of the VH 
domain could be helpful in increasing its solubility. Therefore, the final objective of this 
thesis included the camelization of the VH domain of the scFvM12 antibody fragment at 
positions H44, H45 and H47.  
The goals of this thesis can be summarized as follows: 
1. Optimisation of expression in Escherichia coli and purification of single chain 
antibody fragment M12 (scFvM12).  
2. Crystallization of scFvM12 alone as well as in complex with MUC1 antigen.  
3. Stability analysis of scFvM12 and its correlation to crystallization. 
4. Generation of the single antibody domain(s) of scFvM12 through limited proteolysis 
and their crystallization alone as well as in complex with MUC1 antigen.  
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5. X-ray analysis of the crystal(s) and structure determination for the corresponding 
dataset. Furthermore, the deposition of the determined structure to the Research 
collaboratory for Biological Structures/Protein Data Base (RCSB/PDB). 
6. Protein engineering of the M12-VH domain based on the crystal structure. 
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II MATERIALS AND METHODS 
 
II.1 Materials 
 
II.1.1 Chemicals 
 
Biochemical grade chemicals were purchased from Fluka (Taufkirchen, Germany), ICN 
(Eschwege, Germany), Sigma (Deisenhofen, Germany) or Pierce (Rockford, IL, USA) and 
Roth (Karlsruhe, Germany). 
II.1.2 Laboratory consumables 
 
BCA protein assay kit      Pierce (Rockford, USA) 
Bradford protein assay kit      Bio-Rad Laboratories Inc., USA  
Dialysis tubing (MWCO- 3.5kDa & 10kDa)    Roth, Kleinfeld, Hannover, Germany 
Falcon tubes (15ml & 50ml)  Becton Dickinson, Heidelberg, 
 Germany  
HybondTM C nitrocellulose membrane (0.45µm)  Amersham Life Science, Sweden  
Plasmid isolation Kit      Qiagen, Germany  
Parafilm         American National, Canada  
Pipette tips (10µl, 200µl, 1000µl)     Gilson, Villiers-le Bel, France 
Pipettes (2.0µl, 10µl, 20µl, 200µl, 1000µl)    Gilson, Germany 
Plasmid isolation kit (Mini)     Qiagen (Hilden) 
Plastic disposable pipettes (1ml, 5ml, 10ml)    Falcon, Germany  
Sterile filters (0.22µm, 0.45µm)     Millipore, Molsheim, Germany  
Syringes (1ml, 2ml, 10ml, 20ml)    Braun, Melsungen, Germany  
Whatman paper (No.1)     Whatman (Maidstone, UK) 
II.1.3 Laboratory equipment 
 
Autoclave      Bachofer, Reutlingen, Germany  
Bio-bench in-situ bioreactor  Applikon dependable Instruments, 
Schiedam, Holland 
Centrifuge  
 AvantiTM 30 and AvantiTMJ-25  Beckman, California, USA 
 Biofuge A     Heraeus, Hanau 
 Sigma 3-10 and Sigma 4-10   Sigma, St. Louis, Missouri, USA 
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RC5C and RC5B plus  Sorval instruments, Du Pont, Bad 
Hamburg 
Chambers for SDS-PAGE and western blotting Bio-Rad Laboratories GmbH  
Gel air dryer       Bio-Rad Laboratories Inc., USA 
Gel electrophoresis equipment   Bio-Rad Laboratories GmbH  
(Mini PROTEAN IITM) 
InnovaTM 4340 incubator shaker   New Brunswick Scientific, 
Nürtingen, Germany 
Magnetic stirrer      Heidolph M2000 Bachofer, Germany   
MAR-Research image plate, mar345  MARresearch, Hamburg, Germany  
Mass spectrometer     Micromass UK Limited, Manchester, 
UK 
Octane workstation     Silicon Graphics Incorporation, USA 
pH-meter       WTW, Germany 
Quartz cuvettes      QS Hellma, Germany   
Rotors 
0650, F2402H, JLA 10.500 and JA 25.50 Beckman, California, USA 
#1140 and #11222    Sigma, USA 
RLA-300, SS-34 and GS-3   Du Point, Hamburg  
Single beam spectrophotometer   Eppendorf, Germany  
Sonicator      Braun Biotech, Melsungen, Germany 
X-ray generator RU2000    Rigaku, Tokyo, Japan 
II.1.4 Chromatography columns 
 
Pre-packed columns (Superdex 75 HiLoad 16/60, MonoQ HR 10/10, MonoS HR 10/10) and 
resins used were from Amersham-Pharmacia Biotech (Freiburg), self-pack column from 
Millipore (Eschborn) and Bio-Processing (Consett, Co. Durham, England). For protein 
purification, the Äkta-FPLC (Amersham Phramcia Biotech) set up was used. 
II.1.5 Media, stock solutions and buffers 
 
Standard media and buffers were prepared according to standard procedures (Ausubel et al., 
1998; Coligan et al., 1998; Sambrook et al., 1996) using deionized water (R-18.3Ωcm-1). 
Heat-sensitive components such as antibiotics were prepared as stock solutions, filter-
sterilized (0.2µm) and added to the medium/buffer after cooling to room temperature. 
Compositions of non-standard solutions or buffers are listed at the end of the respective 
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method section. Media for cultivating bacteria were sterilized by autoclaving (121°C/1-2 
bar/20min). 
The following bacterial growth media were used: 
I. Small scale (shake flask): 
Luria-Bertini (LB) medium 
Bacto-peptone  1.00% (w/v) 
Yeast extract  0.50% (w/v) 
NaCl   1.00% (w/v) 
The LB agar plate was prepared with LB medium containing 100µg/ml of ampicillin. 
2xTY medium 
Bacto-peptone  1.60 % (w/v) 
Yeast extract  1.00 % (w/v) 
NaCl   0.50 % (w/v) 
    SOC medium 
Bacto-peptone  2.00% (w/v) 
Yeast extract  0.50% (w/v) 
NaCl   0.05% (w/v) 
Glucose  55.55 mM 
MgCl2   10.00 mM 
MgSO4  10.00 mM 
II.  Large scale (fermenter): The composition of the minimal medium used for high 
cell density fermentation (II.2.2.2) is as follows: 
KH2PO4  1.660 % (w/v) 
NH4PO4  0.400 % (w/v) 
CaCl2.2H2O  0.007 % (w/v) 
FeSO4.7H2O  0.014 % (w/v) 
MgSo4.7H2O  0.150 % (w/v) 
Glucose  2.500 % (w/v) 
Citric acid  0.210 % (w/v) 
L-arginin-HCl  0.020 % (w/v) 
Trace metal solution*  0.400 % (v/v) 
Ampicillin   100.00 mg 
*The composition of trace metal solution (PTM1, Invitrogen) is as follows: 
    Biotin      0.82 mM 
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    H3BO3      0.32 mM 
CoCl2.6H2O     2.10 mM 
CuSO4     24.00 mM 
FeSO4   230.00 mM 
NaI       0.53 mM 
MnSO4    19.87 mM 
Na2MoO4.2H2O     0.83 mM 
ZnCl2       0.15 mM 
II.1.6 Antibodies, antisera and peptides 
 
Mouse anti-c-myc tag monoclonal antibody (9E10) (ATCC clone number CRL-1729) was 
used for detection of scFv-fragments by immunoblot (Figure III-4B, III-6B etc). Mouse anti-
His6 (Qiagen, Germany) antibodies were also used for detection of scFv fragments. Alkaline 
phosphatase (AP) or horseradish peroxidase (HRP)-conjugated to goat anti-mouse IgG 
(H+L, Fc) (Dianova) antibodies were used as secondary antibody in immunoblot analysis 
(Figure III-4B). NBT/BCIP (Bio-Rad Laboratories Inc., USA) were used as substrate for 
detection of immobilized proteins in immunoblot (Figure III-4B). 
The C-terminal biotinylated MUC1 peptide APDTRPAPGSTAPPAHGVTSK-ε-
biotin was purchased from Anaspec, San Jose, USA (II.2.9.1.3 & II.2.9.1.4). The peptide 
was dissolved in 20mM sodium acetate buffer, pH 5.0 and stored at –20oC. 
II.1.7 Bacterial strains 
 
E. coli strain DH5α was used as a host cells for subcloning. BL21 and TG1strains were used 
for expression of the soluble periplasmic scFv-fragments and VH domains.  
Table II-1 Names, suppliers and genotypes of E. coli strains used. 
 
Strain  Source  Genotype 
DH5α 
 
Stratagene F-,Φ80dlacZ∆M15, endA1, recA1, hsdR17 (rk-
,mk+), supE44, thi-1, gyrA96, relA1, ∆ (lacZYA-
argF)U169,λ- 
TG1 Stratagene F´ traD36 lacIq∆ (lacZ)M15 proA+B+/supE ∆ 
(hsdM-mcrB)5 (rk-mk+McrB-) thi ∆ (lac-proAB) 
BL21 (DE3) Novagen  B F– dcm ompT hsdS(rB– mB–) gal λ (DE3) 
BL21- Codon 
plus(DE3)-RIL 
Stratagene B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ (DE3) 
endA Hte [argU ileY leuW Camr] 
 
II.1.8 Software 
 
I. General - Windows NT 4.0 operating system (Microsoft Corporation, USA), 
Adobe Photoshop 6.0 (Adobe Systems GmbH, Germany); Origin 6.0 (Data analysis and 
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technical graphics, Microcal Software, Inc.), Bioexpert NT 3.0 beta (Applikon, Schiedam, 
Holland). 
II. Crystallography – DENZO/SCALEPACK (Otwinowski & Minor, 1997); 
CCP4 program suite (version 4.2.2, Collaborative Computational Project, Daresbury, UK, 
1994); PHASES (William Furey, University of California, San Francisco, USA); O (Jones et 
al., 1991); CNS & X-PLOR (Cooke et al., 1991), Insight II (Biosym Technologies/MSI, San 
Diego, CA, USA) and PROCHECK (Laskowski et al., 1993). 
II.2 Methods 
 
All experiments related to the genetic engineering were performed according to the 
Regulations of “S1-Richtlinien” and were officially approved by the “Regierungspräsidium 
des Landes NRW” (RP-Nr.: 23.203.2 AC 12, 21/95) and “BGA” [AZ 521-K-1-8/98:AI3- 
04/1/0866/88 (S1). 
II.2.1 Recombinant DNA techniques 
 
General DNA recombinant techniques like restriction enzyme analysis, DNA ligation and 
DNA agarose gel electrophoresis were performed according to the standard protocols 
described in Sambrook et al. (1989) and Ausubel et al. (1995) or according to the 
manufacturers instructions when using kits. The recombinant DNA work was supported by 
Melanie König (RWTH Aachen, Institute for Molecular Biotechnology, Aachen, Germany). 
II.2.1.1 Analytical gel electrophoresis 
 
Undigested plasmid DNA, restriction enzyme fragments and PCR products were 
electrophoretically separated on 1.2% (w/v) agarose gel prepared in TBE buffer containing 
0.1µg/ml ethidium bromide. The gel was run at 120V for approximately 30 min in minigel 
chambers (Bio-Rad). Known amount of DNA molecular marker such as 1kb ladder and PstI 
digested lambda marker were used to evaluate the size, integrity and to determine DNA 
concentration. The DNA was visualized on an UV transilluminator at 302 nm and 
documented using a black and white E.A.S.Y.429K camera (Herolab). 
II.2.1.2 Preparative gel electrophoresis 
 
PCR amplified DNA segments or restriction enzyme digested DNA fragments were isolated 
through preparative gel electrophoresis prior to cloning. After electrophoresis, DNA 
fragments were excised from the gel using an UV transilluminator. The ‘Qiaquick Gel 
extraction kit’ (Qiagen) was used to isolate DNA from excised gel pieces according to the 
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manufacturers instructions. The concentration of the isolated DNA was determined either 
spectrophotometrically or by agarose gel electrophoresis. 
II.2.1.3 PCR amplification of DNA segments 
 
Polymerase chain reaction (PCR) was used for the amplification of DNA segments of 
interest (Saiki et al., 1988). The reaction was performed in 0.2ml PCR reaction tubes 
(Biozyme Diagnostik GmbH, Oldendorg, Germany) using a DNA thermal cycler (MWG 
Biotech). The optimal annealing temperature (TA) was determined either by empirical 
optimization or by the following formula (Wu et al., 1991): 
    TA=[22+1.46{2x(G+C) + (A+T)}] 
PCR amplified products were resolved on 1.2% (w/v) agarose gel with appropriate marker to 
confirm their integrity and amplification. The primers used are listed in the appendix (VI.3). 
The PCR amplification of the different DNA fragments and the conditions used for 
amplification were as follows: 
II.2.1.3.1 Native M12-VH domain 
 
The pSynI vector containing the gene for the scFvM12 antibody was purified from the E. 
coli strain BL21 (DE3) by using the ‘Qiagen mini spin kit’. The 1x master mix used for the 
PCR reaction was as follows: 
  PCR buffer (10x)     5.00 µL 
   dNTP mixture (10mM)   1.00 µL 
   M12-VH forward primer (10pmol/µL) 1.00 µL 
   M12-VH backward primer (10pmol/µL) 1.00 µL 
   Taq DNA Polymerase (5U/µL)  0.65 µL 
   Template DNA (~100ng)   1.00 µL 
   MgCl2      variable  
   distilled H2O added to              34.35 µL 
The master mix was optimized for 0.5mM, 1.0mM, 2.0mM, 2.5mM, 3.0mM, 3.5mM, 
4.0mM and 4.5mM of MgCl2. The amplification was performed for each MgCl2 
concentration under the following condition: 
 95°C   3.0 min Initial denaturation 
  ------------------------------------------------------------------------------ 
 95°C   30.0 sec Denaturation 
35 cycles 55°C   30.0 sec  Primer annealing 
    72°C   1.0 min Primer extension 
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  ------------------------------------------------------------------------------ 
72°C        5.0 min Final extension 
II.2.1.3.2 Camelized M12-VH domain 
 
To mimic the camelids VHH, the M12-VH domain was simultaneously mutated  at position 
Gly44Glu, Leu45Arg and Trp47Gly/His (VI.3). The 1x master mix used was as follows: 
PCR buffer (10x)   5.00 µL 
    MgCl2        (50mM)   3.00 µL 
    dNTP mixture (10mM)  1.00 µL 
    Forward primer (10pmol/µL)  1.00 µL 
    Backward primer (10pmol/µL) 1.00 µL 
    Taq DNA Polymerase (5U/µL) 0.65 µL 
    Template DNA (~100ng)  1.00 µL 
    Distilled H2O added to           37.50 µL 
The PCR reaction was setup, for the amplification of the mutated product, under the 
following conditions:  
95°C   3.0min  Initial denaturation 
  ------------------------------------------------------------------------------ 
95°C   30.0sec Denaturation  
 20 cycles 40°C   30.0sec Primer annealing 
72°C   1.0min  Primer extension 
  ------------------------------------------------------------------------------ 
72°C        5.0min  Final extension 
The camelized M12-VH domain containing the mutation Trp47Gly and Trp47His were 
designated as M12-VHcamG and M12-VHcamH. Both of these domains also contain 
Gly44Glu and Leu45Arg mutations respectively. 
II.2.1.4 DNA digestion 
 
DNA isolated through plasmid DNA minipreparation (II.2.1.7) was restriction digested 
according to the manufacturers instructions in the respective buffer(s). 500ng to 1500ng of 
plasmid DNA was restricted with 16U of enzyme for 3-4 hrs at 37º C. Restriction fragments 
used for ligation (II.2.1.6), 0.5-1µg of vector DNA and 3-8µg of insert DNA depending on 
the size of the insert were digested with 10U of restriction enzyme for 2hrs at the 
recommended temperature. Fragments were subsequently separated by agarose gel 
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electrophoresis (II.2.1.1) and photo-documented (II.2.1.1) or purified. The restriction of the 
genes of interest was performed using the following conditions: 
A. The PCR amplified native M12-VH fragment corresponding to the MgCl2 concentration 
1.0mM, 2.5mM, 3.0mM and 4.0mM was extracted from the agarose gel by using the 
‘Qiagen quick PCR purification kit’ (Qiagen). The buffer mix used for digestion with 
NdeI and XhoI at 37°C was as follows: 
Components                 Native M12-VH 
M12 vector DNA (50ng/µL)                       30.40 µL 
Restriction buffer 4 (10x, NEB)  4.00 µL 
Nde I (20,000U/ml, NEB)   0.80 µL 
Xho I (20,000U/ml, NEB)   0.80 µL 
BSA (NEB, 10x)    4.00 µL 
 distilled H2O added to             40.00 µL 
B. The restriction digestion of the camelized M12-VHcamG/H (Trp47Gly/Trp47His) 
DNA was performed under the following conditions: 
Components   M12-VHcamG  M12-VHcamH 
 Template DNA (50ng/µL) 10.00µL (50ng/µL) 13.0µL (40ng/µL) 
Restriction buffer 2     4.00µL    4.00µL 
(10x, NEB) 
NdeI (20,000U/ml, NEB)   0.80µL    0.80µL 
XhoI (20,000U/ml, NEB)   0.80µL                        0.80µL 
BSA (NEB, 10x)     4.00µL    4.00µL 
distilled H2O added to            40.00µL                      40.00µL 
In all the restriction analysis, pK3C (90ng/µL) vector (appendix) restricted with NdeI and 
pK3C vector (90ng/µL) restricted with NdeI and XhoI was used as positive and negative 
control respectively. 
II.2.1.5 Ligation of DNA inserts 
 
Purified DNA from restriction digest (II.2.1.4) was ligated via their sticky ends (Sambrook, 
et al., 1989). Generally, a vector-insert ratio of 5:1 was used. The ligation mixture was 
centrifuged at 10,000xg for 1min and ligation was carried out at 14ºC for 12hrs. PCR 
products were ligated into bacterial vector pK3C (appendix) digested with XhoI and NdeI 
restriction enzymes. The ligation of the M12-VH fragments into the pK3C vector was 
performed under the following conditions:  
 
  II-MATERIALS AND METHODS 
 34
Components    Native M12-VH M12-VHcamG     M12-VHcamH 
pK3C vector DNA   2.0µL   10.0µL  10.0µL  
(50ng/µL)     (5ng/µL)   (10ng/µL)   (10ng/µL) 
Template DNA    2.0µL (3ng)     2.0µL (20ng)         2.0 µL (20ng) 
T4 Ligation buffer (1x)  2.0µL       2.0µL          2.0µL  
(10x, NEB) 
T4 DNA Ligase   0.5µL     0.5µL          0.5µL 
(1U/µL; NEB) 
distilled H2O added to             20.0µL   20.0µL        20.0µL 
In all the sticky end ligation reactions, the pK3C vector digested with NdeI and XhoI 
was used as negative control while the single-cut vector was used as positive control. The 
M12-VH DNA fragment was diluted 10x in water. 100µL of E. coli DH5α competent cells 
were transformed with 20µL of the ligated product(s) using the heat shock method (II.2.1.9). 
II.2.1.6 PCR based analysis of recombinant bacterial clones 
 
Bacterial clones harboring the plasmid having the gene of interest were identified by PCR 
(Jesnowski et. al., 1995). Single colonies were picked with sterile toothpicks and used to 
inoculate a ‘masterplate’ and then dipped into a PCR tube containing 10µL of sterile water. 
15µL of the PCR mix was added to the PCR tube. Specific primers annealing to the 5’ and 
3’ends of the cloned gene or primers for the specific vector backbone were used for the PCR 
amplification reaction. The reaction conditions were the same as before (II.2.1.3.1), except 
initial denaturation of the DNA was performed for 10 minutes. 10µL of the PCR amplified 
product was analyzed on a 1.2% (w/v) agarose gel (II.2.1.1). The recombinant bacterial 
clones were checked by PCR  (II.2.1.3) using the following buffer: 
   PCR buffer (10x)    5.0 µL 
   Forward primer (10pmole/µL)  1.0 µL 
   Backward primer (10pmole/µL)  1.0 µL 
   dNTP’s (10mM)    1.0 µL 
   MgCl2 (50mM)    3.0 µL 
   Taq polymerase (5U/µL)   0.5 µL 
   distilled H2O added to            38.5 µL 
The reaction cycle was same as mentioned in II.2.1.3.2. 
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II.2.1.7 Isolation of plasmid DNA from E. coli 
 
Mini-preparations of plasmid DNA were performed using the ‘Spin mini-prep’ kit (Qiagen), 
based on the alkaline lysis method (Sambrook et al., 1989), according to the manufacturers 
instructions. DNA concentration and purity were determined spectrophotometrically. An 
O.D.260nm of 1 corresponds to ~50 µg/ml of dsDNA, ~40 µg/ml of ssDNA and RNA and 
~20 µg/ml of ss-oligonucleotides. The purity of the nucleic acid was ascertained by 
determining the ratio O.D.260/ O.D.280 according to Müller et al., (1993) and Sambrook et 
al., (1996). An O.D.260/ O.D.280 = 1.8 for DNA and 2.0 for RNA are acceptable. 
Contaminants like phenol and proteins lower the ratios. Isolated plasmid DNA was stored at 
-20°C. 
II.2.1.8 DNA sequencing and sequence analysis 
 
DNA sequencing was performed with the dideoxy chain termination method of Sanger et al., 
(1977). Fluoresceins labeled oligonucleotides were used for DNA sequencing of the gene of 
interest using ‘Thermosequenase fluorescence labeled cycle sequencing kit’ and a LICOR 
4200 IR2 automated DNA sequencer (MWG Biotech). The sequencing reaction mix was 
resolved on denaturating (6.0M) polyacrylamide gel (4.0 –6.0% (w/v)).  
The ‘Chromas software package’ (Technelysium Pty Ltd., Australia) was used to 
display the chromatogram files from the LICOR automated sequencer. The files were 
exported to ‘DNAsis’ (Hitachi Software Engeenering Company Limited, Kanagawa, Japan) 
and ‘GCG software package’ (Accerlys Incorporation, USA) for evaluation of sequencing 
data. 
The PCR amplified product was subjected to sequence analysis by using the T7 
promoter and termination primer in the following buffer mix:  
    PCR amplified DNA (80ng/µL)    3.0 µL 
   Forward primer (10pmole/µL)    1.0 µL 
   Backward primer (10pmole/µL)    1.0 µL 
   distilled H2O added to    11.0 µL 
II.2.1.9 Preparation of E. coli competent cells 
 
II.2.1.10 Preparation of heat shock E. coli competent cells 
 
Heat-shock competent cells were prepared according to the procedure of Inoue et al. (1990). 
The heat-shock competent cells were prepared from 100mL of a log-phase culture 
(O.D.600nm ~ 0.5) in LB medium. The bacterial suspension was centrifuged (10min, 
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4500xg, 4°C) after cooling on ice at 4°C for 10min. The cell pellet was gently re-suspended 
in 40mL of filter sterilized (0.2µm) ice-cold TB buffer [10mM PIPES, pH6.7; 15mM CaCl2; 
250mM KCl; 55mM MnCl2]. After cooling on ice for 10min, the suspension was centrifuged 
(10min, 2300xg, 4°C). The pellet was gently re-suspended in 8ml of ice-cold TB buffer and 
pure ice-cold DMSO was added to 7.0 % v/v (final concentration). After cooling the 
suspension on ice for 10min, aliquots of 200µL were shock-frozen in liquid N2 and stored at 
–80°C. 
II.2.1.10.1 Transformation of heat shock E. coli competent cells 
 
E. coli was transformed by the heat-shock method as described (Hanahan et al., 1985). For 
transformation, an aliquot of competent cells was thawed on ice, mixed with 100ng of 
plasmid DNA or a ligation product (Sambrook et al., 1989). After incubating for 30min on 
ice, a 2min heat-shock was given at 42°C. The heat-shock cells were incubated for 5min on 
ice. The volume of the aliquot was made up to 1ml with sterilized SOC medium (II.1.5) and 
allowed to grow (1h, 150 r.p.m., 37°C) and subsequently plated on LB agar supplemented 
with ampicillin (100µg/mL) for the selection of recombinant clones. 
II.2.1.10.2 Efficiency of bacterial transformation 
 
Efficiency of transformation of each new batch of competent cells was measured by test 
transformations with known concentrations of supercoiled plasmid pUC18. The 
transformation rates of greater than 109/µg pUC18 and 108/µg pSyn & pK3C vectors were 
obtained. 
II.2.1.10.3 Culturing and glycerol stock preparation 
 
Individual colonies of all strains were obtained by plating the respective strain on a LB agar 
plate containing 100µg/ml of ampicillin with subsequent incubation at 28oC for overnight. 
The plates were stored at 4oC for short periods (less than 2 weeks). LB medium (II.1.5) 
containing 100µg/ml of ampicillin and 1%  (w/v) glucose was inoculated with a single 
recombinant colony of E. coli and grown overnight at 28°C with vigorous shaking 
(200r.p.m.). Glycerol stocks were prepared by suspending the pellet of 1ml fresh culture in 
500 µl of sterile buffer [25mM Tris, pH 7.5; 100mM MgSo4; Glycerol 50% (w/v)]. Glycerol 
stocks were stored at -80°C. 
II.2.2 Bacterial expression of antibody fragments 
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II.2.2.1 Small scale expression  
 
A freshly transformed colony of E. coli TG1 (II.1.7) harboring recombinant plasmid, having 
scFvM12 gene, was inoculated in 5.0 ml of 2xTY medium (II.1.5) containing 1% (w/v) 
glucose and 100 µg/ml ampicillin and cultivated overnight at 37°C with vigorous shaking 
(180 r.p.m.). The following day, 500 ml (4x) of sterilized 2xTY containing 0.1% (w/v) 
glucose, dipotassium hydrogen phosphate (3g/L), 100µL of MgSO4 (25.0%, w/v) and 100 
µg/ml of ampicillin was inoculated with 1.0 ml of overnight culture and allowed to grow at 
37°C/200r.p.m. to an O.D.600nm of 0.7-0.8. Expression of recombinant proteins was then 
induced by the addition of 1mM IPTG (final concentration) after reducing the cultivation 
temperature to 28°C. At the time of induction, 50ml of sterile yeast extract (3 g/L) was also 
added to the culture. After 4-5hrs of incubation, the cell suspension was harvested by 
centrifugation (10 min/4000 r.p.m. /4°C).  
The M12-VH fragments were expressed under the same conditions as the scFvM12, 
except 2xTy medium was used for the expression. 
II.2.2.2 Large scale expression of scFvM12 
 
Few recombinant colonies of freshly transformed E. coli TG1 were inoculated overnight at 
37°C in 5ml of LB medium containing 1.0% (w/v) glucose and 100µg/mL ampicillin. One 
milliliter of the pre-culture was used to inoculate 150ml of LB medium containing 1.0% 
(w/v) glucose and 100 µg/mL ampicillin and allowed to grow at 37°C for 12hrs. This culture 
was used to inoculate 4L of sterilized minimal medium in a 7L working volume stirred-tank 
reactor (Biobench fermenter, Applikon, Holland). Glycerol-fed-batch phase was carried out 
prior to induction using a 50% (v/v) glycerol feed containing 14.7g/L MgSO4 and 4ml/L 
PTM1 trace salts. The aeration rate was set at 0.5vvm (vessel volume per minute) or 
2ml/min. The rate of aeration was controlled through synchronized stirrer speed (appox. 
between 500-1100 r.p.m.). The growing culture was maintained at pH 6.8 and the pH was 
controlled by using 25% (v/v) NH4OH. Three six-bladed Ruston impellers of one-third the 
vessel diameter provided agitation. The culture was grown at 37°C until an O.D.600nm of 50 
was reached and then the temperature was reduced to 28°C prior to before induction with 
1.0mM of IPTG (final concentration). The culture was harvested after 6-8 hrs of induction 
by centrifuging the suspension at 5000xg for 15 min. The pellet was stored at –80°C. The 
supernatant (1L) was processed through a Ni-NTA column (II.2.3.1.2) after re-centrifugation 
at 7000xg for 30 min. 
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II.2.3 Purification of antibody fragments 
 
II.2.3.1 scFvM12 purification 
 
The entire purification procedure was performed at 4°C. 
II.2.3.1.1 Periplasmic extraction 
 
The periplasmically expressed scFvM12 was purified by osmotic shock (Ausubel et al., 
1989) to E. coli TG1 suspended in 30mM Tris, pH 8.0, 20% (w/v) sucrose and 1mM (final 
concentration) of EDTA. The suspension was gently stirred for 15min and then centrifuged 
at 5000xg. The pellet was re-suspended in 30mM Tris, pH 8.0, 5mM of ice-cold MgSO4 and 
a cocktail of protease inhibitors (Roche, Germany). The suspension was gently stirred for 
20min and centrifuged twice at 15000xg for at least 20min. 
II.2.3.1.2 Ni-NTA chromatography 
 
An appropriate volume of chelating sepharose fast flow resin [nitrilo-acetic acid (NTA), 
Amersham Pharmacia Biotech] was packed in a column and charged with Ni2+ ions. The 
excess metal ions were removed by passing 5 column volumes (CV) of weak acetic acid 
(0.02M). The column was equilibrated with 10 CV of binding buffer (50mM Tris pH 8.0, 
500mM NaCl, 20mM imidazole and 2mM benzamidine-HCl). The clear supernatant 
containing the periplasmic protein was loaded on the Ni-NTA column at a flow rate of 
1ml/min. After washing with 40CV of binding buffer, the column was connected to the 
Äkta-FPLC (Pharmacia Biotech) and the protein was eluted with step gradients of 45mM, 
65mM, 80mM and 500mM of imidazole in the elution buffer (50mM Tris pH 8.0, 500mM 
NaCl, 500mM imidazole and 2mM benzamidine-HCl). The protein fractions were pooled 
and dialyzed overnight against at least 5L of 30mM sodium succinate pH 4.4, 20mM NaCl, 
2mM EDTA and 2mM benzamidine-HCl. The dialyzed protein fraction was filtered through 
0.2µm filter. 
II.2.3.1.3 Cation-exchange chromatography 
 
The dialyzed and filtered Ni-NTA purified protein (II.2.3.1.2) was loaded on a MonoS HR 
10/10 column (Amersham Pharmacia Biotech) pre-equilibrated with at least 5 CV of binding 
buffer (30mM sodium succinate pH 4.4, 20mM NaCl, 2mM DTT, 2mM EDTA and 2mM 
benzamidine-HCl). After washing the column with 10 CV of binding buffer, the protein was 
eluted with a 20 CV linear gradient from 0.02M to 0.7M NaCl (30mM sodium succinate, pH 
4.4, 2M NaCl, 2mM DTT, 2mM EDTA and 2mM benzamidine-HCl) at a flow rate of 0.6ml 
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/min. The desired protein fractions were pooled and dialyzed against 5L of 30mM Tris, pH 
8.0, 20mM NaCl, 2mM EDTA and 2mM benzamidine-HCl–HCl. 
II.2.3.1.4 Anion-exchange purification 
 
Cation exchange purified, dialyzed and filtered protein (II.2.3.1.3) was loaded at 1ml/min on 
a MonoQ HR 10/10 column (Amarsham Pharmacia Biotech) pre-equilibrated with at least 5 
CV of binding buffer (30mM Tris, pH 8.0, 20mM NaCl, 2mM DTT, 2mM EDTA and 2mM 
benzamidine-HCl). After washing with 8 CV of binding buffer, the protein was eluted with 
20 CV linear gradient from 0.02M to 0.6M NaCl (30mM Tris, pH 8.0, 2M NaCl, 2mM DTT, 
2mM EDTA and 2mM benzamidine-HCl) at a flow rate of 0.6ml/min. 
II.2.3.1.5 Size-exclusion chromatography 
 
Anion-exchange purified protein (II.2.3.1.4) was concentrated to an appropriate volume 
using Centricon 20 plus concentrators (Amicon) and loaded on a Superdex 75 Hiload 16/60 
column (Pharmacia). The isocratic elution was performed at 0.5ml/min in 20mM Tris, pH 
8.5, 20mM NaCl, 0.5mM EDTA and 1mM DTT. The column was calibrated in the 
respective buffer with aprotinin (6.5 kDa), cytochrome C (12.4 kDa), carbonic anhydrase (29 
kDa), BSA (66 kDa) and dextran blue  (2000 kDa) as molecular weight standards (Fluka). 
II.2.3.2 Purification of the cytoplasmic M12-VH domain 
 
II.2.3.2.1 M12-VH domain inclusion bodies 
 
The bacterial pellet (II.2.2) was suspended in resuspension buffer 50mM Tris, pH 8.0; 
500mM NaCl; 20mM MgSO4; 2mM CaCl2; 2mM benzamidine-HCl containing 0.5mg/ml 
lysozyme and 1U/ml of benzonase-II. The suspension was incubated on ice for 1hr. Triton-
X100 was added to the final concentration of 1% (v/v) and the suspension again incubated 
for 1hr on ice. The suspension was sonicated (Braun Biotech Sonicator) with 0.5 repeating 
cycle using a power level of 50W. The sonication was performed for 30 sec on ice bath with 
intermittent cooling of 5-6min. After sonication, the suspension was centrifuged at 25,000xg 
for 30min at 4°C and the supernatant kept separately. The pellet was washed twice with 
washing buffer (resuspension buffer containing 1% (v/v) Triton-X100 but no lysozyme). 
Then, the pellet was resuspended in 50mM Tris, pH8.0; 100mM NaCl; 6M guanidine-HCl 
and incubated for 1hr on ice with intermittent vortexing. The insoluble material was removed 
by centrifugation at 25,000xg for 30min at 4°C. The supernatant was loaded on Ni-NTA 
column, pre equilibrated with equilibration buffer (50mM Tris, pH 8.0; 500mM NaCl; 5mM 
imidazole; 6M guinidine-HCl; 2mM benzamidine-HCl). The column washed with 
equilibration buffer followed by washing with a linear gradient of 25CV of equilibration 
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buffer without guanidine-HCl. The protein was eluted with 15CV of 50mM Tris, pH 8.0; 
500mM NaCl; 250mM Imidazole; 2mM benzamidine-HCl. 
II.2.3.2.2 Soluble M12-VH domain purification 
 
The bacterial pellet (II.2.2.1) was thawed on ice and subjected to lysis in buffer made up of 
25ml of 25mM Tris, pH7.5; 500mM NaCl; 5mM imidazole; 2mM benzamidine-HCl; 
mixture of protease inhibitors (Roche, 1mg/ml each of aprotinin, leupeptin, pepstatin, 
100mM PMSF), 1U/ml benzonase-II and 1mM of lysozyme. After incubation for 4hrs on 
ice, the suspension was sonicated as in II.2.3.2.1. After sonication, the suspension was 
centrifuged at 18000xg for 30min at 4°C. The supernatant was loaded on 0.5ml of Ni-NTA 
resin column (II.2.3.1.2). The column was washed with 8 CV of wash buffer (25mM Tris, 
pH7.5; 500mM NaCl; 20mM imidazole; 2mM benzamidine-HCl). The protein was eluted 
with 5 CV of elution buffer (25mM Tris, pH7.5; 500mM NaCl; 500mM imidazole; 2mM 
benzamidine-HCl). 
II.2.4 Protein analysis 
 
II.2.4.1 Concentration and dialysis 
 
Small samples were concentrated using ‘NanoSep or MicroSep’ concentrators (Pall Filtron, 
Dreieich, Germany). Larger samples were concentrated in a stirred cell (Millipore) under N2 
gas pressure (6bar). In all cases, a membrane with molecular weight cut-off (MWCO) of 
10kDa was used. 
Buffer exchange between chromatographic steps or after purification was performed 
in a classical way by using the ServaporTM (Serva Electrophoresis GmbH, Heidelberg) 
dialysis tubing (diameter 16mm and 26mm, MWCO-10 kDa). 
II.2.4.2 Protein quantification 
 
The concentrations of the proteins were determined in duplicate on the assumption that an 
O.D.280nm of 1.0 is approximately equal to 0.7mg/ml of scFv using a single beam 
spectrophotometer (Eppendorf, Germany). 
The BCA protein assay Kit (Pierce) was also used to determine the concentrations of 
purified proteins according to the manufacturers protocol using bovine serum albumin (BSA) 
as standard. The Pierce BCA protein assay is a detergent-compatible formulation based on 
bicinchoninic acid (BCA) for the colorimetric detection and quantification of proteins (Smith 
et al., 1985; Sorensen and Brodbeck, 1986). This method combines the reduction of Cu+2 to 
Cu+1 by proteins in an alkaline medium with a sensitive and selective colorimetric detection 
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of cuprous cations (Cu+1) coupled with bicinchoninic acid (Wiechelman et al., 1988). The 
standard curve was prepared in an appropriate solvent for every assay. 
II.2.4.3 SDS-PAGE and IEF 
 
Proteins were electrophoretically separated by SDS-PAGE (Laemmli, 1970, Ausubel et. al., 
1998) by using the Mini Protean II system (BioRad) and self-cast 12% gels at 150V for 60 
min. Before loading onto the gel, the samples were boiled with 4µl of 3x Laemmli loading 
dye buffer for 3-5min [for 10 ml buffer - 2.4 ml Tris-Cl (1M) pH 6.8, 3 ml SDS (20.0% 
w/v), 3 ml Glycerol (100.0%), 1.6 ml β-mercaptoethanol, 0.0006 % (w/v) bromophenol blue 
dye (stored at –20°C)]. The protein bands were detected after staining the gel with 
Commassie brilliant blue R250 (0.1% (w/v) in destaining solution) for 30 min at room 
temperature under constant rocking. The gel was destained until the protein bands become 
clearly visible in destaining solution [methanol (10% v/v); glacial acetic acid 10% (v/v)]. 
The SDS electrophoresis buffer used was 25mM Tris, pH 8.3; 192mM glycine; 0.1% (w/v) 
SDS. Protein Marker M12 (Invitrogen) was used as reference. 
For iso-electric focusing (IEF), Phast IEF gels (pH 3-9) were used. Electrophoresis and 
staining procedures for the Phast-system were used according to protocols supplied by the 
manufacturer (Amersham Pharmacia Biotech). The following buffers were used for casting 
the gels:  
   4x Separating gel Buffer* (100ml) 
   2M Tris-HCl, pH 8.8              75.0 ml 
   10% (w/v) SDS           4.0 ml 
   de-ionized water              21.0 ml  
   4x Stacking gel Buffer* (100ml) 
   1M Tris-HCl, pH6.8              50.0 ml 
   10% (w/v) SDS         4.0 ml 
   de-ionized water              46.0 ml 
* Both buffer solutions are stable for months in the refrigerator. 
The calculation for an X% separating gel was performed using the formula: 
 Acrylamide solution      X/3 ml 
[30% (w/v) acrylamide, 0.8% (w/v) bis-acrylamide] 
4x Separating gel buffer    2.50 ml 
deionised water     (7.5- X/3) ml 
10% (w/v) ammonium persulphate   50.0 µL 
TEMED       5.0 µL 
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The 5% stacking gel (2x) was prepared as follows: 
   Acrylamide solution       0.67 ml 
   4x Stacking gel buffer        1.00 ml 
   deionised water       2.30 ml 
10%  (w/v) ammonium persulphate   30.0 µL 
TEMED        5.0 µL 
II.2.4.4 Western blotting 
 
Immuno-blotting was performed essentially as described by Towbin et al., (1979). Protein 
samples were subjected to SDS-PAGE (II.2.4.3) and electro-blotting transferred protein to a 
Hybond CTM nitrocellulose membrane (0.45µm) (II.1.2) at a constant current of 200mA for 
55 minutes by using the transfer buffer [25mM Tris-HCl, pH8.3; 92mM glycine; 20% (v/v) 
methanol]. The blot was blocked with 1xPBS (pH 7.4; 137 mM NaCl; 2.7mM KCl; 8.1mM 
Na2HPO4x2H2O; 1.5mM KH2PO4) containing 5% (w/v) skimmed milk powder (Marvel) for 
30min. The blot was probed with a primary antibody for 45min (murine monoclonal 
antibody anti 9E10, which recognizes the c-myc tag or murine monoclonal anti-Histidine 
antibody which recognizes the histidine tag; each in 1:4000 dilution of a 1.5mg/ml stock 
solution in 1xPBST). Bound primary antibody was detected with alkaline phosphatase 
labeled secondary antibody for 45min (goat anti-mouse mAb in 1:4000 dilution of 1.5mg/ml 
stock solution; Dionova). Alkaline phosphatase activity was visualized upon addition of 
NBT substrate (Pierce) prepared in AP-buffer. Washing and dilutions were performed using 
the 1x PBST, pH 7.4. 
Sufficient amount of crystals were collected from the hanging drops and centrifuged 
at 500xg for 1min. The crystal pellet was washed twice with 10µl of 50mM Tris, pH 8.0. 
The crystal pellet and supernatant were stored overnight at 4°C and then boiled for 3-5 min 
with an appropriate volume of protein loading dye buffer before loading on SDS-PAGE 
(II.2.4.3) for western blotting. 
II.2.4.5 Silver staining 
 
For silver staining, the silver stain Plus kit (Bio-Rad Laboratories Inc., USA) was used. 
Briefly, the manufacturers procedure is as follows: after gel electrophoresis, the gel was 
washed in 200ml of de-ionized water for 15min with gentle agitation and then incubated for 
20 minutes in fixative enhancer solution [reagent grade methanol, 50% v/v; reagent grade 
acetic acid, 10% (v/v); fixative enhancer concentrate, 10% (v/v) and deionized water, 30% 
(v/v)]. The gel was rinsed twice for 20min with 400ml of deionised water with gentle 
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agitation. The gel staining solution was prepared as follows: 35ml of deionised water was 
taken in a clean beaker and 5ml of silver complex solution was added, followed by the 
addition of 5ml of reduction moderator solution and 5ml of image development reagent. All 
solutions were mixed well. In this mixture, 50ml of development accelerator solution was 
added just before gel staining. Then, the mixed solution was added to the gel-containing 
vessel. The gel was allowed to develop in the dark until the protein bands were stained. The 
staining reaction was stopped by placing the gel in 5% (v/v) acetic acid solution for at least 
15min. Finally; the gel was rinsed twice in deionised water for 5 minutes. 
II.2.4.6 Discontinuous non-denaturing electrophoresis 
 
Native gel electrophoresis was performed as SDS-PAGE (II.2.4.3) without SDS in 
separating and stacking gel buffer (Schägger et al., 1994). The sample-loading buffer 
included 25ml Tris-HCl (0.5M), pH 6.8; 20ml glycerol (100% v/v); 1mg (w/v) bromophenol 
blue dye. The separation of the protein was performed at a constant current of 100mA for 4-5 
hrs using the native gel electrophoresis buffer (25mM, Tris base; 192mM, glycine). 
The crystals were collected under the microscope, centrifuged at 400xg for 3min and 
the supernatant collected separately. The crystallized pellet was dissolved in an appropriate 
volume of buffer 50mM Tris, pH8.5. 8µL of dissolved crystal pellet were mixed with 5µL of 
2x non-denaturing sample loading buffer dye and then electrophoresed on a 12% non-
denaturing discontinuous gel at 100mA constant current for 5hrs. 
II.2.5 Stability analysis 
 
The stability of the gel filtration (II.2.3.1.5) purified scFvM12 in 20mM Tris, pH (7.5, 8.0 
and 8.5); 20mM NaCl; 0.5mM EDTA and 1mM DTT was studied as a function of pH, 
temperature and salt concentration. Sodium chloride was added to scFvM12 solution to a 
final concentration of 100mM. Different pH solutions with and without added salt were 
incubated at 4°C and room temperature for 60-120 days. The stability of the protein was 
checked through silver staining and MALDI-TOF mass spectrometry. 
II.2.6 Mass spectrometry 
 
The protein sample was dialysed against 5mM Tris, pH 8.0 and the dialyzed sample was 
mixed with the MALDI-TOF matrix solution [10mg/ml sinapinic acid, 50% (v/v) 
acetonitrile, 0.1% (v/v) trifluoroacetic acid], so that the final concentration of the protein 
should be in the range of 5-10µmole. A 1.0µL of the mixture was placed on the MALDI-
TOF target and allowed to dry at room temperature. The molecular mass was analyzed using 
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a MALDI-TOF mass spectrometer (Tof spec 2E, Micromass UK Limited, UK) in its linear 
mode. 
For electrospray mass spectrometric (ESI-MS/MS) analysis, the SDS-PAGE 
separated bands were excised from the gel. The excised bands were reduced with 10mM 
dithiothreitol in 0.1M NH4HCO3. After reduction the bands were alkylated with 55mM 
iodoacetamide in 0.1M NH4HCO3 at room temperature for 20min in dark. The alkylated 
protein was washed with 200µL of 0.1M NH4HCO3 for 15 min. The gel particles were 
suspended by spinning. The suspended gel particles were rehydrated at 4°C in the digestion 
buffer 50mM NH4HCO3, 5mM CaCl2 and 12.5ng/µL of trypsin for 30-35min. The sample 
left at 37°C overnight after covering the gel pieces with the rehydration buffer without 
trypsin. After overnight typtic digestion, the gel particles washed in 10-15µL of 25mM 
NH4HCO3 at 37°C. After spinning, acetonitrile equal to 1-2 times volume of gel particles 
was added and the mixture incubated at 37°C with shaking for peptide extraction. In the 
supernatant 40-50µL of 5% formic acid was added and the mixture vortexed for 15min. at 
37°C. The extraction was repeated twice and the resulting supernatant mix was dried in a 
vacuum centrifuge. The vacuum dried powder dissolved in distilled water having 5% formic 
acid and 30% acetonitrile. 1-2µL of the dissolved peptide mixture was subjected to ESI-
MS/MS analysis (Micromass UK Limited, UK). 
II.2.7 Flow cytometric analysis 
 
The stability and qualitative functionality of the scFvM12 was determined by flow 
cytometric (FACS) analysis. Human breast cancer cell lines COS and MDA MB231 were 
purchased from the American Type Culture Collection (ATCC, Bethesda, USA). The cell 
lines were maintained at 37°C with 5% (v/v) CO2 in RPMI 1640 medium (Gibco BRL) 
supplemented with 10% (v/v) foetal calf serum (FCS). 
The scFvM12 (10µg) and scFvH10 (10µg, as negative control) was incubated with 
approximately 5x106 cells. The scFvM12 and the scFvH10 (as negative control) bearing the 
c-myc tag were detected with the murine monoclonal anti9E10 antibody (7.5µg), followed 
by an anti-mouse Fc specific phycoerythrin conjugated  (Fab’)2 antibody fragment (Jackson 
Immunoresearch). The fluorescence intensity was analyzed with a flow cytometer (FACScan 
instrument from Becton-Dickinson) and the mean fluorescence intensity was determined on 
a log scale. All incubations were carried for 30 min out on ice. Every incubation step was 
followed by a wash step, using ice-cold 1xPBS and cells sedimented at 500xg at 4°C. 
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II.2.8 M12-VH domain generation 
 
Proteins are often composed of several individual domains connected by relatively 
unstructured linker domain. The reduction of a multidomain protein into its individual 
domains through proteolysis provides a mechanism for structural characterization of the 
protein. Limited proteolysis has been used either in the improvement of protein crystal 
quality (Nieves-Alicea et al., 1998) or to crystallize the number of other conformationally 
heterogeneous proteins (McPherson et al., 1990 and Chitarra et al., 1995). Proteolytic 
clipping of the scFv linker region is a useful technique for the crystallization of scFv’s 
domains. It would be more challenging and interesting to generate the single antibody 
domains for crystallization without using the recombinant DNA technology. In this thesis, 
the in-drop limited proteolysis was used to generate and crystallize the single antibody 
domain of scFvM12. 
Single antibody domain (M12-VH) of scFvM12 antibody have been generated through 
limited in-vitro proteolysis using low concentration of broad-spectrum and non-specific 
proteases at 4°C and 17°C. Three proteases were screened to digest the scFvM12 antibody at 
1:1000 molar ratio (protease:protein) for generating the isolated single antibody domain. The 
enzymes used in the study were subtilisin Carlsberg [from B. licheniformis (Sigma), which 
has preference for large uncharged residues], thermolysin [from B. thermoproteolyticus 
rokko (Sigma), which cleaves preferentially before Leu residues] and ProteinaseK (from 
Tritirachium album, Qiagen), which cleaves peptide bonds mostly after the carbonyl group 
of N-substituted hydrophobic aliphatic and aromatic amino acids]. 
For M12-VH domain generation, as shown later on by mass spectrometric analysis, 
the scFvM12 (in 50mM Tris, pH 8.5; 20mM NaCl; 1mM DTT and 0.5mM EDTA) was 
buffer exchanged to 20mM Tris, pH7.5. Buffer exchanged scFvM12 solutions (8 to 13.5 
mg/ml), were supplemented with as follows: 
A. subtilisin Carlsberg was added in 1:100 molar ratio (protease:protein) just before 
setting the hanging drops. 
B. thermolysin was added in 1:50 molar ratio (protease:protein). Zinc chloride (ZnCl2) 
was added to a final concentration of 1µM to the mixture, since thermolysin activity is Zn2+ 
ion dependent. The mixture was incubated at room temperature for 30min before setting up 
the trials using the sparse matrix screen (Hampton Research) at 22°C. 
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II.2.9 Crystallization 
 
II.2.9.1 Hanging drop method 
 
The general aspects of the crystallography are dealt briefly in appendix (page 158). 
Conditions for the crystallization of the antibody fragments were screened at 4°C by the 
sparse matrix approach (Cudney et al., 1994) using the hanging-drop method (McPherson, 
A., 1982) in 24-well VDX Linbro plates (Hampton Research). A 3µL protein drop was 
suspended on silanized glass cover slips (22mm diameter, Hampton Research) and inverted 
over 500µL of reservoir solution and sealed using silicone grease coated on the periphery of 
the wells. 
II.2.9.1.1 M12-VH domain crystallization 
 
Preliminary crystallization for M12-VH domain was screened by using the ‘Crystal Screen I 
& II’ (Hampton Research) and sodium malonate screen. The M12-VH domain was generated 
in the hanging drop as described in II.2.8. The initial crystal conditions were optimized as 
follows:  
A. The M12-VH crystals generated after subtilisin treatment in 100mM MES, pH6.5, 
10mM ZnSO4, 25% (v/v) PEG 550monomethylether, 4mM DTT and 0.04% (v/v) NaN3. The 
condition was optimized and improved by changing the following variables: 
Protein concentration (at 4°C): The protein to well buffer (v/v) ratio was changed 
from 1:1 to 1:2 & 2:1 to observe the effect of the difference in the rate of vapor 
diffusion on the crystal morphology. 
pH screening: The pH is a major variable in the crystallization of proteins; therefore, 
for the desirable pH screening, the buffers having their pKa value close to the 
desirable pH were chosen. 
At 4°C: The screening was performed around the initial screen pH value of 6.5 
at pH intervals of 0.5 units. Sodium citrate at pH 4.0, 4.5, 5.0, 5.5, MES at pH 
6.0, 6.5, MOPS at pH 7.0, HEPES at pH7.5 and Tris at pH8.0 and 8.5 were 
used respectively at a concentration of 100mM. 
At 17°C: The pH screening was performed using MES (100mM) at pH 6.0 to 
6.5 and Tris (100mM) at pH 8.0 to 8.5 with an interval of 0.1 units 
respectively. 
PEG screening (at 4°C): PEG is an important precipitant in the development of the 
crystals. Therefore, by varying the composition of PEG, it is possible to manipulate 
the crystal morphology and its quality. 
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The percentage of PEG 550MME was changed to observe its effect on crystal 
formation. The concentration (% v/v) was changed from 5.0 to 60.0 at 5 unit intervals. 
Higher molecular weight PEG’s was tested instead of PEG 550MME to obtain 
bigger mono-crystals. The PEG’s tested were PEG 750MME, PEG 1000, PEG 1500, 
PEG 3000 PEG 5000 and PEG 8000. 
Zinc sulfate screening (at 4oC): The effect of zinc sulphate effect at concentrations 
ranging from 0 to 100mM was screened at 10mM intervals. 
Effect of subtilisin: Since the cleavage of the scFvM12 antibody is a function of both 
the incubation time and the concentration of the protease, these variables were 
considered for improvement of the crystal morphology and their quality. 
Effect of metal compounds: It has been observed that different metal ions not only 
induce the crystal formation but also have the ability to change their appearance. 
Therefore, zinc sulfate was substituted with other divalent metal ions such as lithium 
sulphate, magnesium chloride, cadmium chloride, and cobalt chloride to study their 
influence on crystal morphology. 
Effect of additives: In addition to their inherent influence, viscous additives like 
glycerol might be helpful in the production of more symmetrical crystals by slowing 
down the rate of vapor diffusion and drop super saturation. The generation of crystals 
in the presence of glycerol can be further useful due to the cryo-protectant effect of 
glycerol. The glycerol concentrations added to the reservoir solution were ranged 
from 5%-50%  (v/v) at 5% (v/v) intervals. 
N-octyl-β-D-Glucopyranoside is considered a mild detergent, which has been 
proven to be especially useful in the crystallization of hydrophobic proteins by 
exerting solubilizing effects. The M12-VH fragment has a strong hydrophobic 
interface, which usually interacts with the VL domain in the scFv’s. This detergent 
was used at 20mM concentration to improve the quality of the M12-VH fragment 
crystals. 
B. The M12-VH crystals generated by thermolysin treatment of scFvM12 in 100mM 
HEPES pH7.5, 2.0M ammonium sulphate, 2.0% (v/v) PEG 400 and 0.04% (v/v) NaN3. This 
condition was optimized as follows:  
pH: HEPES buffer (100mM) of variable pH i.e. 7.2, 7.4, 7.6, 7.8 was used. Sodium 
acetate (100mM) was used for pH6.2 and 6.8. 
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Precipitant type and concentration: The PEG 400 concentration was varied form 
1.0 to 6.0 at 2.0% (v/v) intervals to improve the crystal quality. The effect of PEG 
550MME at 0.5%, 1.0%, 2.0%, 5.0% (v/v); instead of PEG 400 was also investigated. 
Salt concentration: Ammonium sulphate concentration was varied from 1.0M to 
1.8M at 0.2M intervals. 
Protein to protease ratio: The thermolysin was added to scFvM12 solution in 100:1, 
200:1 and 400:1 molar ratio (protein:protease) and incubated for 30 min at room 
temperature before setting the hanging drops at 17°C. 
Buffer: Tris-HCl (100mM) was used at pH 7.2, 7.4 and 7.8 instead of HEPES buffer 
to study the effect of buffer on the crystal quality. 
C. Sodium malonate screen: Sodium malonate has been recently shown to be as an 
effective reagent in the crystallization of many different proteins (McPherson, A., 2001). 
M12-VH fragment crystallization has been tested in sodium malonate at pH 6.5, 7.5 and 8.5. 
Since the saturation of sodium malonate is temperature and pH dependent, the sodium 
malonate solution was separately saturated at room temperature for different pH values. 
II.2.9.1.2 scFvM12 crystallization 
 
Preliminary crystallization screening of the scFvM12 using the Crystal Screen I, II and the 
ammonium sulphate grid screen (Hampton Research, CA, USA) produced either micro 
crystals or micro needles.  The following conditions:  
I 100mM Tris pH8.0, 1.5M LiSO4, 4mM DTT, 0.04% (w/v) NaN3. 
II 100mM Sodium citrate pH 5.0, 1.6M ammonium sulphate, 4mM DTT, 0.04% (w/v) 
NaN3.  
were optimized to get the improved crystals at 4°C, 17°C and 25°C. 
A. Optimization of condition II.2.9.1.3.I 
Initially at 4°C, few sea urchins like crystals were observed after 4-5 days of incubation. The 
following parameters were varied to improve the crystal quality - 
Effect of pH and LiSO4 concentration: Trials were setup at different pH values pH 
5.0 (100mM sodium citrate), pH 6.5 (100mM MES), pH 7.0 (100mM MOPS), pH 7.5 
(100mM HEPES), pH 7.8, 8.0, 8.2 and 8.5 (100mM Tris) and salt combinations. The 
LiSO4 concentration was varied from 0.8M to 1.6 M at 0.1M unit intervals. The pH 
value was also optimized by using different buffers such as MES (6.0 and 6.5), MOPS 
(7.0), HEPES (7.2, 7.4 and 7.6) and Tris (7.8 and 8.5) for the condition: 1.5M LiSO4; 
10mM hydroxyectoine; 4mM DTT; 0.04% (w/v) NaN3 at 4°C. 
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Effect of compatible solutes: In general, compatible solutes enhance the solubility of 
the proteins. Since, the scFv’s have the tendency to undergo multimer formation 
during storage, compatible solutes were added to reduce this phenomenon in hanging 
drops. The compatible solutes added to the hanging drops in buffer [100mM Tris 
pH8.0, 1.5M LiSO4, 4mM DTT, 0.04% (w/v) NaN3] were betaine (0.25, 0.5, 0.75 & 
1M), mannose (0.25, 0.5, 0.75 & 1M) and hydroxyectoine (25, 50, 75 & 100mM). 
The LiSO4 salt concentration was also optimized for 100mM HEPES pH7.6, LiSO4 
[0.5M, 1.0M, 2.0M and 2.5M), 10mM hydroxyectoine, 4mM DTT, 0.04% (w/v) 
NaN3] at 4°C. 
B. Optimization of condition II.2.9.1.3.II 
The ammonium sulphate screening (Hampton Research) of scFvM12 (~5.00 or 10.0 mg/ml) 
resulted in micro-crystals at 4°C and 25°C. The following parameters were optimized to 
improve the crystal quality: 
Alteration of pH and salt: Different combination of pH and ammonium sulphate 
concentration was used. The pH of sodium citrate buffer was varied from 4.6 to 5.2 at 
0.2 unit intervals, while the concentration of ammonium sulphate were altered up to 
0.6, 1.0, 1.2, 1.4, 1.6, 1.8 and 2.0M by changing one variable at one time. 
Effect of buffer: Sodium citrate buffer was replaced with HEPES (100mM) at pH 
7.4, 7.6, 7.8 and Tris (100mM) at pH 8.0, 8.2 and 8.4 with 0.6, 0.8, 1.0 and 1.2M 
ammonium sulphate. 
Effect of the sodium citrate concentration: The sodium citrate concentration at pH 
5.6 was varied from 0 to 100mM at 10mM interval. 
Effect of additives: Glycerol (88% v/v) at 2% and 5% (v/v), hydroxyectoine at 10, 
50, and 100mM, PEG 550MME at 1%, 5%, 10%, 15% and 20% (v/v) and n-octyl-β-
glucopyranoside at 0.5% (w/v) were used as additives in 100mM sodium citrate pH 
5.6, 1.2M ammonium sulphate, 4mM DTT, 0.04% (w/v) NaN3. Different PEG types 
(300, 600, 750, 1000,1500, 2000, 3000, 5000 and 8000) at 1% (v/v), glycerol (88% 
v/v) at 0.5%, 1.0% and 1.5% (v/v), ethanol (100% v/v), dioxane at 1%, 2% and 5% 
(v/v) and ethylene glycol at 1%, 2% and 5% (v/v) were used in a 100mM sodium 
citrate pH 5.6, 1.2M ammonium sulphate, 4mM DTT, 0.04% (w/v) NaN3 buffer 
condition to improve the quality of the crystals. 
Effect of divalent metal ions: CdCl2 (10mM), ZnCl2 (10mM), CoCl2 (10mM) and 
MgCl2 (10mM) were added in 100mM sodium citrate pH 5.0, 1.2M ammonium 
sulphate, and 4mM DTT and 0.04% (w/v) NaN3 at 25°C to improve the crystals. 
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Effect of temperature: The trials were setup at 30°C and 37°C with 100mM sodium 
citrate pH5.0, 1.2M ammonium sulphate, 4mM DTT, 0.04% (w/v) NaN3. 
Effect of the Alan D’arcy oil: To reduce the rate of vapor diffusion and therefore 
slowing down the rate of drop super saturation, Al’s oil (Hampton Research) was 
layered over the well buffer (500 µL) using different volumes (100, 200, 300, 400 
µL). The oil was layered over the buffer after the buffer was mixed with the protein 
solution for setting the hanging drops. 
Sodium malonate screen: The hanging drops were setup at 17°C and 25°C in sodium 
malonate at pH 7.5 (50% saturated at RT) and 8.5 (60% saturated at RT). 
II.2.9.1.3 M12-VH and MUC1 complex crystallization 
 
Crystals of M12-VH in complex with MUC1 peptide were obtained by soaking method at 
4°C. Firstly, the M12-VH domain crystals were generated through hanging drop method by 
mixing the scFvM12 and subtilisin in 250:1 and 500:1 (protein:protease) molar ratios 
(II.2.9.1.1). This resulted in the generation of suitable M12-VH domain crystals after one 
year (III.3.4). The drop containing M12-VH domain crystals supplemented with 2µL of 
MUC1 (5mg/ml in 20mM sodium acetate, pH 5.0) and the drop was examined for any 
change in morphology for another two months. 
II.2.9.1.4 scFvM12 and MUC1 complex crystallization 
 
For crystallizing the scFvM12 in complex with the MUC1 peptide, the gel purified scFvM12 
(~10mg/ml, in 20mM Tris, pH 8.5) was mixed with synthetic c-terminal biotinylated MUC1 
peptide (20mg/ml, in 20mM sodium acetate, pH 5.0) in a molar ratio of 1:5 (protein to 
peptide) and the protein was allowed to saturate with the peptide overnight at 4oC. After 24 
hrs, the hanging drops were set up at 17°C with the mixture by using the sparse matrix 
crystal screen I and II (Hampton Research). After 5 months, the potential complex crystal 
producing conditions were identified and optimized as follows:  
A. 100mM HEPES pH 7.5, 2% (v/v) PEG 400, 2M ammonium sulphate, 4mM DTT, 
0.04% (w/v) NaN3: The condition was optimized at 17°C in terms of pH, ammonium 
sulfate concentration and polyethylene glycol types. The pH of the HEPES buffer was 
varied from 6.9 to 7.8 at 0.1 unit intervals. The ammonium sulphate concentration 
was varied from 1.0M to 2.4M at 0.2 unit intervals. The different PEG types used at 
1% (v/v) were PEG 400, 550MME, 1000, 1500 and 3000. Effect of few additives like 
glycerol (%, v/v) 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 15.0 and dioxane (%, v/v) 0.1, 0.2, 
0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 8.0 and 10.0 were also studied. 
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C. 100mM sodium acetate pH 4.6, 10mM CoCl2, 1.0M 1,6-hexane-diol, 4mM DTT, 
0.04% (w/v) NaN3: The condition was optimized in terms of sodium acetate buffer 
pH from 4.0 to 5.2 at 0.2 unit intervals, the concentration of sodium acetate at pH 4.6 
from 10 to 100mM at 10mM intervals, cobalt chloride concentration at 0.2, 0.5,1.0, 
2.0, 5.0, 8.0, 10.0mM and the concentration of 1,6-hexane-diol from 0.7M to 1.4M at 
0.1M unit interval with and without cobalt chloride (10mM). Effect of additives like 
glycerol at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5 and 4.0 % (v/v) and dioxane at 0.1, 0.2, 0.5, 
0.8, 1.0, 1.5, 2.0 % (v/v) were also studied. 
D. 100mM MES pH6.5, 50mM CsCl2, 30% (v/v) jeffamine M600, 4mM DTT, 0.04% 
(w/v) NaN3: The condition was optimized in terms of MES buffer pH from 5.8 to 7.0 
at 0.2 unit intervals, the concentration of MES buffer at pH 6.5 from 20mM to 100mM 
at 10mMunit interval, cesium chloride concentration from 0mM to 80mM at 10mM 
unit interval and the concentration of jeffamine from 5 to 50 at 5(%, v/v) intervals. 
E. Sodium formate concentration: The sodium formate concentration was varied from 
1.5, 2.0, 2.5, 3.0 and 3.5M for a 5:1 molar ratio between MUC1and scFvM12.  MUC1 
and the scFvM12 in 3:1 molar ratio trials were also setup at 3.1, 3.2, 3.3 and 3.4M 
concentration of sodium formate. 
F. Sodium malonate condition: The scFvM12 and the MUC1 peptide were mixed in a 
10:1 molar ratio and kept overnight at 4°C. Subtilisin Carlsberg was added to the 
mixture in a 100:1 molar ratio (protein mixture to protease). The 3 µL hanging drop 
was set up with 1.5µL of protein and 1.5µL of well buffer i.e. sodium malonate (50% 
saturated at room temperature) at pH 8.0 and 8.5. 
II.2.9.2 Gel crystallization 
 
Gels are very efficient media for growing macromolecular crystals (Robert et al., 1988). 
Silica gel is particularly advantageous in terms of stability and usability over a wide range of 
temperature (0-60°C) and compatible with a wide variety of precipitants and additives used 
for crystal growth. Depending upon the macromolecule and selected conditions, gels can 
reduce nucleation (heterogeneous and secondary) and sedimentation, provide additional 
stability and allow crystals to larger sizes.  
For gel crystallization of scFvM12 (~8.5mg/ml), the ‘Silica Hydrogel Kit’ (Hampton 
Research) was used. The sitting drops (5µL, Figure VI-4A) were set up according to the 
manufacturer instructions with slight a modification of the protocol at 4°C and 17°C. The gel 
was cured at room temperature for 1-2 hrs and the precipitant was allowed to absorb for 7-8 
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hrs by the silica gel. The precipitant and protein volume was 5µL and 10 µL respectively. 
The drops were setup in the following buffer conditions:  
A. 100mM HEPES pH7.5, 1.5M LiSO4, 4mM DTT, 0.04% (w/v) NaN3 
B. 100mM Tris pH8.0, 1.5M LiSO4, 4mM DTT, 0.04% (w/v) NaN3 
C. 100mM Tris pH8.5, 1.4M LiSO4, 4mM DTT, 0.04% (w/v) NaN3  
D. 100mM Tris pH8.5, 1.5M LiSO4, 4mM DTT, 0.04% (w/v) NaN3 
E. 100mM Sodium citrate pH 5.0, 1.6M ammonium sulphate, 4mM DTT, 0.04% 
(w/v) NaN3 
The gel crystallization of the MUC1 and scFvM12 complex in 5:1 molar ratio was 
performed at 17°C, using the procedure described above in the following buffer condition: 
A. 100mM HEPES pH 7.5, 2.2M ammonium sulphate, 5% (v/v) PEG 550MME, 
4mM DTT, 0.04% (w/v) NaN3 
B. 100mM Tris pH 7.5, 2.2M ammonium sulphate, 2% (v/v) PEG 550MME, 
4mM DTT, 0.04% (w/v) NaN3 
II.2.9.3 Streak seeding 
 
To improve the quality of the crystals, the streak seeding technique described by Ducruix A. 
and Giege’ R. (1999) (in ‘Crystallization of Nucleic acids and proteins: A practical 
approach’, text book, page no. 185-186) was used. Cat whiskers were defatted with 70% 
(v/v) ethanol, washed with deionised water and dried. Seeds were taken from the drop 
(40mM sodium citrate pH 5.0, 1.2M ammonium sulphate, 4mM DTT, 0.04% w/v NaN3). 
Seeds were transferred to the hanging drops, pre-equilibrated (72hrs) against 100mM sodium 
citrate pH 5.0, 0.5M ammonium sulphate, 4mM DTT, 0.04% (w/v) NaN3. The source and 
the receiving wells were resealed immediately after the transfer. 
II.2.9.4 Crystal growth in meta-stable zone 
 
It has been argued that the meta-stable zone is an optimum zone for crystal growth to avoid 
excessive nucleation and to facilitate the slow growth rate (Stura et al., 1992). Recently, a 
simple method for growing the large crystals in the meta-stable zone using the vapor 
diffusion technique was described (Saridakis et al., 2000). This method induces crystal 
growth in meta-stable zone by decoupling it from nucleation. The hanging drops of scFvM12 
(~8mg/ml) were setup at 25°C in 40mM sodium citrate pH 5.0, 1.2M ammonium sulphate, 
4mM DTT, 0.04% (w/v) NaN3. After different time intervals i.e. 0, 24, 36, 48, 56, 72, and 84 
hrs, the drops were transferred to the wells containing 40mM sodium citrate pH 5.0, 1.0M 
ammonium sulphate, 4mM DTT, 0.04% (w/v) NaN3 as well buffer. 
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II.2.9.5 Macroseeding 
 
For macroseeding, the protocol described in ‘Crystallization of Nucleic acids and proteins: A 
practical approach’ (text book, page no. 191-196) by Ducruix A. and Giege’ R. (1999) was 
used. Maintaining the humid environment around the source and recipient drops performed 
the seeding. Macroseeding is done under a dissecting microscope where the small amount of 
heat generated from the microscope stage light bulb may actually be slightly beneficial in 
increasing the humidity level around the drop. Seeds are washed in a slightly dissolving 
solution (reservoir solution having slightly low concentration of precipitant than the seed 
reservoir solution) to remove the top layer of protein of the seed; the top layer might contain 
possible defects. From the wash solution, each seed is then transferred to the protein-
precipitant drop. The seeds of the scFvM12 and MUC1 peptide complex were obtained from 
the drop grown at 17°C in 4M sodium formate buffer. 2µL of MUC1 peptide and scFvM12 
protein complex solution were mixed with 2µL of well buffer (4M sodium formate) and 
allowed to equilibrate at 17°C against 1 ml of well buffer. After 24 hrs, these drops were 
opened one at a time and seeded with few washed crystals by using a microwick. 
II.2.10 Crystal mounting 
 
II.2.10.1 M12-VH domain alone and in complex with MUC1 
 
Crystals were morphologically examined and manipulated under a stereomicroscope (Leica). 
The thin plates of the M12-VH domain were mounted on small diameter rayon loops after 
series of brief washing in reservoir solution [100mM MES pH 6.5, 10mM ZnSO4, 25% (v/v) 
PEG 550MME, 4mM DTT, 0.04% (w/v) NaN3] containing 5%, 10%, 15%, 20%, 25% and 
30% (v/v) of glycerol as cryo-protectant. The crystal was transferred in approximately 10-
20sec on goniometer head (45°) and immediately flash cooled at 100K using a nitrogen 
cryostream  (Oxford Cryosystems Ltd, UK). The crystals remained frozen in liquid nitrogen 
for one month. 
The crystals of M12-VH in complex with MUC1 peptide (II.2.9.1.3) were washed and 
flash cooled using 40%  (v/v) glycerol as cryo-protectant. These crystals remained frozen in 
liquid nitrogen for ten months before data collection. 
II.2.10.2 scFvM12 antibody fragment 
 
Crystals of scFvM12 (II.2.9.1.2) from the following conditions were flash cooled using PEG 
400 (40% v/v) and glycerol (30% v/v) as cryo-protectant (II.2.10.1) and remained frozen in 
liquid nitrogen for approximately 13 months before testing with X-rays: 
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A. 100mM NaH2Citrate pH 5.0, 1.2M ammonium sulfate and 2% v/v glycerol 
(88% v/v). Crystals started appearing after approximately one week at 
25°C. 
B. 100mM NaH2Citrate pH 5.0, 1.2M ammonium sulfate and 10mM 
hydroxyectoine. Crystal started appearing after approximately one week at 
25°C. 
C. 100mM NaH2Citrate pH 5.0, 1.2M ammonium sulfate and 1% (v/v) PEG 
550MME. Crystal started appearing after approximately 15-20days at 
25°C. 
D. 40mM NaH2Citrate pH 5.0, 1.2M ammonium sulfate and 0.5mM ZnCl2. 
Crystal started appearing after approximately 15-20days at 25°C. 
E. 40mM NaH2Citrate pH 5.0, 1.2M ammonium sulfate and 0.5mM CdCl2. 
Crystal started appearing after approximately 15-20days at 25°C. 
II.2.10.3 scFvM12 antibody fragment in complex with MUC1 
peptide 
 
Tiny crystals of the scFvM12 and MUC1 complex (II.2.9.1.4) were flash cooled using 40% 
(v/v) glycerol as cryo-protectant in the reservoir solution (3.5M sodium formate) as above 
(II.2.10.1). The crystals remained frozen for ten months before being analyzing on 
synchrotron beamline X13 (DESY, Hamburg). 
II.2.11 Data collection and data processing 
 
The frozen thin plate like M12-VH domain crystal (Figure III-14) was mounted on an X-ray 
generator (Center for Protein Engineering, University of Liege, Belgium). 125 images were 
collected on Mar345 image plate using X-ray radiation from a rotating copper anode (CuKα 
radiation at 1.542Å, Rikagu, Japan) operated at 40kV and 100mA. The spindle was rotating 
for 1° with 3 oscillations for each image in 30 minutes and a crystal to film distance was 
130cm. The crystal diffracted to a high resolution of 1.8Å. The diffraction data was collected 
using a single crystal.  
The data for frozen crystal of M12-VH in complex with MUC1 peptide (Figure III-19) 
was collected at the synchrotron beam line X13 (λmax - 0.802 Å, DESY, Hamburg), having a 
beam polarization of 0.900. In total, three crystals were tested on the beamline. The first 
crystal showed a twinning effect, while the diffraction pattern of the second crystal had 
distinct ice-rings, which indicates problems during flash cooling. The third crystal was found 
well ordered, defectless and data from this crystal was collected to 1.5Å resolution using 
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CCD detector (Bruker Nonius, Germany). The data collection was started at 55° and 
terminated at 196° using an oscillation angle of 0.5°. Completeness of the data insured by 
collecting 210 images. Due to overexposures for the low-resolution diffractions, 100 images 
at low resolution ~ 50Å were collected with a 2° oscillation angle. The crystal to detector 
distance was 130.00cm and the radiation dose was 1500 for the high-resolution data and 500 
for the low-resolution data collection.  
The diffraction data were indexed and integrated using DENZO and SCALEPACK 
(Otwinowski & Minor, 1997). The data from the different images were integrated separately 
and optimized for mosaicity, resolution, spot ellipticity and background. After optimization, 
the two datasets were merged together. The cell dimensions were refined by least squares 
methods. The collected data set for both the M12-VH fragment alone and its complex with 
MUC1 revealed that the crystal belongs to space group C2. 
II.2.12 Phasing 
 
II.2.12.1 Molecular replacement 
 
II.2.12.1.1 M12-VH domain (1.8Å) 
 
The tertiary structure of M12-VH domain was solved (by Dr. Kurt M.V. Hoffmann, refer to 
VI.4) through molecular replacement method by using the AMoRe program (Navaza, J., 
1994) incorporated into the CCP4 program suite (II.1.8). The VH fragment of the theoretical 
model (PDB code - 1H0U, Hougs et al., 1999) was used as a search model for determining 
the phases for M12-VH (1.8Å). 
II.2.12.1.2 M12-VH domain in complex with MUC1 peptide (1.5Å) 
 
The M12-VH domain structure (1.8Å) solved in-house (by Dr. Hoffmann, 2001, RWTH-
Aachen, Aachen, Germany) was used as a search model for determining phases for the M12-
VH domain in complex with MUC1 peptide (1.5Å) through molecular replacement. 
II.2.13 Model building and refinement 
 
II.2.13.1 M12-VH domain (1.8Å) 
 
The initial model obtained as a result of molecular replacement was subjected to reciprocal 
refinement and simulated annealing (Brünger et al., 1987) by using the CNS Program suite. 
The percentage of reflections used for the calculation of the Rfree was 10.0%. The refinement 
was carried out within the resolution range of 8.0-2.0Å. Atoms were removed from the 
search model if they did not correspond to atoms in the M12-VH fragment or did not fit to the 
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electron density. After this, the model was subjected to initial rounds of simulated annealing, 
using harmonic restraints. Simulated annealing was performed at 2500K with a cooling rate 
of 25K. After rigid body refinement, 2F0-FC and F0-FC electron density maps contoured at 1σ 
were prepared and visualized in the ‘O’ program (Jones et al., 1991). The resulting model 
was not suitable for electron density interpretation; therefore, the phases of the model was 
further improved by using the PHASES program (Furey et al., 1997). The resulting model 
was visualized in ‘O’ and modified accordingly by using electron density as template. 
Refinement continued for an additional ten cycles with improvements of stereochemistry, 
following the addition of the water molecules. Refinement was terminated when no peaks 
greater than 3σ were observed in an F0-FC difference Fourier map. 
II.2.13.2 M12-VH domain in complex with MUC1 peptide (1.5Å) 
 
The model building and refinement for the M12-VH in complex with MUC1 peptide 
complex was carried out by using the automated protein model building and structure 
refinement package wARP/ARP (Perrakis et al., 1999). The wARP/ARP package is based on 
a unified approach to the structure solution process by combining electron density 
interpretation using the concept of a hybrid model, pattern recognition in an electron density 
map and maximum likelihood model parameter refinement. The major drawback of the 
package is its requirements to provide the diffraction data at 2.5Å or higher resolution. The 
automated model building was performed using the initial model of M12-VH in complex 
with MUC1 peptide complex as a result of molecular replacement. Initially, 5% of the 
reflections were kept aside to observe the progress of refinement. The autotraced chain of the 
protein was docked after 7 cycles of autobuilding. Autotracing was carried out by using the 
limited depth-first alpha carbon recognition algorithm. Difference Fourier maps 2m|Fo|-D|Fc| 
and m|Fo|-D|Fc| were used to guide manual fitting of the model in the program ‘O’ (Jones et 
al., 1991). After manually observing the partial model in ‘O’, the electron density for the 
MUC1 peptide was not observed; therefore, the resulting model is regarded, treated and 
presented as M12-VH domain structure in the following results and discussion chapters. The 
refinement was performed with the REFMAC program (Murshudov et al., 1997) within the 
CCP4 suite using the restrained maximum likelihood method with a bulk solvent correction. 
In the final set of refinement, all data were included. Water molecules are located 
automatically with the program wARP/ARP (Perrakis et al., 1999). 
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II.2.14 Structure validation 
 
The overall quality of the structure was checked by using the program PROCHECK 
(Laskowski et al., 1993) and SFCHECK (Vaguine et al., 1999). 
II.2.15 Structure interpretation 
 
CDR residues were defined according to Kabat et al., (1991). Structural superpositions were 
performed with the Insight II software (Biosym Technologies/MSI, San Diego, CA, USA). 
The calculation of the accessible surface areas was performed by using the Connolly (1993) 
algorithm implemented in the Insight II software. The VH germline family assignment was 
performed by using the V-Base database (www.mrc-cpe.cam.ac.uk/vbase-
ok.php?menu=901). For the comparison of sequential and structural features of the antibody 
structures (< 2.5Å) having PDB codes: 1DLQ (Vetting et al., 2000), 1IGM (Fan et al., 
1992), 1AQK (Faber et al., 1998), 1F2X (Decanniere et al., 2000), 1HCV (Spinelli et al., 
1996), 1JTP (Decanniere et al., 2001), 1MEL (Desmyter et al., 1996) and 1VHP 
(Reichmann, L., 1996) were utilized. 
  III-RESULTS 
 58
III RESULTS 
 
III.1 Bacterial expression of scFvM12 
 
III.1.1 Small scale expression 
 
The scFvM12 antibody expression vector was made according to Wong et al., (2001), using 
pSynI (see appendix) for the periplasmic bacterial expression. The recombinant plasmid was 
isolated and transformed into E. coli BL21 (DE3) & TG1 strains. After identifying 
recombinant E. coli TG1 colonies for optimum yield of scFvM12, the conditions for 
bacterial periplasmic expression of the protein was optimized in terms of temperature, pH, 
medium type, additives, IPTG concentration to obtain maximized yields (data not shown). 
The optimum expression of the protein was observed at 28°C in 2xTy medium supplemented 
with yeast extract (3g/L) and the pH (~7.0) of the medium regulated by the addition of the 
dipotassium hydrogen phosphate (3g/L). Induction was induced with 1mM IPTG. To obtain 
the higher yield of scFvM12, the best combination of parameters in shake flasks was found 
as pH 6.8, 28°C, 1mM IPTG (final concentration), and 4-5hrs of incubation after induction. 
The yield of the protein after purification was estimated to be 0.4-0.6 mg scFvM12 per liter 
of the culture medium. 
III.1.2 Large scale expression 
 
In general, the crystallographic study needs a fairly large amount of pure protein (at least 
5mg), therefore, it was essential to scale-up the scFvM12 expression using fermentation 
technology. The large-scale bacterial expression of the scFvM12 antibody was based on the 
parameters optimized for shake flasks (III.2.1.1). For large-scale fermentation, a fixed-
volume fed-batch high-cell-density fermentation (HCDF) strategy was selected because this 
is a good alternative for the production of large quantity of recombinant proteins in small 
volume of culture maintained at high density (O.D.600nm ~60).  
For the HCDF fermentation of the antibody, synthetic modified minimal medium 
(II.1.5.II) was used. During the growth phase, the bacterial culture was maintained at 37°C. 
The fermenter was inoculated with 4% (v/v) E. coli TG1 strain harboring the pSynI bacterial 
expression vector containing the scFvM12 gene and the ampicillin resistance gene. After 
inoculation, the culture remained in the latent phase for about 2-3hrs until an increase in the 
metabolic activity of the bacteria was indicated by enhanced oxygen consumption. The 
culture was grown to an O.D.600nm ~25 (Figure III-1). From 18hrs to 23hrs, a reduced O2 
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requirement of the culture with a slight increase of the pH was observed which indicated the 
depletion of the carbon source. After 23hrs, additional carbon was fed in the form of a 50% 
glycerol solution. As soon as the feeding started, a sudden surge in O2 requirement was 
observed. The initial feeding of the culture resulted into significant increase of the culture  
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Figure III-1 HCDF fermentation profile of scFvM12. scFvM12 expressed in modified 
minimal medium (II.1.5.II) at 28°C and induced with 1mM IPTG. 
 
density up to ~50 within 6hrs. At O.D.600nm~52, the culture was induced by adding 1mM 
of IPTG (final concentration) and the temperature was reduced to 28°C. Half an hour after 
induction, the feed rate was changed to maintain the culture in a stationary phase. The 
continuous slow increase in the culture density after induction indicates the presence of 
suitable conditions for the culture growth. The rise of the pH just after induction was due to 
the culture adaptation after a long starvation. 
 
 
 
 
 
 
 
 
 
Figure III-2 Western blot analysis (II.2.4.4) for scFvM12 expressed in bacterial periplasm 
and its leakage in to the bacterial supernatant during HCDF (II.2.2.2). scFvM12 was 
separated on 12% SDS-PAGE (II.2.4.3) and transferred to nitrocellulose membrane. The blot 
was developed with anti-his antibody (1:4000 dilution). M: Pre-stained molecular weight 
marker (10µL). Lanes 1 and 2 indicates that the scFvM12 protein is present in the 
supernatant (20µL) and in the pellet (1mg, wet weight) respectively. 
 
23kDa
34kDa27kDa
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The oxygenation of the culture was controlled automatically by the synchronization of the 
stirrer speed throughout the fermentation. Foaming was controlled by the addition of 
antifoaming agent. The culture was harvested 16 hrs after induction by centrifuging for 20min 
at 5000xg.The pellet was stored at –80°C while the supernatant was kept at 4°C for protein 
purification, as the expression of the scFvM12 is leaky from the periplasm. Figure III-2 
indicates the presence of significant amounts of protein in the bacterial supernatant.  
HCDF work was carried out in co-operation with Dr. Stephan Hellwig (Fraunhofer IME, 
RWTH, Aachen, Germany) as when the scFvM12 expression was needed. 
III.2 Purification of the scFvM12 
 
Since the protein quality required for crystallization should be of highest purity (above 99%), 
three techniques namely affinity-, ion exchange and size-exclusion chromatography were 
used to purify the scFvM12. 
III.2.1 Ni-NTA chromatography 
 
The protein was extracted from the E. coli TG1 HCDF pellet by osmotic shock and loaded 
on a Ni-NTA column, where protein binding was based on the c-terminal His6 tag in 
scFvM12. The binding of the protein to the affinity column occurs as a result of formation of 
a co-ordination complex between the histidine amino acids and immobilized transition metal 
ions such as Ni2+ and Zn2+. However, the His6-tag binding strength is dependent on 
experimental conditions and can vary from protein to protein. 
        
          A                            B 
Figure III-3A Ni-NTA purification profile of scFvM12. Ni-NTA (II.2.3.1.2) loaded scFvM12 
was eluted in 50mM Tris pH 8.0, 500mM NaCl, 500mM imidazole and 2mM benzamidine-HCl 
at a flow rate of 1ml/min by using 2ml of fast flow chelating sepharose resin column having 
immobilized Ni2+ ions. 
 
Figure III-3B SDS-PAGE (II.2.4.3) analysis of scFvM12 eluates from the Ni-NTA column 
(II.2.3.1.2). Lane 1: Periplasmic extract, Lane 2: Flow-through, Lane 3: Wash, Lane 4-9 are 
the various fractions collected during 60, 70, 80, 85, 90 and 95 ml of elution volume of protein 
elution (20µL of each sample was loaded). M - Molecular weight standard (10µL of Mark 12). 
 
M    1 2   3   4    5   6     7    8    9
31kDa 27kDa
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The conditions for the affinity purification of the scFvM12 antibody were optimized (data 
not shown) and the protein purification was performed with step gradients of 5%, 8%, 10% 
and 100% of 500mM imidazole in the elution buffer (Figure III-3A). The purified protein 
was checked through SDS-PAGE (Figure III-3B). The eluted protein was still contaminated 
with low amounts of proteins of bacterial origin. These non-specific and unwanted proteins 
bind to the Ni-NTA column along with the desired proteins, presumably through surface-
accessible histidines or other amino acids present in the native molecule, such as cysteine, 
aspartate, and glutamate (Janson and Ryden, 1989). 
III.2.2 Ion-exchange chromatography 
 
The Ni-NTA purified scFvM12 antibody was further purified through ion-exchange 
chromatography. The conditions for the binding of the scFvM12 to the ion-exchange column 
were optimized in terms of ionic strength and pH (data not shown).  
The cation-exchange purification profile of scFvM12 on MonoS column at pH 4.4 
shows the appearance of four peaks A, B, C, D respectively (Figure III-4A). The peaks B, C 
and D were found positive for scFvM12 after western blotting with anti-9E10 antibody 
(Figure III-4B). 
                
                               A                             B 
Figure III-4A Cation-exchange (II.2.3.1.3) elution profile of scFvM12. 15ml of Ni-NTA 
(III.2.1) purified scFvM12 was loaded on to MonoS column and eluted at a flow rate of 
1ml/min with a linear gradient of NaCl at pH 4.4. Western blotting (Figure III-4B) of the 
different peaks A, B, C and D raveled that all of them belongs to scFvM12. 
 
Figure III-4B Western-blot (II.2.4.4) analysis for different scFvM12 eluates obtained after 
cation-exchange purification (Figure III-4A). The blot was developed with anti-9E10 
antibody (1:4000 dilution). Lane 1: Peak D, Lane 2: Shoulder to peak D, Lane 3: End of peak 
C, Lane 4: Peak C, Lane 5:  Shoulder to peak C, Lane 6: Peak B, Lane 7: Peak A, Lane 8: 
Flow through. M: 10µL of pre-stained molecular weight standard. 20µL of each sample were 
loaded on SDS-PAGE (12%). 
 
The different peaks observed during the cation exchange purification were kept separately 
and the major peak C was loaded on a MonoQ column for anion-exchange purification. 
The MonoQ purification profile of scFvM12 antibody showed the presence of distinct peaks 
1       2     3    4      5    6     7   8   M
27kDa 31kDa
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C & E and three shoulders A, B and D (Figure III-5A). The peak C was composed of 
multiple peaks, which indicated scFvM12 present in more than one form. The western-blot 
analysis with the anti-9E10 antibody indicated that the shoulders and the peaks belong to the 
scFvM12 antibody (Figure III-5B). The existence of these peaks could be explained on the 
basis of the presence of either different aggregated forms or different conformational forms 
of the protein. 
 
 
 
 
 
 
 
 
 
 
             A                 B 
Figure III-5A Anion-exchange (II.2.3.1.4) elution profile scFvM12. 20ml of scFvM12 was 
loaded on MonoQ HR 10/10 column and the bound scFvM12 was eluted with a linear gradient 
of NaCl at pH 8.0. Western blot analysis (Figure III-5B) of the different eluted peaks revealed 
that all of them belong to scFvM12. 
 
Figure III-5B Western-blot (II.2.4.4) analysis for different peaks (Figure III-5A) of 
scFvM12 eluted during anion-exchange purification. The blot was developed with the anti-
9E10 antibody (1:4000 dilution). Lane 1: Flowthrough, Lane 2: 100ml, Lane 3: 106ml, Lane 4: 
108ml, Lane 5: 110ml, Lane 6: 117ml, Lane 7: 120ml. M: 10µL of pre-stained molecular 
weight standard. 20µL of each sample loaded on SDS-PAGE (12%). 
 
The pooling of the fractions corresponding to different MonoQ purified peaks were avoided 
and each anion-exchange purified peak was subjected size-exclusion chromatography 
separately. 
III.2.3 Size-exclusion chromatography 
 
The ion exchange purified protein fractions were further purified through size-exclusion 
chromatography using the isocratic elution method in low salt buffer (II.2.3.1.5). Although, 
the possibility of protein binding to the column matrix (Superdex) can not be ruled out, a low 
salt concentration in the gel purification buffer was chosen to keep the protein ready for the 
crystallization setups just after elution. The protein elutes as a single peak during gel filtration 
(Figure III-6A) and showed a single band on SDS-PAGE, which indicates that, a major 
fraction or the whole protein is intact. The integrity of the protein was also confirmed by 
27kDa31kDa
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western blotting (Figure III-6B). The yield of the protein after gel purification was 24mg per 
kg (wet weight) of HCDF pellet. 
 
  
   A              B 
Figure III-6A Size-exclusion chromatography (II.2.3.1.5) elution profile for peak C of 
MonoQ purified (Figure III-5A) scFvM12. Anion exchange purified protein was concentrated 
(II.2.4.1) to an appropriate volume (~1ml) and loaded on a Hiload superdex 75 16/60 column. 
scFvM12 was eluted 0.5ml/min flow rate. The column was calibrated with B (bovine serum 
globulin, 66 kDa), CA (carbonic anhydrase, 29 kDa), CY (cytochrome C, 12.4 kDa) and A 
(aprotinin, 6.5 kDa) as reference (Fluka). 
 
Figure III-6B Western-blot (II.2.4.4) analysis of gel-purified scFvM12 (Figure III-6A). The 
blot was developed with anti-9E10 antibody (1:5000 dilution). Lane 1: 1µL scFvG19 
(15mg/ml) as positive control, Lane 2: 2µL of gel-purified scFvM12 (8.5mg/ml). M - 10µL of 
pre-stained molecular weight standard. 
 
III.2.4 Iso-electric focusing and mass spectrometry 
 
The identification of the purification tags through western blotting only confirms the  
 
 
 
 
 
 
 
 
 
Figure III-7 Iso-electric focusing (IEF, II.2.4.3) of gel-purified (Figure III–6A) scFvM12. M 
- 2µL of IEF Standard (pI 3-9, SERVA). scFvM12 (1µL of 13mg/ml) loaded on cathode (lane 
1) and anode side (lane 2) separately. The gel was run according to the manufacturers 
instructions (Amarsham Pharmacia Biotech). 
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integerity of the protein but it does not explain the existence of different peaks during ion-
exchange chromatography. To reveal the presence of different conformational forms of the 
protein, the gel-purified protein was subjected to iso-electric focusing (IEF), which illustrates 
the pI of the protein and also helpful in illustrating the conformational heterogeneity of the 
protein. The IEF gel (Figure III-7) showed the presence of two major and two to three minor 
bands. The presence of the two distinct bands suggests the existence of protein in more than 
one conformational state. The IEF analysis indicates that scFvM12 is acidic in nature having 
a pI around 6.5 (theoretical pI–6.16). 
The purity and the molecular weight of the gel-purified scFvM12 were determined by 
MALDI-TOF mass spectrometry (Figure III-8). The mass spectrum showed a distinct parent 
peak of 27.450 kDa, which closely corresponds to theoretical molecular weight of scFvM12 
monomer (27.478 kDa).  
 
Figure III-8 MALDI-TOF mass analysis (II.2.6) of gel-purified (Figure III-10A) scFvM12. 
10µl of gel-purified scFvM12 (2mg/ml) in 5mM Tris, pH 8.0 was used for analysis. 
 
The peak of 13729.25Da is due to the double protonation [M+2H]2+ of scFvM12 during 
measurement. The absence of the peaks corresponding to the degradation products in the 
MALDI spectrum indicates that the different forms observed in the IEF (Figure III-7) were 
based on the conformational heterogeneity. 
scFvM12 were leaked into the fermentation supernatant was purified in the same 
manner as described for periplasmic protein (data not shown). The yield of the gel-purified 
protein was approximately 7.0 mg per liter of bacterial supernatant. 
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III.3 Crystallization of antibody fragments 
III.3.1 Crystallization of scFvM12 
 
Preliminary crystallization screening for the gel-purified scFvM12 (27.47kDa) was 
performed using the crystal screens I & II and ammonium sulphate grid screen (Hampton 
Research) at 4°C, 17°C and 25°C. The initial conditions resulted either in microcrystals or 
microneedles conditions and require extensive optimization to study the effect of different 
variables on the crystal quality. The variables of the initial conditions listed in II.2.9.1.3, 
II.2.9.2, II.2.9.4 and II.2.9.5 were varied either alone or in combination. The effect of these 
alterations did not alter the rate of nucleation and the crystal quality significantly. 
The intact scFvM12 was crystallized in the form of small rods using ammonium 
sulphate as precipitating agent at 17°C (Figure III-9A). The integrity of the protein in the 
crystal form was checked through silver staining (Figure III-9B). The silver staining revealed 
that the protein was crystallized without any degradation. 
                                                 
  A         B 
Figure III-9A The rod shaped crystals of full size scFvM12 (27.45kDa) antibody grown in 
100mM sodium citrate pH5.0, 1.2M ammonium sulfate, 4mM DTT and 0.04% (w/v) NaN3 
at 17°C (II.2.91.2). The crystals appeared within 5-7 days as small needles and grew to the 
size suitable for diffraction data collection within 6-8months. 
 
Figure III-9B Study of integrity of scFvM12 in crystal form by using the silver stained 
(II.2.4.5) SDS-PAGE (12%). M - Molecular weight standard (10µL of Mark12). Lane 1: 0.3 µL 
of gel-purified scFvM12 (8.5mg/ml) was used as positive control. Lane 2: Solubilized 
scFvM12 crystals. 
 
The scFvM12 crystals diffracted very poorly (III.5.1). The probable reason could be the 
existence of profound conformational heterogeneity inside the crystallization drop.  
The functionality of the gel-purified scFvM12 (peak C of MonoQ pure scFvM12) was 
tested through FACS analysis (Figure III-10) to find out the cleavage of the linker after 
incubating the protein for an extended period of time at 4°C. The functionality of the 
scFvM12 was tested in 20mM Tris pH8.5, 20mM NaCl, 1.0mM DTT and 0.5mM EDTA. 
31kDa
21kDa 27kDa
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The active nature of the protein indicates towards the integrity of the scFvM12 with no linker 
cleavage. 
Based on functionality analysis of the scFvM12 it seems that the conformational 
heterogeneity is the major reason for the appearance of disordered scFvM12 crystals. 
Trimming the highly flexible regions such as purification tags can reduce the conformational 
heterogeneity. Using very low concentration of proteases can facilitate the trimming. 
          
                                        A              B 
Figure III-10 Flow cytometric (II.2.7) analysis for assessing the functionality of scFvM12 
antibody stored for 1.5 months at 4°C. Figure 10A & 10B showing the FACS profile of 
scFvM12 with MDA cells, which over-expresses the MUC1 antigen and with COS cell lines 
which are negative for MUC1 expression. The fluorogram shows the FACS analysis without 
any antibody (magenta), scFvH10 antibody as negative control (green) and with scFvM12 
(purple) respectively. The detection was carried out by using goat anti-mouse phycoerythrin 
conjugated F(ab’)2 fragment (Jackson Immunoresearch) which recognizes the Fc fragment of 
anti 9E10 antibody specific for the c-myc tag. 10µg of each antibody was used for the 
analysis. The slight shift in negative COS cell lines is the result of non-specific binding. 
 
III.3.2 Limited proteolysis of scFvM12 
 
To reduce the conformational heterogeneity (Figure III-7) of the scFvM12, limited 
proteolysis was performed. The observed conformational heterogeneity may be either due to 
the linker joining the two domains or the purification tags of the scFvM12. Limited in-vitro 
proteolysis of scFvM12 was performed using three non-specific and broad-spectrum 
proteases. The scFvM12 digestion profile (Figure III-11) revealed that the scFvM12 is a 
good substrate for proteinaseK. ProteinaseK digests scFvM12 completely within 6hrs while 
subtilisin and thermolysin seems to be equal in their proteolytic behavior and degrades only 
a minor fraction of scFvM12. No band accumulation proportional to the disappearance of 
undigested scFvM12 protein was observed. 
It can be predicted that the entire process is progressing in such a manner that firstly 
the protein is breaking down into its components namely the VH or VL, linker, tags and then 
or simultaneously these components are degrading in order of preferences. 
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The scFvM12 degradation rate with subtilisin and thermoylsin is much slower in 
comparison to proteinaseK; therefore, these two proteases can be helpful in reducing the 
conformational heterogeneity of the protein. Irrespective of protease, there is an appearance 
of a single band (~12kDa) during the digestion study. This band might represent either the 
VH or VL domain of the scFvM12 antibody. 
 
 
 
 
 
 
 
 
 
 
Figure III-11 SDS-PAGE (18%, II.2.4.3) showing the digestion profile of scFvM12 (27kDa) 
with three broad spectrum proteases at 22°C. 1µL of the digested sample (II.2.8) was 
loaded in each lane. The samples are loaded in order of digestion with subtilisin, proteinaseK 
and thermolysin [1:1000 molar ratio (protein to protease enzyme)] from left to right for each 
time interval. M: Molecular weight standard (10µL), Lane 1: 1µL of scFvM12 (25mg/ml) used 
as a positive control. Lanes 2, 3 & 4: digestion for 0 min, Lanes 5, 6 & 7:  digestion for 5 min, 
Lanes 8, 9 & 10: digestion for 60 min, Lanes 11, 12 & 13: digestion for 6 hrs.  
 
Since, the scFvM12 was constructed in VH- (G4S)3-VL-cmyc-his6 configuration, western blot 
analysis was performed to access the type of the fragment(s) produced as a result of  
 
 
 
 
 
 
 
 
Figure III-12 Western-blot (II.2.4.4, 18% SDS-PAGE) showing the subtilisin cleavage 
pattern of scFvM12 (27kDa) with respect to time at 4°C. Subtilisin to scFvM12 molar ratio 
was 1:100 (II.2.8). The blot was developed with anti-9E10 antibody (1:5000 dilution). M: 
Prestained molecular weight standard (10µL). 1, 2, 3, 4, 5, 6, 7 are the lanes for the digested 
samples (5µL) withdrawn at 0, 2, 5, 10, 30, 60 min, 6hrs and 24 hrs interval respectively.  
 
scFvM12 digestion with proteases subtilisin Carlsberg and thermolysin.  No band  (Figure 
III-12) was observed after the cleavage of scFvM12 with subtilisin at different intervals of 
time, which indicate either the resulting fragment is VH domain or the VL domain whose 
27kDa
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associated the marker tags had been cleaved and therefore, made it impossible to detect. 
Similar study performed by using thermolysin (data not shown). 
The single prominent band (~12kDa) generated as result of subtilisin and thermolysin 
limited proteolysis of scFvM12 was extracted from the gel and subjected to ESI-MS/MS 
analysis. The sequence determination of the peptides obtained after the MS analysis indicates 
that the bands generated, as a result of the two different protease digests, belongs to the VH 
domain of the scFvM12 (data not shown). 
Since, the scFvM12 was constructed by assembling the VH and VL domains from two 
different human phage libraries (Sheets et al., 1998) and the sequence analysis revealed that 
the VL gene sequence of the scFvM12 is nearly identical to one of the germline V-genes 
while the VH gene has undergone multiple mutations; the VH domain should dominantly 
contribute to the affinity of the scFvM12 towards the MUC1 antigen. Therefore, the 
crystallization of the VH domain of scFvM12 was performed through limited proteolysis. 
III.3.3 M12-VH domain crystallization 
 
The cleavage activity of the proteases was found as a function of enzyme to substrate ratio 
(Figure III-13). 
 
 
 
 
 
 
 
 
 
Figure III-13 SDS-PAGE (18%, II.2.4.3) showing the effect of subtilisin concentration at 
22°C on the cleavage pattern of scFvM12. 5µL of digested sample was loaded in order of 
1:100, 1:500 and 1:1000 molar ratios (protease:protein) from left to right for each time 
interval. M: Molecular weight marker (10µL), Lane 1: 2µL of scFvM12 (8mg/ml) used as 
positive control. Lanes 2, 3 & 4: digested for 0 min, Lanes 5, 6 & 7: digested for 5 min, Lanes 
8, 9 &10: digested for 60 min, Lanes 11, 12 &13: digested for 6 hrs and Lane 14: digested for 
24hrs. 
 
The ratio was chosen carefully to generate the isolated M12-VH fragment in abundance with 
in the crystallization drop so that the drop get supersaturated and forces the fragments to 
crystallize even if they are susceptible to further proteolysis.  Initially, a protein to protease 
molar ratio of 100:1 and 50:1 was selected for subtilisin digestion. 
Similar digestion study was performed to optimize the molar ratio of thermolysin and 
scFvM12 (data not shown). 
27kDa
M  1   2  3  4   5   6  7   8  9 10  11 12 13   14
31kDa
14kDa
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III.3.3.1 By subtilisin treatment of scFvM12 
 
Crystallization trials were set up at 4°C after adding the subtilisin Carlsberg protease to 
scFvM12 solution in 1:100 molar ratio (enzyme:protein) by using the crystal screen I and II 
(Hampton Research). Numerous star shaped crystals appeared in 3-5 days in 100mM MES 
pH6.5, 25% (v/v) PEG 550MME, 10mM zinc sulfate heptahydrate, 4mM DTT and 0.04% 
(w/v) NaN3 buffer. The condition was found reproducible both at 4°C and 17°C. The 
optimization of the initial condition was performed as follows: 
A. Effect of metal ions (II.2.9.1.1.A): It was observed that the absence of Zn2+ 
ion results in micro-crystals while the replacement of zinc ions with other 
divalent metal ions, such as lithium, magnesium, cobalt, cadmium certainly 
increases the crystal dimension after long time (appox. 30 days) but mostly 
resulting in the defective crystals. However, the replacement of SO42- ions with 
chloride ions i.e. ZnCl2 used in place of ZnSO4, the chloride ions shows some 
synergistic effect with zinc ions in improving the crystal quality but the crystal 
growth rate was substantially slower (30-40 days). 
B. Protein concentration effect (4°C, II.2.9.1.1.A): Change of the protein to 
precipitating buffer ratio of 1:1 in hanging drops to 1:2 and 2:1 did not affect 
the morphological symmetry of the crystals. The only noticeable difference 
was the number and the rate of appearance of the crystals. They are less in 
number and slower in growth in the 1:2 ratio by using a 2:1 ratio (v/v), grown 
within 30hrs, which is expected, due to the difference in protein concentration. 
C. Effect of pH and temperature (II.2.9.1.1.A): The morphology of the crystals 
varies with pH and temperature. The change in pH (at 4°C) towards more 
acidic conditions resulted into phase separation, skin or aggregates of tiny 
crystals while a shift in pH (at 4°C & 17°C) towards the basic conditions 
resulted in to the formation of either isolated or aggregated thin plates. 
D. Effect of polyethylene glycol (PEG): PEG 550MME concentration from 5 to 
15% (v/v) and above 40% (v/v) produced either amorphous or gelatinous 
precipitates (II.2.9.1.1.A). The rise in PEG 550MME concentration above 25 
% up to 40% (v/v) increases the rate of nucleation and resulted in multiple 
aggregates of star shaped crystals. 
E. Incubation time effect: The most critical point in the development of the 
crystals was the incubation time of the protein with subtilisin before setting up 
the trials.  It was observed that crystals developed only when the subtilisin 
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mixed with protein solution just prior to setting the hanging drops. Pre-
incubation of the protein with the enzyme resulted only either in precipitation 
or skin in the drops rather than crystals of any shape. The most probable 
reason for no crystal growth was the complete digestion of the protein by 
subtilisin as observed in the protein digestion study (Figure III-19). 
F. Effect of additives (at 4°C): 
i. Glycerol (10% v/v) resulted in the formation of isolated thin plates but 
increases the crystal growth time by a factor of ten. 
ii. n-octyl-β-D-Glucopyranoside (20mM) produced large number of 
benzene shaped small thin plates in 25-30 days. 
G. Sodium malonate screen: Recently, sodium malonate was reported as one of 
the best crystallizing substance for a number of different proteins (McPherson 
A, 2001). The trials for the subtilisin treated scFvM12 in 10%-100% 
saturation range of malonate were set up at pH6.5, 7.5 and 8.5 at 17°C at 10% 
intervals (II.2.9.1.1.A). After three weeks, the 50% saturated sodium malonate 
condition at pH 8.5 resulted in the formation of club shaped crystals growing 
lengthwise having broom like proximal end and sharp distal end. After 5-6 
weeks, the 60% saturated sodium malonate at pH 7.5 resulted in the crystals 
similar in morphology as at pH 8.5. 
M12-VH domain crystals were obtained after optimizing the temperature condition. The 
optimization of the other parameters did not affect the crystallization. After optimization, thin 
    
Figure III-14 M12-VH domain crystals (150 x 50µm; after 5-7 days) grown at 17°C in 
100mM MES pH 6.5, 10mM ZnSo4, 25% (v/v) PEG 550monomethylether, 4mM DTT, 
0.04% (w/v) NaN3 (II.2.8). The protease was added to the scFvM12 solution (20mM Tris, 
pH7.5) in 1:100 molar ratio (protein:protease) just before setting the hanging drops. The 
protein to well buffer dilution was 1:2. 
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plates like crystals appeared at 17°C by using polyethylene glycol as precipitating agent 
(Figure III-14). The collected crystals were washed several times in the reservoir solution and 
dissolved overnight at 4°C in 50mM Tris, pH8.0. 
The dissolved crystals were tested to analyse the integrity of the marker tags. 
Theoretically, the tags are a flexible portion of the antibody and therefore, most susceptible 
towards the proteolytic digestion. Furthermore, they are present at the C-terminal end of the 
scFvM12 antibody, therefore, prone to digestion. The western blot (Figure III-15) shows the 
absence of the tags upon proteolytic digestion. 
 
 
 
 
 
 
 
 
 
 
           A                                                      B 
Figure III-15 Western-blot (II.2.4.4, 15% SDS-PAGE) for solubilized VH fragment crystals 
developed with anti-9E10 antibody (II.1.6, 1:5000 dilution, A) and anti-His antibody 
(II.1.6, 1:5000 dilution, B) respectively. M: 10µL of pre-stained molecular weight standard. 
Lane 1: 2µL of scFvM12 (8mg/ml) used as positive control, Lane 2: 5 µL of dissolved VH 
fragment crystal. The crystals were collected and dissolved in 50mM Tris pH8.0 and the 
solution kept overnight at 4°C before western blotting. The difference in the marker position is 
due to the difference in gel running. 
 
 
 
 
 
 
 
 
 
 
Figure III-16 MALDI-TOF mass spectrum (II.2.6) of the solubilized crystals obtained 
after in-drop digestion of scFvM12 antibody fragment with subtilisin Carlsberg at 4°C 
and 17°C. The crystals were washed in reservoir solution and dissolved in deionized water. 
2µL of this solution (~2mg/ml) was diluted to 10µL with deionized water. 2µL of diluted 
solution mixed with MALDI matrix solution containing 0.1% (v/v) TFA (trifluroacetic acid) in 1:1 
ratio and loaded on the MALDI target. 
 
31kDa
27kDa
M    1    2
31kDa 27kDa
M    1      2
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Mass spectrometry was used to assess the identity of the crystals generated as result of 
subtilisin digestion of scFvM12. The mass spectrum of the solubilized crystals (Figure III-
16) indicated the clear peak of 12.346kDa, which is in close correspondence with the 
theoretical mass (12.348kDa) of the M12-VH domain. Therefore, the mass analysis suggests 
that the subtilisin protease cleavage of scFvM12 produced the isolated M12-VH domain 
crystals. 
The sequence of the solubilized M12-VH domain crystals was analyzed by using 
electrospray ionization tandem mass spectrometery (ESI-MS/MS; Q-tof-2TM, Micromass UK 
Limited, UK) (Figure III-17). The analysed sequence belongs to M12-VH domain. 
        
Figure III-17 ESI-MS/MS spectrum (II.2.6) of the N-terminal peptide generated after 
tryptic digestion of the solubilized crystals. bMax indicates the b-ions, representing the N-
terminal peptide sequence of the VH domain of the scFvM12 antibody fragment. 
 
III.3.3.2 By thermolysin treatment of scFvM12 
 
Trials were setup using the mixture of the scFvM12 and thermolysin (50:1 molar ratio) 
produced microneedles after 10 days. To improve the quality of the crystals, the variables 
listed in II.2.9.1.1 were altered. The change of the protein to protease molar ratio from 50:1 to 
200:1 substantially increased the duration of crystal appearance to 5-6 months and resulted in 
compact but disordered crystals (Figure III-18). These crystals undervent dissolution and 
complete cleavage after storing for some time (~1month). These solubilized crystals were 
subjected to ESI-MS/MS mass spectrometry to find out which scFvM12 domain has been 
crystallized. After sequence analysis (data not shown), it was observed that the obtained 
crystals belong to the M12-VH domain. 
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Figure III-18 M12-VH fragment crystals generated after thermolysin cleavage of 
scFvM12 antibody at 17°C (II.2.8). Thermolysin was added to scFvM12 solution (in 20mM, 
Tris, pH 8.5; 1µM, ZnCl2) in 200:1 (protein to protease) molar ratio and the mixture incubated 
for 30 min at room temperature. The crystals were grown within 5-6 months in 100mM Tris, 
pH 7.5; 1.6M ammonium sulphate, 3.0% (v/v) PEG 400, 4mM DTT and 0.04% (w/v) NaN3 
buffer. 
 
III.3.4 Crystallization of M12-VH in complex with MUC1 
antigen 
 
The crystallization of the M12-VH domain in complex with MUC1 peptide was performed 
by the soaking method (II.2.9.1.3). Firstly, M12-VH domain crystals were generated through 
protease treatment at 4°C by adding the subtilisin Carlsberg to scFvM12 in 1:250 molar 
ratio. The compact and nicely looking crystals appeared in approximately 12 months (Figure 
III-19). The MUC1 peptide was added to the drops containing the M12-VH crystals and the 
crystals remained soaked for another 2 months. During the incubation of the crystals with 
peptide, the crystals were frequently examined for any morphological change. No 
morphological changes could be observed. After 2 months, the crystals were flash cooled 
using a nitrogen cryostream. 
          
Figure III-19 Crystal of M12-VH domain (~180x60x60µm) soaked with the MUC1 peptide 
antigen (II.2.9.1.3). 
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III.3.5 Co-crystallization of scFvM12 in complex with 
MUC1 peptide 
 
The scFvM12 has affinity towards the hydrophilic epitope ‘PDTRP’ of the MUC1 mucin 
(Wong et al. 2001). Until now, several structures of either murine or humanized Fab 
antibody fragments directed against MUC1 have been solved (Dokurno et al., 1998 and 
Banfield et al., 1997). Using co-crystallization, crystallization of scFvM12 antibody in 
complex with MUC1 peptide antigen was achieved.  
During co-crystallization, protein of interest is incubated with its ligand and the 
resulting complex subjected to crystallization either directly or pre-purified through size-
exclusion chromatography. The scFvM12 was incubated with the MUC1 peptide overnight 
at 4°C and the mixture directly subjected to crystallization. Microcrystals (II.2.9.1.4) was 
observed in few preliminary screens performed by using the ‘Crystal Screen I & II’ 
(Hampton Research). Tiny but good looking crystals were collected and dissolved in non- 
 
 
 
 
 
 
 
Figure III-20 Native gel electrophoresis (II.2.4.6) of scFvM12 and MUC1 peptide complex 
crystals (II.29.1.4). M: 3µL of scFvM12 (8mg/ml) used as marker. Lanes 1, 2 & 3 refer to 
solubilized crystals taken from the conditions respectively. The collected crystals were 
centrifuged at 500xg for 4min and the crystal pellet dissolved in 15µL of 50mM Tris pH 8.5. 
8µL of solubilized protein were mixed with 5µL of 2x non-denaturing loading dye for native gel 
electrophoresis. 
 
denaturating loading dye buffer to confirm the complex crystal formation by using the native 
gel electrophoresis (Figure III-20). 
 
Figure III-21 Tiny and thin plate like crystals of the scFvM12 in complex with MUC1 
peptide (II.2.9.1.4). The scFvM12 and the MUC1 peptide were used in a 1:5 molar ratio in 
3.5M sodium formate at 17°C. 
 
27kDa
M      1                  2                  3
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The variables of the initial condition listed in II.2.9.1.4, II.2.9.1, II.2.9.3 and II.2.9.4 
were varied either alone or in combination. The effect of these alterations did not prove 
successful in increasing the size of the complex crystals. 
The pyramidal tiny thin plate-like crystals were observed in 3.5 M sodium formate 
buffer. Initially, the crystals start appearing after 40-60 days (Figure III-21) but after the 
optimization of the initial condition, the duration of crystal appearance has been reduced to 
10 days. 
III.4 Data Collection 
 
III.4.1 scFvM12 
 
The rod shaped crystals (Figure III-9A) were flash cooled and tested for diffraction on a 
Rigaku X-ray generator (Center for Protein Engineering, University of Liege). The observed 
diffraction pattern of the crystal was too poor to collect the dataset. Therefore, to collect a 
good quality dataset, the crystal growing conditions and the cryo-protectant type for the 
crystals had to be optimized. The probable reason for the poor diffraction of the scFvM12 
was the conformational heterogeneity (Figure III-13) and therefore the resulting disorder 
inside the crystal. The disordered crystals usually have either poor diffraction or they do not 
diffract at all. 
III.4.2 scFvM12 in complex with MUC1 peptide 
 
The tiny crystals (Figure III-21) of the complex were too small for data collection on a 
laboratory scale X-ray generator; therefore, these crystals were tested on synchrotron 
beamline X13 (EMBL outstation, DESY, Hamburg, Germany). These frozen crystals failed 
to diffract even using the intense X-ray beam. However, few crystals showed very poor 
diffraction, which was not sufficient to record. The most probable reason could be their 
small size or the internal disorder. 
III.4.3 M12-VH domain 
 
The M12-VH domain dataset was first collected on an in-house X-ray generator and the 
structure was solved at 1.8Å resolution with unit cell parameters a = 72.01Å, b = 38.35Å, c = 
37.57Å, α = γ = 90, β = 109.746 and R-factors as Rcryst23.54 (%) & Rfree28.69 (%). The 
refined model lacks the residues 40-43, 52-56, 93-107 and 112-113. The structure has 80 
water molecules. This structure lacks some of the CDR region residues, which are 
responsible for antigen binding. 
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Meanwhile, improved and very compact M12-VH crystals were grown (II.2.10.1). The 
frozen crystal stored in liquid nitrogen was mounted on a synchrotron beamline X13 (EMBL 
outstation Hamburg, DESY, Germany). In total three frozen crystals were tested. The first 
crystal was discarded due to the presence of ice-rings in the diffraction image. Ice-rings 
indicate the formation of ice during flash cooling of the protein crystal. Twinning was 
observed for the second crystal probably as a result of the simultaneous growth of the two 
crystals from the same nucleus (data not shown). The third crystal was well-ordered and 
diffracted to 1.5Å resolution (II.2.11) (Figure III-22). Overloading was tolerated for a first  
 
Figure III-22 Single diffraction image for the M12-VH domain collected (II.2.11) at 
synchrotron beamline X13 (DESY, Hamburg, Germany). 
 
Table III-1 Data collection statistics for M12-VH domain at 1.5Å resolution. Rmerge is 
defined in legend of Table III-2. 
Parameters Values 
Space group C2 
Unit-cell length (Å) a = 71.336, b = 37.965, 
c = 37.187 
Unit-cell angles (°) α = γ = 90, β = 109.674 
Mathew’s coefficients (Å3 Da-1) 1.92 
Solvent content (%) 35.94 
Unit cell volume (Å3) 94832.64 
Number of molecules in the 
asymmetric unit 
1 
Observed reflections 34592 
Unique reflections 13739 
Wavelength (Å) 0.802 
Maximum resolution (Å) 1.5 
Highest resolution shell (Å) 1.53 - 1.50 
Observed completeness 
         overall 
         high-resolution shell 
 
(90.7%) 
(92.9%) 
Rmerge 
        overall  
        high-resolution shell 
  
(0.047) 
(0.158) 
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dataset to collect the maximum number of unique reflections. In order to increase the 
completeness of the data at low resolution, a second set of dataset was collected at longer 
exposure times resulting in no overloads. This data was collected using a rotation angle of 2° 
in order to speedup data collection. No decay of the crystal was observed during data 
collection as a result of intense x-ray beam exposure. 
The processing of the data with DENZO/SCALEPACK indicated that the obtained 
data belonged to the space group C2. The space group was confirmed by the intensity pattern 
of the data and the absence of systematic absences for this space group. After processing, the 
data was found to exhibit good data statistics (Table III-1). The data was found to have a 
mosaicity of 0.8. 
III.5 Quality of M12-VH domain dataset 
 
The overall quality of the high-resolution dataset was evaluated by using the standard data 
quality indicators calculated per resolution shell. The overall data quality was excellent  
Table III-2 Data statistics breakdown with resolution for M12-VH domain dataset (1.5Å). 
The values correspond to the X-ray wavelength (0.802Å). *Rmerge is defined as 100Σn|<I>-
In|/ΣhklΣnIn, which is summed over all reflections, where <I> is the mean intensity of the 
reflection hkl and In is the intensity of the nth observation of a reflection hkl.  *I/σ is defined as 
<I> divided by the average error on I. 
 
 
Resolution 
shells (Å)  
 
Reflections in 
each shell 
 
Chi2 
 
Rmerge 
(%)* 
 
I/σ* 
 
Completeness 
(%) 
100.00 - 4.07 688 1.185 0.036 26.01 86.5 
4.07 - 3.23 755 1.202 0.034 33.00 97.2 
3.23 - 2.82 759 1.067 0.034 36.79 99.9 
2.82 - 2.56 770 1.141 0.037 36.60 100.0 
2.56 - 2.38 749 0.944 0.043 31.05 100.0 
2.38 - 2.24 758 1.025 0.046 30.35 100.0 
2.24 - 2.13 761 0.986 0.046 29.72 100.0 
2.13 - 2.04 758 1.154 0.053 28.13 100.0 
2.04 - 1.96 764 0.952 0.055 24.59 100.0 
1.96 - 1.89 753 1.092 0.067 21.78 100.0 
1.89 - 1.83 748 0.972 0.076 20.01 100.0 
1.83 - 1.78 749 0.831 0.084 17.34 100.0 
1.78 - 1.73 756 0.792 0.094 15.98 100.0 
1.73 - 1.69 746 0.735 0.113 14.08 100.0 
1.69 - 1.65 761 0.767 0.127 13.15 100.0 
1.65 - 1.62 740 0.773 0.150 11.31 100.0 
1.62 - 1.58 767 0.766 0.158 10.72 100.0 
1.58 - 1.55 736 0.745 0.180 9.71 100.0 
1.55 - 1.53 754 0.656 0.188 8.61 100.0 
1.53 - 1.50 745 0.651 0.214 7.26 99.5 
All reflections 15017 0.917 0.047 27.70 99.1 
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(Table III-2). In most of the resolution shells the data completeness was 100% or very close to 
it. The data collected separately for high and low resolution terms (II.2.11) were merged and 
the Wilson plot for the merged data was observed with no regions of irregularity. 
III.6 Model building and refinement for the M12-
VH domain 
 
Initial phase determination was performed through molecular replacement by using AMoRe 
(Navaza, J., 1994). The M12-VH domain structure resolved at 1.8Å was used as a search 
model (see appendix). 
The Matthew’s coefficient (VM) for M12-VH domain crystal having the space group 
C2 found to be 1.92 suggesting the presence of the single molecule in the asymmetric unit of 
the unit cell. The solvent content of the crystal calculated as 35.94%.  
After obtaining the phase information through molecular replacement, the model 
building for the M12-VH domain was performed through wARP/ARP package (Perrakis et 
al., 1999). After the whole refinement, the refined model provided the statistics listed in 
Table III-3. The side chain of the amino acid is manually fitted to the electron density by  
Table III-3 Summary of structure refinement statistics for M12-VH domain (1.5Å). 
 
Resolution range 20.00-1.50Å 
Number of unique reflections 14358 
Number of atoms refined 1024 
Average B-factor (Å2) 
                main-chain 
                side-chain 
 
16.67 
21.60 
Observation to parameter ratio 
                initial 
                final 
 
3.72 
2.99 
R-factor (%) 
               initial 
               final 
 
33.7 
15.8 
Rfree factor (%) 
               initial 
               final 
 
32.7 
19.7 
Connectivity index 0.96 
Overall figure of merit 0.8810 
Correlation coefficient 
               overall 
               free 
 
0.973 
0.947 
r.m.s. deviation 
               bond distances (Å) 
               bond angles (°) 
               torsion angles (°) 
 
0.018 
1.735° 
6.651° 
 
using the program ‘O’ in between refinement cycles. During refinement the geometry of the 
model was examined by using the program ‘PROCHECK’. After the R-factor ceases to 
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improve further, the refinement cycle stopped. 141 water molecules were added to the refined 
model along with a single polyethylene glycol molecule. 
III.7 Overall structure of the M12-VH domain 
 
The M12-VH gene belongs to the human gene family subgroup 3 (DP47) and locus 3-11 
(Tomlinson et al. 1992). The VH3 subgroup is the germline family, which is most frequently 
observed in phage-display libraries based on human genes (Sheets et al., 1998). In overall 
appearance, the M12-VH has a main-chain resemblance to other human VH fragments. The 
residue numbering scheme and CDR definitions follow the standard Kabat conventions 
(Kabat et al., 1991). The final refined model of M12-VH fragment has Rcryst of 15.8% and 
Rfree of 19.7% within the resolution range of 19.43-1.50Å. The structure has good 
stereogeometry, as expected at this resolution, none of the residues is outside of the allowed 
regions in the Ramachandran plot (Figure III-36) and it meets or exceeds all main chain and 
side chain tests of PROCHECK (Laskowski et al., 1993). The r.m.s. deviation for bond 
angles, and torsion angles is with in the acceptable range (Table III-3). The Luzzati mean co-
ordinate error for the structure is 0.20Å (Luzzati, P. V., 1952). The σA error estimate is 0.293 
Å (Read, R. J., 1986). The r.m.s. deviation is 2.54778°. The average B-factor for the 
structure is 19.39Å2. The structure had poor electron density for the side chains of the 
residues 40-43 due to an apparent conformational disorder. The electron density for the rest 
of the structure is clearly visible and well modeled.  In M12-VH domain, the electron density 
for three atoms Arg19 (NH1), Gln39 (NE2), Lys75 (NZ) was absent and distinct 
conformations were observed for residues Ser7, 12, 17, 21, 49, 50, 59, 77, 112 (OG) and 
Val12, 37(CG1, CG2) in the final structure model. The structure has 1024 atoms in total and 
141 water molecules and a single molecule of PEG500. The structure has been deposited to 
the Protein Data Base (PDB) with an accession code of ‘1T2J’.  
The M12-VH domain displays the well-characterized immunoglobulin fold, in which 
VH consists of two twisted, anitparallel β-sheets packed tightly against each other. Like many 
other VH structures, this domain also has the polypeptide backbone segments of the CDR 
loops of the heavy chains swept away and flattened against the globular body of the VH 
domain. The net effect is the production of a broad surface suitable for the antigen binding. 
The CDR-H3 loop contains series of hydrophobic side chains (TrpH96, MetH99, ValH102), 
projecting directly into the solvent. Leu-H11 and Met-H99 are the most accessible amino 
acids of the M12-VH domain with on accessibility surface area greater than 30%.  
The major portion of the hydropathic plot (Figure III-23) has negative value, which 
indicates that most of the residues are hydrophilic in nature, while some of the residues 
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especially in the CDR’s are strongly hydrophobic, as indicated by their positive values in the 
plot. Depending upon the overall theoretical hydropathic values, it can be predicted that the 
isolated protein will be more water soluble with reduced chances of undergoing precipitation 
or aggregation as observed in most of the isolated VH domains. 
 
 
 
 
 
 
 
 
 
Figure III-23 Average hydrophobicity of the M12-VH domain residues calculated by 
using the ‘Hydropathy’ program. 
 
The overall molecular surface area for M12-VH is 6443.78Å2. The figure III-30 indicates the 
surface charge of the M12-VH domain. The three CDR regions indicate the occurrence of 
non-polar residues, which are required for the maximum affinity of the antibody towards 
binding of the PDTRP epitope. 
 
 
 
 
 
 
 
 
 
 
 
Figure III-24 Surface charge potential of the M12-VH (1.5Å). The numbers indicate 
residues involved in the VH/VL interface. The red color shows the acidic amino acids 
(negative) while the blue color represents the basic amino acids (positive) and white region 
represent a neutral surface charge. The figure was prepared by using the ‘GRASP’ program 
(Nicholls et al., 1991). 
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III.8 Structure description of the M12-VH domain 
 
The M12-VH fragment structure displayed the typical immunoglobulin fold. The 
immunoglobulin fold (Ig fold) constitutes a class of β-proteins presenting a sandwich 
architecture where the strands, distributed in two sheets, are connected in a typical way.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-25 M12-VH domain structure (1.5Å). The domain possesses 10 strands, which are 
labeled according to Halaby et al., (1998). The N and C represent the N and c-terminus of the 
protein. CDR regions are labeled according to Kabat et al., (1979). The domain exhibits the 
typical beta-sandwich structure, which is characteristic for immunoglobulins. 
 
The connectivity of the strands is used to differentiate between the Ig fold and other similar 
Greek Key β-architecture. The M12-VH domain has a V-domain type β–strand topology with 
10-strands constituting the two beta sheets (Figure III-25). 
The nomenclature for the topologically identical V-type immunoglobulins is used 
(Williams et al., 1988). The β-sandwich is subdivided into a four-stranded β-sheet consisting 
of strands D, B, E, A and a six-stranded β-sheets formed by strands C, C’, C’’, F, G and A’. 
QVQLQESGGG     LVQPGGSLRL     SCAASGFTFS   NSAMSWV RQA   PGKGLEWVSS 
  |           |      | CDR-H1       |          | 
              10  20      30       40         50 
ISGSGGNTYS       ADSVKGRFTI     SRDNAKNSLY  LQMNSLRAED    TAVYYCARDW 
    |     CDR-H2      |       |    | | |        |             CDR-H3 
 52a                60      70             82abc   90 
YGMDVWGQGT   TVTVSS 
       |  |           | 
     99 101       113 
Figure III-26 Amino acid sequence of the M12-VH domain. The numbering and CDR's 
(underlined) were defined according to Kabat et al. (1991). 
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The secondary structure was assigned by using the ‘Insight-II’ program (II.1.8.II). The 
stereogeometry of the model was verified with PROCHECK program (Laskowski et al. 
1993). 
The V-domain is characterized firstly by the presence of an extra loop between strand 
C and D and secondly the occurrence of the conserved disulphide bonds. In V-related 
domains, there are about 65-75 residues between the two cysteines (Halaby et al., 1998).The 
amino acid sequence of M12-VH used for tracing the electron density map is shown in Figure 
III-26. The amino-acid sequence of the scFvM12 is given in the appendix. 
The conserved disulfide bridge (Cys-H22 and Cys-H92) in the M12-VH domain is 
right-handed spiral type (Figure III-27) and has the following dihedral angle geometry: 
 
 
 
                 
 
Figure III-27 Conserved disulphide bridge (Cys22-Cys92) of the M12-VH domain. A: VH 
domain peptide backbone chain. Green bar: Sulfur atom. SS bond length- 2.06Å. Remaining 
numbers represents the bond angle. The figure was made using the ‘O’ program. 
 
 
 
 
 
 
 
 
 
 
Figure III-28 Difference fourier (2F0-FC map, 1.5Å) map contoured at 1σ showing the 
presence of PEG500 molecule sandwiched between two hydrophobic residues. The 
figure was made with ‘O’ program. 
 
The quality of the 2F0-FC map, contoured at 1σ was very fine. Even upon refinement, the 
observed extra electron density did not allow to interpret the structure in terms of amino acids 
PEG
Typ47
Tyr97
22C C S S C C 96β
112.43°         114.34°       67.2°           110.95°              31.84° β
α α
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for residues 40-43. The coordinates of the PEG500 molecule was downloaded from the 
HICUPP database for heterogeneous residues (Uppsala Software factory, Sweden) and 
manually modeled in to the electron density by using the ‘O’ program (Figure III-28). The 
obtained electron density indicated the presence of a single molecule of PEG500.Ordered 
water molecules are generally appearing in well-defined spheres of electron density. The 
refined model of the M12-VH fragment contained 141 water molecules 
The majority of the ion-pairs found in proteins consist of two charges of opposite 
sign, the arginine was observed in unusual arrangement (Magalhaes et al. 1994). The M12-
VH domain has the ArgH66-ArgH83 interaction at the surface of the protein and is well 
hydrated. This interaction is not bridged through water molecules rather the interaction is 
surrounded by water molecules (Figure III-29). 
         
Figure III-29 Arginine-arginine (H66-H83) interaction in M12-VH domain. Arg-Arg pair is 
presented in the hydrated region. Figure prepared in ‘O’ program. 
 
III.8.1 Antigen binding loops of the M12-VH domain 
 
Mostly, the CDR region of antibodies contains non-polar and hydrophobic residues to 
interact with the antigen. Glycine residues are frequently present to allow the sharp turns 
because of the flexibility permitted to this residue due to the lack of the side chain. The 
specificity and affinity of antibodies towards antigen is a function of the canonical structure 
present in the hypervariable region, the size, shape and chemical character of its surface 
residues and their positions relative to each other. 
Water molecules within the M12-VH domain structure have been observed in 
hydrogen bonding with only CDR-H2 residues. The canonical structure classification was 
performed using the software implemented on the antibodies-structure and sequence server 
(www.bioinf.org.uk/abs/chothia.html, Martin et al., 1996). A variation exists in the groove 
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for antigen binding created by the CDR's in different antibodies. In the M12-VH domain, the 
groove is not very deep (data not shown) and the surface is more or less flat. Usually, flat 
surfaces provide reduced surface area for the antigen binding in antibodies. 
III.8.1.1 CDR-H1 loop 
 
The CDR-H1 loop packs across the top of the M12-VH domain, bridging two beta sheets. On 
the basis of sequence variation, residues 31 to 35 were defined by Kabat et al. (1979) as the 
first CDR. Structural work has shown that the region outside the beta sheet frameworks are 
able to adopt different conformation and comprises residues 26 to 32. It was shown that the 
size variations in this region involved insertions at position 31 (Chothia et al., 1992). The 
CDR-H1 size in M12-VH domain is 10 residues (H26-H35), while structurally it consists of 
only five residues (H31-H35). Three canonical structures have been observed for this region 
(Chothia et al., 1992). Of these, the canonical structure 1 is the most commonly observed 
conformation. The CDR-H1 loop in M12-VH fragment (Figure III-30) corresponds to known 
canonical structures, predictable from its sequence (Al-Lazikani et al., 1997) and is similar  
 
 
 
 
 
 
 
 
 
 
Figure III-30 CDR-H1 loop of the M12-VH domain at 1.5 Å. The dashed red lines indicate 
the hydrogen bonds. The figure was prepared by using Swiss pdb viewer (Guex et al., 
1997). 
 
to the canonical class 1/10A. The CDR-H1 loop structure is determined by a sharp turn 
around Gly-H26 and the conformation of the residues Ala-H24, Phe-H27, Phe-H29 and Met-
H34. The unique feature of this CDR-H1 loop is the presence of Ser-H32 (Chothia et al., 
1992) residue. Normally, the allowed residues at position H32 are Ile, His, Tyr, Phe, Thr, 
Asn, Cys, Glu and Asp. The Phe-H29 side chain is buried between the side chains of 
residues Thr-H28 and Ser-H30. In M12-VH domain, additional hydrogen bonds are present 
between the side chains of Ser-H32 and Ala-H33. The additional hydrogen bond stabilizes 
the CDR-H1 loop and leads to the torsion angle deviation of residues H27 and H28 from the 
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average torsion values (Table III-4). The inaccessibility of the Ser-H32 indicates the 
potential loss of its contribution on the antigen binding. 
III.8.1.2 CDR-H2 loop 
 
On the basis of sequence variation, residues H50 to H65 were defined by Kabat et al. (1979) 
as the second CDR region in VH domains.  Subsequently, it was shown that residues 56 to 58 
form the short C’’ strand and that the region showing conformational variation is limited to 
residues 52 to 56. Four canonical structures have been observed for this region. The CDR-
H2 loop in M12-VH domain has 16 residue (H51-H65) depending upon the sequence 
variability and belongs to the canonical class similar to class 3/10B having unobserved 
residues at positions H50 and H59. Structurally, the CDR-H2 loop is made up of six amino 
acids (H52-H56).  
 
 
 
 
 
 
 
 
 
 
 
Figure III-31 CDR-H2 loop (main-chain) of the M12-VH domain at 1.5Å. The dashed red 
lines indicate the hydrogen bonds. The figure was prepared by using Swiss pdb viewer 
(Guex et al., 1997). 
 
The residue 52a and 55 determine the H2 hairpin loop conformation in the VH 3 family. The 
M12-VH domain, has glycine at H52a and H55 positions, therefore, they can adopt any 
conformation (Figure III-31). The M12-VH domain has serine at H50 and H59 while the 
most allowed residues (Chothia numbering) at these positions are Gly, Thr, Tyr, Phe, Ile, 
Gln, and Val at H50 and tyrosine at H59 respectively. The main chain of the CDR-H2 loop 
adopts a Type I beta turn (Ser52 –Gly54). 
The phi and psi angles for the CDR-H2 loop show a significant deviation from the 
average values (Table III-4). The reason for this deviation is the high sequence similarity of 
the CDR-H2 loop to subclass 3C of the CDR-H2 canonical structure 3 (Al-Lazikani et al., 
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1997). The torsion angle at H54 position (82.8/6.7) is almost exactly similar to the camel 
VHH antibody (83/7, PDB code-1MEL). 
Table III-4 Deviation (bold) of dihedral angles of CDR-H1 & CDR-H2 loop residues in 
M12-VH domain from reference values. Reference values are taken from Al-Lazikani et al., 
1997. Reference values for the H2 loop belong to subclass 3B of H2 canonical structure 3. 
 
 
Reference 
values 
 
 
H1 & H2 loop of 
M12-VH Domain 
 
 
Residues 
Phi Psi Phi Psi 
27 -158 157 -155.4 170.1 
28 -88 111 -85.9 93.2 
52a -71 -177 -51.8 -41.3 
53 80 -110 -85.3 -19.5 
54 -156 32 95.1 3.7 
55 -68 180 -69.2 -20.3 
56 -57 160 -138.6 134.8 
 
The structural comparison of the CDR-H2 region from different antibodies with M12-VH 
domain indicated that the CDR-H2 region of antibody does not have much similarity 
regarding their torsion angle. The torsion angles are not only a function of the sequence 
variability but also determined by the hydrogen bonding between the different residues of the 
CDR region. In general, the insertion and deletion of one residue in the CDR regions does 
not have a profound influence on the binding affinity of the antibody towards the antigen 
(Lantto et al., 2002). 
The comparison of dihedral angles for CDR-H2 loop of high-resolution antibodies 
and M12-VH (Table III-5) indicated a deviation from all antibodies except 1VHP, which is a 
camelized human VH domain  
Table III-5 Comparison of dihedral angle values for CDR-H2 loop of high-resolution 
solved VH domains with M12-VH domain. The PDB accession codes are listed as headings 
in the Table. 1AQK is a Fab fragment; 1IGM is an Fv fragment while 1VHP is an isolated 
camelized human VH domain. The dihedral angle differences of isolated VH domains is 
highlighted. 
 
1AQK 1IGM 1VHP M12-VH Residue 
Phi Psi Phi Psi Phi Psi Phi Psi 
52 -66.9 167.9 -106.1 88.5 -83.0 147.3 -70.2 160.5 
52a -55.6 -38.1 - - 68.9 -165.8 -51.8 -41.3 
52b - - - - -46.9 -25.8 - - 
52c - - - - 143.2 -10.1 - - 
53 -100.7 3.6 49.3 -75.3 -44.0 -37.0 -85.3 -19.5 
54 78.3 7.1 -72.1 -7.8 -90.6 138.8 95.1 3.7 
55 -78.9 -18.0 74.7 37.8 -147.1 149.4 -69.2 -20.3 
56 -127.7 150.3 -83.0 -116.9 -125.2 156.8 -138.6 134.8 
 
camelized human VH fragment. It is also interesting to note that in both isolated domains the 
torsion angles of residues 53-56 are deviated significantly from the average value which 
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suggests the role of these residues either participate in some kind of bonding with the 
framework residues or interacts with the residues of the VL partner.  This shows that the 
isolation of the VH from its VL partner does have some effect on the overall constraint of the 
molecule, which is more compact due to the exposure of the hydrophobic surface to the 
hydrophilic environment. The camelization of the VH domain was also documented to 
influence the geometry of the VH domain (Riechmann, L. 1996). 
III.8.1.3 CDR-H3 loop 
 
On the basis of sequence variation, variable heavy chain residues 95 to 102 were defined by 
Kabat et al. (1979) as the third CDR region. The relations between the sequences and the 
structures of the CDR-H3 loop are not well understood as for the other CDR’s. The 
insertions in this region can be placed after residue 100 and numbered as 100a, 100b etc by 
Kabat et al. (1979). The CDR-H3 loop of M12-VH domain structurally has seven residues 
(H95-H102) but its formation is neither of the kinked type or of the irregular type but has 
more an open U-shaped like structure, which is normally only present in 10-residues long 
CDR-H3. This relatively short CDR-H3 has been observed in other antibodies (Dokurno et 
al., 1998 and Kala et al., 2002). The M12-VH has one deletion at H100 position according to 
the Kabat numbering system. The M12-VH domain did not have accessible surfaces for Asp-
H95, Gly-H98, Asp-H101 and Val-H102 residues. Therefore, hydrophobic residues are 
probably the major contributor for antigen binding. The structure of the CDR-H3 loop in 
M12-VH domain was further investigated. 
III.8.1.3.1 CDR-H3 torso 
 
Until now, 49 CDR-H3 loops have been classified (Morea et al., 1998). The CDR-H3 torso 
region is of the bulged type in M12-VH fragment, which is characterized by the presence of a 
β-bulge at residue H101 (Figure III-32). The bulge is stabilized by hydrogen bond 
interactions between the side-chain of the conserved Trp-H103 and the side chain carbonyl 
oxygen of Asp-H101. In addition, a salt bridge commonly occurs between Arg (or Lys) H94 
and Asp-H101 leading to a C-terminal β-bulge in 41 of the 49 CDR-H3 loops in what would 
otherwise be a β-hairpin (Morea et al., 1998). The conserved salt bridge is also present in the 
M12-VH CDR-H3 torso region. Smith and Xue (1997) pointed out that the first residue of the 
CDR-H3 is predominantly Gly, while the amino acid at this position is inherently variable 
based on the junctional diversity that arises during the V-D-J rearrangement (Smith et al., 
1997). They also stated that the amino acid at position 95, second to Gly, is Asp. In M12-VH 
domain, first and second amino acids are Asp-H95 and Trp-H96. Aburatani et al., (2002) 
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stated that the presence of Asp at position 95 also strengthens the interaction between VH and 
VL domains. 
 
 
 
 
 
 
 
 
 
 
 
Figure III-32 CDR-H3 loop of the M12-VH domain (1.5Å). The dashed red lines indicate the 
hydrogen bonds. Beta-bulge is stabilized by the hydrogen bond interaction between Asp-
H101 and Trp-H103. Figure was prepared by using Swiss pdb viewer (Guex et al., 1997). 
 
III.8.1.3.2 CDR-H3 apex 
 
Until now, the apices of 62 CDR-H3 loops have been classified (Morea et al., 1998) and it is 
reported that the head of the shorter loops (less then 14 residues long) has the form of a short 
hairpin. The conformation of the short hairpin depends primarily on the sequence of the 
residues within the loop and in particular on the position of the a Gly, Asn or Asp which are 
more frequently observed to have conformations with positive values of phi and psi or a Pro 
which can more easily accommodate a cis peptide (Chothia et al., 1987). In M12-VH 
fragment Gly-H98, Tyr-H97 and Asp-H101 main-chain amino groups are involved in single 
hydrogen bonding with the side-chain carbonyl oxygen of Asp-H95 while the main chain of 
Met-H99 is involved in the formation of two hydrogen bonds with the side-chain carbonyl 
group of Asp-H95 (Figure III-32). An additional electrostatic interaction was observed 
between the main-chain Gly-H98 and side-chain carbonyl oxygen of Asp-H95. As a result of 
these extensive hydrogen bonding within the apex of CDR-H3 loop, the loop is directed 
towards the VH-VL interface. 
III.8.2 Hydrogen bonding 
 
The M12-VH domain has antiparallel and mixed type of β-sheets. The antiparallel sheet 
consists of 4 β-strands having the topology (-1-2x 1) and the mixed sheet consists of 6 β-
strands having the topology (3x 1 1 –3 –1). The intramolecular hydrogen-bonding profile for 
the whole structure is documented the appendix. The structure mainly consists of anti-parallel 
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beta strands and three 310-helices (Table III-6). One inverse gamma turn is also present in the 
structure. 
 
Table III-6 β-Strand boundaries and turns. Boundaries of the beta strands are defined by 
the hydrogen-bonding patterns of the structural model and the classification of turns was 
performed on the basis of their phi/psi angles. The Table was prepared using the program 
PROMOTIF (Hutchinson et al., 1996). 
 
Element Type Boundaries 
β -Strand A  Gln3-Val7 
β -turn II Glu13-Gly16 
β-Strand A’  Gly10-Val12 
β-Strand B  Leu18-Ser25 
γ-turn Inverse Phe27-Phe29 
Helix 310 Ala28-Gly32 
β-Strand C  Met34-Gln39 
β -turn II Ala40-Lys43 
β-Strand C’  Leu45-Ile51 
β -turn I Ser52-Gly54 
β-Strand C’’  Thr57-Ser59 
β -turn I Ala60-Val63 
β -turn I Asp61-Lys64 
β -turn II Val63-Arg66 
β -turn IV Lys64-Phe67 
β-Strand D  Phe67-Arg72 
Helix 310 Asn73-Lys75 
β-Strand E  Ser77-Met82 
β-turn IV Met82-Leu82c 
Helix 310 Arg83-Thr81 
β-Strand F  Ala88-Ala93 
β-turn I Asp95 – Gly98 
β-turn IV Gly98-Val102 
β-Strand G  Thr107-Val111 
 
Table III-7 Hydrogen bonding of CDR residues to the remaining M12-VH domain 
residues. Antibody residues having atoms within 4.0Å distance to the loop residues were 
included. 
 
 
Antibody residues 
contacting the loop 
region 
Interacting Loop 
residues 
Arg-H71 
Ile-H51 
Asp-H93 
Arg-H71 
Asn-H73 
Ser-H35 
Glu-H6, Arg-H94,Trp-H103 
Phe-H29,Ser-H32 
Met-H34 
Ser-H35 
Ser-H52 
Gly-H52a 
Asp-H95, 
Gly-H98 
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Figure III-33 Secondary structure elements, relative accessibility and the hydropathic 
profile for the M12-VH domain. TT: Turn/Loops, η: Helix, β: Beta sheets, Gray star: 
Residues with alternate conformations, acc: Relative accessibility, hyd: Hydropathy, bottom 
line characters: intermolecular contacts, Green digit: disulphide bridge. The figure was 
prepared using the ENDscript program (Gouet et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-34 Two-dimensional pictorial representation of intra-molecular hydrogen 
bonding profile of VH domain. Blue colored line indicates the sequence of beta strands 
connection to each other. Brown colored arrowed lines indicate hydrogen bonds with the 
arrow pointing from the (NH) donor residue to the (CO) acceptor group. Amino-acids are 
represented by one letter code. Oval represents the helix while square indicates the beta 
strands. Amino acids are numbered sequentially not by Kabat System. The V-domain strand 
type was defined according to Halaby et al. 1998. 
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All buried polar sidechain atoms are involved in hydrogen bonds. The buried polar side chain 
atoms are all associated with some distinct conformational feature of the domain. The 
hydrogen bonds (Figure III-34) were calculated for H-O distance less than 2.5Å, with an N-
H-O angle between 120° and 180° and H-O-C angle between 90° and 150°. Ser-H25 (Oγ ) 
bond to the carboxyl oxygen of Glu-H3 stabilizing the first turn. Carboxyl oxygen of Thr-
H28 bound to main-chain nitrogen of Gln-H31 and carboxyl oxygen of Phe-H29 bound to 
carboxyl oxygen of Ser-H32 to stabilize the 310-helix turn.  
M12-VH domain exhibits all the conserved hydrogen bonds except such as side chain to side-
chain (Figure III-40): Asp-H86 and Tyr-H90, Arg-H94 and Asp-H101, side chain to main-
chain CO: Arg-H66 and His-H82a, Thr-H87 and X84. Main chain NH to side chain: X69 and 
His-H59, X75 and Asp-H72. M12-VH has Gln, while usually histidine is observed at position 
82a. In this list, X refers to positions without dominant residue preference.   
III.8.3 VH-VL interface 
 
The VL interface of the VH domains, when part of Fv fragments, is formed mainly by β-
strands C’ and G, which both include a β-bulge and the CDR-H3 loop. Within the C’ strand 
residues H44, H45 and H47 contributing most of the VL interface (Chothia et al., 1985). In 
M12-VH fragment, residue H44 is a glycine, the most frequently occurring residue at this 
position (Kabat et al., 1991) and the residue H45 is a Leu and H47 is a Trp. These conserved 
hydrophobic residues contribute significantly to the interface interaction of the VH with the VL 
domain. In most of the VL-associated VH domain, the side chain of Val-H37 and Trp-H103  
Table III-8 Comparison of the amino acids of the M12-VH domain present at the VH/VL 
interface with conserved residues for each equivalent position. Residues in blue form 
the core at the VH-VL interface. Bold residues are part of CDR regions. The number in 
superscript indicates the frequency of occurrence of the residues. 
 
Variable Heavy chain 
Kabat 
residu
e 
Numbe
r 
Conserved 
residues 
Residues 
in M12-VH 
domain 
35 H1001N636S402E184 S 
37 V2336 I200 V 
39 Q2518 K67 Q 
45 L2636 P16 L 
47 W2518 L64 Y50 W 
91 Y2149 F479 Y 
93 A2202T222V102 A 
95 Y399G375S340D340R226 D 
100 F1285M450 deletion 
103 W1469 W 
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are in contact with the VL while the Arg-H38 side-chain is buried within the VH. It has also 
been observed that the H39 makes a hydrogen bond contact with L38 residue of the at VH-VL 
interface. The M12-VH domain has all the conserved residues at the VH/VL interface except 
at position 100, which has undergone a deletion in M12-VH.  
 
 
 
 
 
 
 
 
 
Figure III-35 Antigen binding groove defined by the three CDR’s of the M12-VH domain. 
CDR-H1, -H2 and -H3 represents the three CDR regions. The arrow represents the VH/VL 
interface groove. The diagram made by using ‘GRASP’ software (Nicholls et al., 1991). 
 
The surface curvature of the whole molecule indicates the presence of a groove at the VH/VL 
interface (Figure III-35). The pocket at the interface indicates the burial of the hydrophobic 
amino acids to facilitate the VH/VL interaction. The conformations of the interacting residues 
39, 44, 45 and 47 have not undergone any change when compared to the other VH/VL 
structures. 
III.9 M12-VH structure quality assessment 
 
The M12-VH domain structure (1.5Å) has 91.8% residues in the most favored regions of the 
Ramachandran plot (Figure III-36). The rest of the residues are in the additional allowed 
regions with no outliers. The majority of the residues are found in the anti-parallel β–strands 
(Φ = -60° to 150° and Ψ = 100° to 170°; Richardson, 1981) region. The Ramachandran plot 
shows the good stereogeometry of the M12-VH domain. 
The M12-VH domain revealed an average B-factor of 16.67Å2. In M12-VH, most of the 
residues having the individual temperature (B) factors values less than 20.0Å2 as expected 
for the structure at this resolution (Figure III-37). In accordance with antibody structures, the 
B-factors were lowest in the regions corresponding to the β–strands. The variation of the 
temperature factors is in accordance with the quality of the electron density. For example, 
the polypeptide backbone and the side chains at the N- and C-terminus exhibited 
significantly higher B values than those for the rest of the VH molecule. Main chain  
H2
H1
H3
CDR-H2
CDR-H3
CDR-H1
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Figure III-36 Ramachandran plot for the M12-VH fragment (1.5Å). 
 
parameters like peptide bond planarity, alpha carbon tetrahedral distortion etc. were average 
with regard to Ramachandran plot quality assessment. A combined plot (Figure III-43) of the 
        
Figure III-37 Individual temperature (B) factor analysis and the real space correlation 
coefficient among the M12-VH residues. The ordinate indicates the residue number while 
the abscissa indicates the individual temperature factor (B) and the real space correlation 
coefficient.  
 
average main-chain B-factors and the real space correlation coefficients (Jones et al., 1991) 
confirmed that all CDR residues are structurally well ordered except the few residues in the 
framework regions e.g. H40, H70 and H103 with an average correlation coefficient of 0.85 
and an average B-factor of 16.67 Å2. 
In this structure, the side chain of few residues was absent within the electron density 
such as ArgH67, ArgH87 and LysH76. The quality of the model was checked (Table III-9) 
against the structure factors by using the ‘SFCHECK’ (Vaguine et al., 1999) program 
incorporated into the CCP4 suite of programs. 
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Table III-9 Statistics of the refined model against the structure factors calculated by 
using the ‘SFCHECK’ program. R_stand (F) is defined as (F) = <σ (F)>/<F>, B: B-factor, 
B_overall: overall B-factor, σ (B): standard deviation of the B-factor. 
 
Parameters M12-VH domain  
Volume not occupied by the 
model 
12.2% 
<B> for atomic model (Å2) 21.9 
σ (B)  (Å2) 9.07 
R_stand (F)  0.029 
B_overall (by Patterson) (Å2) 23.5 
Estimated minimal error (Å) 0.029 
<u> Luzzati plot error     (Å) 0.148 
 
III.10 Crystal packing 
 
In the C2 space group, the asymmetric unit constitutes only 1/4 of the total unit cell volume, 
and in the case of VH fragment, a single monomer is present in the asymmetric unit. Figure 
III-38 shows the packing of molecules within the unit-cell. The overall packing is tight with 
small solvent channels. The solvent content of the crystal was found to be 35.4% by 
assuming the protein density as 1.34. The dense packing of the protein in the crystal lattice 
was favorable for both high quality and high-resolution diffraction. The intermolecular 
crystal contacts formed due to the result of packing of the molecules are listed in the 
appendix. The crystal contacts are calculated for <4Å distance. 
 
 
 
 
 
 
 
 
Figure III-38 Crystal packing of Cα trace of M12-VH domain (1.5Å) in the unit cell. The 
packing is drawn in Z (0,0,0) axis. 
 
The major crystal contacts between the molecules related by symmetry involved the CDR 
residues Thr-H28, Asn-H31, Ser-H53, Gly-H55, Asn-H56, Trp-H96, Asp-H101 and Val-
H102. A contact with these symmetry-related molecules was also formed at the rim of the 
aromatic rings of the CDR residues Gly-H26, Gly-H54 and Met-H99. 
The following crystal contacts are observed commonly in the molecular packing of VH  
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domain (1.8Å and 1.5Å): 
5Gln-31Asn, 7Ser-28Thr, 10Gly-45Leu, 14Pro-15Gly, 39Gln-10Gly, 45Leu-10Gly, 
45Leu-110Thr, 55Gly-59Ser, 55Gly-57Thr, 56Asn-58Tyr, 57Thr-57Thr, 58Tyr-55Gly, 
59Ser-55Gly, 64Lys-53Ser, 64Lys-55Gly, 68Thr-70Ser, 68Thr-68Thr, 71Arg-65Gly, 
75Lys-101Asp, 83Arg-83Arg, 84Ala-74Ala, 91Tyr-11Leu, 99Met-110Thr, 99Met- 
87Thr, 99Met-88Ala, 101Asp-75Lys, 102Val-112Ser, 108Thr-99Met, 110Thr-99Met, 
112Ser-102Val 
III.11 M12-VH domain crystallization in complex 
with MUC1 peptide 
 
The attempt to crystallize the M12-VH domain in complex with MUC1 peptide did not 
proved successful.  Since the MUC1 peptide was added to a drop containing the subtilisin 
enzyme it is possible that the peptide might have been cleaved prior to binding. This  
 
 
 
 
 
 
 
 
Figure III-39 ESI-MS/MS mass spectrum (II.2.6) for the reservoir solution [100mM MES, 
pH6.5, 10mM ZnSo4, 25% (v/v) PEG 550MME, 4mM DTT and 0.04% (w/v) NaN3] from the 
wells used to grow the crystals of M12-VH domain in complex with MUC1 antigen 
(II.2.9.1.3). 
 
 
 
 
 
 
 
 
Figure III-40 ESI-MS/MS mass spectrum (II.2.6) for the hanging drops used to grow the 
crystals of M12-VH domain in complex with MUC1 antigen (II.2.9.1.3). MUC1 peptide was 
added to the hanging drops after the formation of M12-VH crystals and incubated for 
approximately 2 months. 
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possibility was explored by using the ESI-MS/MS of the mother liquor (in which the crystals 
were allowed to grow) in comparison to the well buffer solution. The ESI-MS/MS mass  
spectrum indicated the presence of peptide in the mother liquor (Figure III-40); therefore, the 
disintegration of the peptide is not responsible for the absence of binding of the peptide to 
the CDR residues of the M12-VH domain. The lack of MUC1 peptide binding to the M12-VH 
domain is explained in the next chapter (IV.2.4) on the basis of the M12-VH structure. 
III.12 Stability analysis of scFvM12 
 
The stability and the conformational homogeneity of a protein are essential for its 
crystallization. Therefore, it is a prerequisite to perform the stability analysis, to find out 
possible source(s) of heterogeneity (both macro or micro) generated in the crystallization 
drops as a result of change in temperature, pH or ionic strength. Silver staining and MALDI-
TOF mass spectrometry were used to check the protein stability at different time intervals. 
After 120 days of incubation at 4°C, the scFvM12 (~13mg/ml) showed a minor 
degradation at all the pH values (7.5, 8.0, 8.5) but interestingly, the protein aggregated 
strongly at pH 7.5 (Figure III-41).  
 
 
 
 
 
 
  A                                                  B 
Figure III-41 Silver stained (II.2.4.5) SDS-PAGE (18%, 2.4.3) analysis to study the effect 
of pH and ionic strength on scFvM12 stability at 4°C after zero  (A) and 120 days (B) of 
incubation. 2µL of 2.8 mg/ml of protein was loaded in each lane. M: Molecular weight 
standard (10µL of Mark12). Lanes 1, 2, 3 corresponds to scFvM12 at pH 7.5, pH 8.0, and pH 
8.5 respectively, while 4, 5, 6 are the lanes for the scFvM12 at pH 7.5, 8.0, 8.5 with 100mM 
NaCl. Low ionic strength was chosen to mimic the crystallization condition. 
 
Although the degradation product bands (Figure III-42, Lane 4, 5, 6) were slightly clear in 
the presence of NaCl, the ionic strength below the physiological ionic strength is not 
sufficient to disturb the hydrophobic interaction between the VH-VL fragments of the 
scFvM12. 
The protein is shows significant degradation (Figure III-42) irrespective of the pH and 
ionic strength after 60 days of incubation at room temperature, therefore, it can be concluded 
that the protein stability has direct correlation with temperature. Therefore, higher the 
temperature the stronger the degradation of the protein. 
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                    A              B 
Figure III-42 Silver stained (II.2.4.5) SDS-PAGE (18%, II.2.4.3) analysis to study the 
effect of temperature on the scFvM12 stability after incubating at 4°C (40days, A) and 
room temperature (60 days, B). 2µL of scFvM12 (2.8mg/ml) was loaded in each well. M: 
Molecular weight standard (10µL). Lanes 1, 2, 3, 4, 5, and 6 corresponds to scFvM12 
incubation at 4°C while the lanes 7, 8, 9, 10, 11 and 12 corresponds to scFvM12 incubation at 
room temperature (RT). The samples loaded from left to right in order of scFvM12 at pH 7.5, 
8.0, 8.5 and pH7.5+100mM NaCl, pH8.0+100mM NaCl, pH8.5+100mM NaCl respectively for 
each temperature. pH was maintained by using 20mM of Tris buffer. 
 
 
 
 
 
 
 
 
                                        A       B 
 
 
 
 
 
 
 
 
  C       D 
Figure III-43 MALDI-TOF (II.2.6) mass spectrums for the stability analysis of scFvM12 
(2.8mg/ml) antibody after four months storage at 4°C. A – 20mM Tris pH 7.5; B – 20mM 
Tris pH7.5, 100mM NaCl; C – 20mM Tris pH8.0, 100mM NaCl; D –20mM Tris pH8.5, 100mM 
NaCl. 
 
In all the mass spectrums (Figure III-43), the main peak emerged was around 25kDa, which 
indicated that the protein degraded during storage. The most susceptible portion is the linker 
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and the marker tag. After linker cleavage, the major fraction of the protein peak should 
appear around 12kDa, corresponding to the isolated VH and VL domains of the protein. 
Since, the 12kDa peak does not correspond to the parent peak in the mass spectrum, 
therefore, this peak should be considered the outcome of protein protonation during the mass 
measurement. The appearance of 25kDa peak indicates either the complete or incomplete 
cleavage of the marker tags. 
The theoretical calculation of the mass corresponding to 25.18kDa and 25.16kDa 
indicates the complete removal of the His6 and the c-myc tag, while the 25.674kDa mass 
indicates the complete removal of the His6 tag along with removal of ten residues of the c-
myc tag. 
The removal or inactivity of the marker tags was confirmed through the western 
blotting by using the anti-c-myc and anti-His antibody (Figure III-50). This confirmed the 
complete cleavage of the marker tags during storage without the addition of the exogenous 
proteases over four months. 
 
 
 
 
 
 
   A                 B 
Figure III-44 Western blot (II.2.4.4) analysis of scFvM12 antibody stored at 4°C for four 
months with and without 100mM NaCl at different pH values. The blot developed with 
anti-9E10 antibody (1:4000 dilution, A) and anti-His antibody (1:4000 dilution, B). M: Pre-
stained molecular weight marker (10µL), Lane: 1, 2, and 3 indicates the scFvM12 antibody in 
20mM Tris at pH 7.5, pH8.0 and pH8.5; Lanes 4, 5, and 6 indicates the scFvM12 antibody in 
20mM Tris at pH 7.5, pH8.0 and pH8.5 with 100mM NaCl. 
 
The scFvM12 antibody in Tris at pH 7.5 revealed a single band, when developed with anti-
9E10 antibody this shows that only the histidine tag is cleaved at this particular pH. The 
occurrence of cleavage due to the presence of the exogenous proteases in the samples can be 
ruled out because there is only loss of purification tags although the linker is also highly 
susceptible to proteolytic cleavage. This phenomenon is difficult to explain. 
III.13 M12-VH domain engineering 
 
The cloning and the expression of the native and camelized M12-VH domains were 
supported by Melanie König (Intitute for Biologie VII, RWTH- Aachen, Germany). 
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III.13.1 Cloning strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-45 Schematic representation of the strategy used for cloning the M12-VH 
domain cDNA from scFvM12 gene. VH: Variable heavy chain, pSynI and pK3C are bacterial 
expression vectors, His6 is the histidine purification tag, NdeI and XhoI are restriction 
enzymes, VHF and VHB are the forward and backward primers (see in appendix) used for the 
M12-VH gene amplification. 
 
For the camelization, the VH domain of scFvM12 antibody was cloned as reference antibody 
fragment for the comparison of the functionality and solubility properties of the native and 
camelized antibody VH domain. The cloning strategy is depicted in figure III-45. 
The VH domain of scFvM12 was cloned from the nucleotides sequence listed in 
appendix. As it is evident from the nucleotide sequence the restriction site for the NdeI and 
XhoI enzymes are not present. Therefore, they had to be introduced with PCR primers. The 
VH domain gene of scFvM12 was amplified directly from the pSynI vector containing the 
gene segment for the full size antibody fragment scFvM12. After amplification, the VH 
domain gene was cloned in the pK3C vector for cytoplasmic expression. The camelized VH 
fragment gene was amplified from the VH gene of the scFvM12 by using the appropriate 
primers (see in appendix) and cloned in the pK3C bacterial cytoplasmic expression vector. 
III.13.2 Amplification of the M12-VH domain 
 
The gene for cloning the native VH domain of scFvM12 was amplified through PCR by 
using the different concentration of MgCl2. The sense and anti-sense primers (appendix) 
used for the gene amplification were same in all the PCR amplification reactions. The 
pSynI
VH/VL
VHB
VHF
NdeI
VH
VH gene amplification
XhoI Restriction
NdeIXhoI
pK3C
pK3C
VH His tag
Cloning of VH gene
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amplified gene fragments were labelled as M12-VH (2/4/5/7) respectively corresponding to 
the different concentrations of MgCl2 (1.0mM, 2.5mM, 3.0mM, and 4.0mM).  
 
 
 
 
 
 
 
Figure III-46 PCR amplification (II.2.1.3.2) of the camelized (Trp47Gly & Trp47His) M12-
VH domain. The camelized M12-VH domain was amplified by PCR and separated on 1.2% 
agarose gel (II.2.1.1). 5µL of amplified product was loaded in each lane. Lane 1: Marker 
digested with Pst I, Lane 2: Primer combination 1a for M12-VHcamG, Lane 3: PCR mix with 
out DNA; negative control, Lane 4: Primer combination 1b for M12-VHcamG, Lanes 5, 7, 9 & 
12 are PCR mix with out DNA; negative control, Lane 6: Primer combination 2a for M12-
VHcamH, Lane 8: Primer combination 2b for M12-VHcamH, Lane 10: M12-VHcamG 
(Trp47Gly), Lane 11: M12-VHcamH (Trp47His). The primer combinations are 1a (M12-VH 
forward primer + M12-VH backward primer, Trp47Gly), 1b (M12-VH backward primer + M12-
VH forward primer, Trp47Gly), 2a(M12-VH forward primer + M12-VH backward primer, 
Trp47His) and 2b (M12-VH backward primer + M12-VH forward primer, Trp47His). 
 
The gene for the camelization of M12-VH fragment was amplified using the original M12-
VH gene (clone number 4) as DNA template. The forward and backward primer combination 
(see appendix) was used for the PCR amplification to introduce the appropriate mutated 
codons for amino acid mutations Gly44Glu, Leu45Arg and Trp47Gly/His. The resulting 
amplified gene products for position 47 were labeled as VHcamG (Trp47Gly) and VHcamH 
(Trp47His) respectively (Figure III-46). 
All the primers used for the amplification of the M12-VH genes possessed overhangs 
to generate the restriction sites for NdeI and XhoI restriction enzymes. 
III.13.3 Restriction and ligation 
 
The PCR amplified gene products (Figure III-46) for the original and the camelized M12-VH 
domains were pooled and purified from the agarose gel. The gel purified M12-VH genes 
were digested with NdeI and Xho I restriction enzymes. The sticky end gene fragments, 
generated after restriction digestion, were ligated into the pK3C vector and the recombinant 
vector was transformed into E. coli DH5α cells by the heat shock transformation. Single 
randomly selected colonies of M12-VH (2/4/5/7) clones were checked through PCR in order 
to confirm the presence of inserts.  All recombinant colonies contained the inserts (data not 
shown). 
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Figure III-47 Restriction analysis (II.2.1.4) of the camelized M12-VH domain with NdeI 
and XhoI restriction enzyme. M: 500ng of lambda Pst1 marker. Lane 1 and 2: M12-VHcamG 
restricted fragments, Lane 3 and 4: M12-VHcamH restricted fragments and Lane 5: 100ng of 
pUC19HAPA2 vector DNA. 
 
The recombinant plasmid containing the camelized genes was isolated from the five 
randomly selected colonies to check the presence of the inserts through PCR (data not 
shown). All the clones tested for the presence of gene of interest were found positive with an 
expected gene fragment size of ~350bp. 
The colonies found to contain the desired native and camelized M12-VH genes were 
selected and the isolated DNA was subjected to sequencing. Only clones carries the correct 
M12-VH gene were used for further analysis.  
The recombinant plasmid harboring the correct sequence of the M12-VH genes were 
isolated from the E. coli DH5α bacterial cells and transformed in to the E. coli BL21 (DE3). 
The expression of the protein was checked through SDS-PAGE (III.2.4.3). 
III.13.3.1 M12-VH domain 
 
The pK3C plasmid (appendix) lacks the pelB leader sequence necessary to express the 
protein in the bacterial periplasm. The vector contains the His6 tag at the c-terminus 
necessary to purify the protein by Ni-NTA affinity chromatography. For the cytoplasmic 
expression of M12-VH fragments, the recombinant plasmids were transformed into the E. 
coli BL21 (DE3) strain and the expression was carried out under the control of the strong 
phage T7 promotor. When protein expression was carried out overnight with 1mM of IPTG 
at 37°C in LB medium, the observed expression level of the protein was very poor (data not 
shown). The reduction of temperature from 37°C to 18°C and the change of IPTG 
concentration did not affect the level of expression. The change of LB medium to more 
nutrient rich medium i.e. 2xTY in improved protein expression but the protein undergone 
misfolding and only expressed in inclusion bodies which can be solubilized by the addition 
of 1% (v/v) Triton X-100 in the purification buffer.  
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To overcome solubility problem of the protein, the recombinant plasmid containing the gene 
of interest was subcloned in to E. coli BL21 (DE3) codon plus RIL strain (Novagen). The 
expression of the protein in the codon plus strain resulted in to increased in expression levels 
(Figure III-48).  
 
 
 
 
 
           A                                                                                  B 
Figure III-48 Western blot analysis (II.2.4.4) to observe the effect of E. coli bacterial 
strains on the cytoplasmic expression of the native and the camelized M12-VH domains 
(II.2.2.1). The blot was developed with anti-His antibody (1:4000 dilution). A: E. coli BL21, B: 
E. coli BL21 codon plus RIL, M: Prestained molecular weight marker (10µL). Lanes 1, 2, 3, 4 
are M12-VH fragment (4), M12-VH fragment (7), M12-VH fragment camG (4) and M12-VH 
fragment camH (6) supernatant. Lanes 5, 6, 7, and 8 are pellets of M12-VH fragment (4), 
M12-VH fragment (7), M12-VH fragment camG (4) and M12-VH fragment camH (6) pellet. The 
pellet was lysed in 15ml of lysis buffer for 3hrs and the supernatant kept separately. The 
pellet was washed in binding buffer containing 1% v/v TritonX-100. The pellet was boiled in 
20µL of 5x sample loading dye buffer before loading onto the Gel. 10µL of each sample 
loaded in each lane of the 12% SDS-PAGE Gel. The numbers included in parenthesis 
represents the selected clone number. 
 
The temperature and the IPTG concentration were optimized but no significant effect on 
protein expression level was observed by changing these variables. The best parameters for 
the obtaining the large yield of the soluble cytoplasmic expression of the VH fragments were 
obtained by using the nutrient rich medium i.e. 2xTY and the change of bacterial strain from 
E. coli BL21 (DE3) to E. coli BL21 (DE3) codon plus. The induction was performed 
overnight at 28°C with 0.5mM IPTG (final concentration). The expression level of the 
proteins was checked through western blotting (Figure III-48). 
III.13.4 M12-VH domains 
 
After lysis of the bacterial pellet through sonication and lysozyme treatment, the His6 tag 
containing protein from inclusion bodies was purified by Ni-NTA chromatography (II.2.3.2). 
The inclusion bodies are subjected to refolding by using the strong denaturant guanidine-HCl 
(6M). It seems that the M12-VH did not refold correctly because it was not binding to the Ni-
NTA column under the selected purification conditions (II.2.3.2.1). The expression level was 
slightly improved by expressing the protein in nutrient rich 2xTy medium (data not shown). 
The protein expression was performed at 37°C in 2xTy medium and the culture was induced 
for 4hrs with 1mM of IPTG (II.2.3.2.2).  
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Figure III-49 Ni-NTA purification (II.2.3.2) of the native and the camelized M12-VH 
domain. M: Molecular weight marker (5µL). Lane 1, 2, 3, 4: 15µL of native M12-VH (4), M12-
VH (7) and camelized M12-VHcamG, M12-VHcamH while the lanes 5, 6, 7, 8 represents the 
filtrate for native M12-VH (4), M12-VH (7) and camelized M12-VHcamG, M12-VHcamH 
respectively. 
 
After purification, the protein was concentrated and loaded on 12% SDS-PAGE.  Since, the 
gel was showing the inclusion of large number of impurities, it is difficult to conclude the 
high level of expression of the desired proteins.  
 
 
 
 
 
 
 
 
Figure III-50 Western blot analysis (II.2.4.4) for the native and the camelized M12-VH 
domains on 18% SDS-PAGE (II.2.4.3). The detection of the separated protein was done by 
using the anti-his antibody (1: 3000 dilution, II.1.6). M: 10µL of Pre-stained molecular weight 
marker, Lane 1: 10µL of scFvM12 (0.2 mg/ml) used as marker, Lane 2: 20µL of M12-
VHcamG, Lane 3: 20µL of M12-VHcamH, Lane 4: 20µL of native M12-VH domain. 
 
Western blot analysis (Figure III-50) of the Ni-NTA purified M12-VH domain revealed that 
the expression is poor but the protein remained intact during the harsh purification procedure 
from bacterial cytoplasm. The M12-VH domain expression was found to be variable 
(Riechmann, L. 1996). To improve the cytosolic expression, the parameters such as 
temperature, length of incubation with IPTG etc needs to be optimized. Once the soluble 
protein is available in sufficient amount, the functionality of the M12-VH domains needs to 
be checked by ELISA. 
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IV DISCUSSION 
The display of antibody on the surface of phages has tremendously increased the potential to 
apply them for the specific targeting of ligands and pathogens presented to them (Winter et 
al. 1994). Antibody domains with specificity for virtually any antigen can be isolated in-vitro 
(Griffiths et al., 1994) and afterwards can be produced in eukaryotic cells or bacteria for 
biotechnological and pharmaceutical applications. Bacterial folding of the entire 
immunoglobulin molecules is less efficient than the folding of their Fv domains or Fab 
domains. For some applications like the targeting of solid tumors, smaller antibody domains 
(e.g. scFv, VH or VL domains) are advantageous over full-size antibodies in respect of their 
biodistribution (Mayer et al., 1999) due to their faster diffusion and clearance. It was 
observed that the variable heavy chain domain of antibodies could sometimes retain a 
significant portion of antigen affinity in the absence of light chains (Utsumi & Karush, 
1964). Recently, antibodies naturally devoid of light chain and retaining full functional 
activity against the antigen were reported (Hamers-Casterman et al., 1993). Since then, 
minimizing the size of antigen-binding proteins to a single immunoglobulin domain has been 
one of the goals of antibody engineering which involves the modification of the human VH 
domain by mimicking camelids heavy chains antibodies (VHH) for their use as a small 
recognition unit (Davies & Riechmann, 1994).  
MUC1 is a polymorphic, type I transmembrane glycoprotein containing a variable 
number of 20 amino acid tandem repeats. The exposure and the extra cellular accessibility of 
the aberrantly glycosylated MUC1 in cancer makes this marker a suitable immunotarget. So 
far, structures of either murine or humanized Fab antibody domains directed against MUC1 
have been solved (Dokurno et al., 1998; Banfield et al., 1997). But there is no report for the 
availability of structural details of a single domain antibody directed against MUC1. This 
thesis work reports the crystallization of human single domain antibodies VH generated 
through limited in-vitro proteolysis of the scFvM12 antibody domain. The structure of the 
M12-VH domain has been determined at high resolution (1.5Å).  
In antibodies, the VH-VL interface is hydrophobic in nature resulting in unstable and 
insoluble the expression of isolated VH domains. The hydrophobic residues mainly involved 
in the VH/VL interaction are H44, H45 and H47. These residues were mutated in the M12-VH 
domain to mimic the camelized VHH domain. Simultaneously, both the native and camelized 
M12-VH domains were expressed in the bacterial cytoplasm. Although the reducing 
environment of the cytoplasm inhibits the disulfide bridge formation in antibodies, certain 
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antibodies were found to be stable in the absence of the conserved disulfide bridge. The 
M12-VH domain inherently posses the Arg-H66 and Ser-H52 residues, which were reported 
to have stabilizing effect and allowed the antibody expression in the cytoplasm (Proba et al., 
1998). Therefore, the bacterial cytoplasmic expression of the single domain antibodies 
should provide further evidence of the stabilizing effect of the Arg-H66 and Ser-H52 on one 
hand and the effect of camelization on the cytoplasmic expression level of these small 
recognition units on the other hand.  
The crystallization of the scFvM12 antibody alone was performed to observe at the 
molecular level how the two domains, VH and VL, coming from two different sources behave 
in terms of their interface interactions. 
The binding of any antibody depends on its CDR regions and it is possible that 
antibody domain affinity towards the antigen can alter in the absence of all natural CDR’s. 
To study the structure-function relationship and the contribution of the VH and the VL 
domain of scFvM12 in antigen binding, the crystallization of both the M12-VH and the 
scFvM12 with and without the MUC1 peptide antigen was investigated. 
IV.1 Expression and purification of scFvM12 
 
IV.1.1 Bacterial expression 
 
Initially, the scFvM12 was expressed in the E. coli BL21 (DE3) periplasm with a yield of 
0.2-0.3 mg/L of bacterial culture. The yield was optimised using the different bacterial 
strains (data not shown). E. coli TG1 was identified to express the highest yield (~0.6mg) per 
litre of the bacterial culture in shake flasks. The reason for this variable expression levels 
appeared to be strain specific. The primary sequence of the antibody affects the folding 
pattern and misfolding of the protein results into the formation of inclusion bodies, which 
can be detrimental to the host cell. Varying the host cells can alter the protein expression 
levels and the folding state of the protein (Kenealy et al., 1987).  
Crystallization trials needed to be set-up using at least 5mg/ml of highly pure protein. 
Obviously, the yield of the scFvM12 in shake flask was not sufficient to meet this demand. 
Therefore, it was essential to scale up the protein expression level. Protein production in E. 
coli could be increased significantly by the use of high-cell-density fermentation (HCDF) in 
batch, fed batch and continuous mode.  These methods can achieve 100g dry cell weight per 
liter of the medium and provides cost effective production of recombinant proteins. The 
HCDF was carried out in batch mode (III.1.2) to increase the scFvM12 yield. The yield of 
the scFvM12 was increased to 24mg/kg of the pellet (wet weight). In HCDF, leaky 
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expression of the scFvM12 was observed (Figure III-2) and the bacterial supernatant was 
found to contain sufficient amount of protein (~7mg per litre). 
IV.1.2 scFvM12 purification 
 
The affinity (Ni-NTA) purification of scFvM12 yielded apparently homogenous protein. 
However, ion-exchange purification, multiple peaks were observed. In cation-exchange 
chromatography, the first broad peak (Figure III-4A, peak A) corresponds to imidazole 
because no reaction was observed with Bradford reagent and no distinct band was observed 
on SDS-PAGE. Therefore, it could be the remaining fraction of the imidazole, which is 
carrying over due to the improper dialysis. Furthermore, the occurrence of multiple peaks 
during ion-exchange purification of scFvM12 could be either due to presence of aggregates 
or presence of different conformational forms or the presence of products of the partial 
degradation of the scFvM12. The multiple peaks were tested through western blotting 
(Figure III-5A & III-5B) and all of them were found to bear the marker tag except the first 
observed peak. Western blotting suggests therefore, that the multiple peaks belong to the 
scFvM12. The iso-electric focusing (IEF) confirmed that the protein was present in different 
conformational forms (Figure III-5). Since, MALDI-TOF mass spectrometry indicated only 
presence of a protein population with a unique mass and the formation of aggregates in 
minor fraction (Figure III-8) and the degradation of the protein also observed upon storage 
(Figure III-42). 
It is advantageous to express the protein in the bacterial supernatant in terms of 
purification. The main difficulty in the protein purification from the bacterial supernatant is 
its slimy nature and the presence of a lot of cell debris, which are difficult to separate 
through centrifugation or filtration. These slimy materials cause frequent obstructing of the 
column and leads to a rapid increase in system backpressure. Tangential flow filtration was 
assessed as an additional clarification step but proved to be ineffective, since filtrate flow 
was unacceptably slow. A possible explanation was the presence of an antifoam additive in 
the supernatant, since; the used silicon polymers may form a layer on the filtration 
membrane surface, preventing the passage of liquid through the pores. An additional 
technical complication is the presence of high concentration of salts in the minimal medium, 
which interfere with the binding of the protein to the Ni-NTA column, possibly due to the 
presence of ions, which can be chelated by the His6-tag in the solution, preventing its binding 
to the Ni-NTA column. During the purification of the protein, the protein of interest remains 
contaminated with bacterial proteins. 
  IV-DISCUSSION 
 107
IV.2 Crystallization of antibodies 
 
IV.2.1 Crystallization of scFvM12 
 
Out of the 509 antibody structures had been reported in the PDB database at the time of 
writing the thesis (Bernstein et al. 1977), only 16 were scFv’s. Most of the antibody 
structures are Fab domains. Out of the 16 scFv’s structures, 8 were solved in complex with 
their ligand. The low number of available of scFv structures in total in the PDB database 
gives an indication about the difficulties encountered in crystallizing these antibody 
fragments. In general, the concentration of scFv’s for crystallization purposes most often 
results in a monomer-multimer equilibrium causing their aggregation, which interferes with 
the crystallization process (Alfthan et al., 1995). The scFvM12 is not an exception to this 
behavior and aggregate formation is observed in MALDI analysis (Figure III-6) for a minor 
fraction of the scFvM12.  
By crystallizing the gel-purified protein, the protein always yields thousands of 
microneedles within 3-4 days after setting the hanging drops through the vapor diffusion 
method. These microcrystals are quite resistant to grow in size. To improve the crystal 
quality, the microseeding or macroseeding technique was tried but the results were not 
encouraging. The observed high nucleation rate and the resistance to grow in size even after 
seeding suggest heterogeneity of the protein in the crystallization drops. The heterogeneity 
could result from the presence of the multimeric form protein (Figure III-6) or its 
degradation with in the drop (Stanfield et al., 1993). These conformational heterogeneities 
can either act as a nucleus for the soluble protein, resulting into thousands of microneedles or 
interfere with nucleation. The resistant of these needles to grow in size can be explained due 
to the contamination of the crystal-growing surface with the multimeric species and/or 
molecules with different conformations.  
To reduce the scFvM12 monomer-multimer equilibrium during crystallization, two 
strategies were applied. Firstly, the most notable is the cleavage of highly flexible regions 
such as the linker joining the VL and VH domains as well as the c-terminal c-myc and His6-
tag with some protease (Essig et al., 1993). We used subtilisin Carlsberg and thermolysin. 
Secondly, crystallization of the scFvM12 in the presence of its ligand i.e. MUC1 in order to 
stabilize its CDR loops. Furthermore, the ligand binding might stabilize the VH/VL 
interaction and avoid rearrangements to other monomeric or multimeric states. 
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IV.2.2 Single antibody domain crystallization 
 
The most flexible portions of the scFv’s are the linker between the VH and VL domain and 
the purification tags. Therefore, theoretically, it is possible to cleave the flexible and 
susceptible portions of the protein to generate either the single antibody domains, a compact 
form of the scFv. We used in-drop limited proteolysis of the scFvM12 to generate the 
isolated VH domain.  
The proteolytic cleavage of the scFvM12 with subtilisin Carlsberg lead to the 
crystallization of a single protein domain. The washed and solubilized crystals, when 
examined through MALDI-TOF, indicated the crystallization of the VH domain (12.346kDa) 
of the scFvM12 antibody (Figure III-14). The crystallization of the M12-VH domain after 
subtilisin treatment indicates that the rest of the scFv portions including the VL domain are 
highly susceptible to this protease and degraded. The further degradation of the M12-VH was 
circumvented by its crystallization, rendering it inaccessible for further degradation. The 
morphology of the crystals varied with pH and temperature (III.4.2.C). The difference in 
morphology at two different temperatures may be the result of the difference: 
1. in the kinetics of the subtilisin protease, 
2. and/or in the rate of drop supersaturation. 
The first explanation is supported by the immuno-blot analysis of scFvM12 digestion 
by subtilisin under the crystallization condition [100mM MES pH6.5, 25% (v/v) PEG 
550MME, 10mM Zinc sulfate heptahydrate, 4mM DTT, 0.04% (w/v) NaN3] at 4°C. The 
reduced catalytic activity of the enzyme under crystallization condition could be due to the 
combined effect of precipitant, high concentration of divalent metal ion and low temperature. 
Similarly, the VH domain crystals were generated through in-drop limited proteolysis 
of scFvM12 by using thermolysin protease (Figure III-16). It is interesting to observe that the 
M12-VH domain crystals, obtained through subtilisin treatment of the scFvM12, remain in 
crystal form while the M12-VH crystals obtained through thermolysin treatment undergoes 
solubilization. This observation suggests that the M12-VH crystallization is an intermediate 
step in the complete proteolytic degradation of the protein. The probable explanation is the 
shift of equilibrium relative to the proportion of the substrate for M12-VH domain generation 
and the increase of the M12-VH domain concentration leads to the drop supersaturation and 
ultimately, the M12-VH domain crystallization. Till the equilibrium remains in favor of the 
supersaturated state, the M12-VH domain remains in crystal form. After the degradation of 
the more susceptible species, the equilibrium reverts back and results in to the dissolution of 
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the crystal. After entering in to solution, the M12-VH domain undergoing the complete 
cleavage. 
IV.2.3 Preference for the M12-VH domain crystallization 
over M12-VL domain 
 
The scFvM12 antibody was derived by selection of an scFv phage display library with a 
diversity of 109 (Wong et al., 2001).  The VH domain of scFvM12 was derived from the 
library constructed by pooling total DNA from human spleen cells and two different samples 
of human peripheral blood lymphocytes while the VL domain was taken from a previously 
constructed scFv phage antibody library derived from peripheral blood lymphocytes (Sheets 
et al., 1998).  
On sequence comparison with the germline database (V-Base), it was observed that 
M12-VL gene sequence is nearly identical to germline V-genes (data not shown) while the 
M12-VH gene had sequence undergone multiple mutations (Figure IV-1).  
1-3 3-48 EVQLVESGGGLVQPGGSLRLSCAASGFTFS  S--YSMN  WVRQAPGKGLEWVS  YISS-- 
1-3 3-21 EVQLVESGGGLVKPGGSLRLSCAASGFTFS  S--YSMN  WVRQAPGKGLEWVS  SISS 
1-3 3-11 QVQLVESGGGLVKPGGSLRLSCAASGFTFS  D--YYMS  WIRQAPGKGLEWVS  YISS— 
M12VH  QVQLQESGGGLVQPGGSLRLSCAASGFTFS  N--SAMS  WVRQAPGKGLEWVS  SISG-- 
1-1 3-13 EVQLVESGGGLVQPGGSLRLSCAASGFTFS  S--YDMH  WVRQATGKGLEWVS  AIG--- 
 
1-3 3-48 SSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR 13 
1-3 3-21 SSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR 12 
1-3 3-11 SGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR 11 
M12-VH  SGGNTYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR 
1-1 3-13 TAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCAR 
 
Figure IV-1 Sequence alignment of M12-VH domain with other VH domains in the V-
BASE database to determine the germline family for the M12-VH domain. 
 
Since the VH and VL domain came from two different libraries in scFvM12 and the M12-VH 
domain has undergone multiple sequence mutations, it is possible that the M12-VH domain 
corresponds to a mature antibody like IgG, while the M12-VL domain belongs to immature 
antibody. Since, the mature antibodies have stronger affinity towards the antigen in 
comparison to the immature antibodies, it might be possible that the M12-VH domain is the 
main contributor towards the binding specificity of the scFvM12 antibody. Furthermore, the 
formation of multimeric forms of the scFvM12 (Figure III-5) might be due to non-ideal 
interaction between the VH and VL domains. This might be due to the non-altering rounds of 
maturation between VH and VL coding genes normally observed in B-lymphocytes during 
maturation. 
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The random combinatorial libraries through which scFvM12 had been constructed has 
potential limitation. The scFvM12 antibody was constructed by randomly pairing the highly 
complex and MUC1 specificity with general and unspecific populations of VH and VL 
cDNA’s. Therefore, the chances for combining the specific VH with its original VL partner 
are negligible. Pairing a VH domain with unrelated VL partner usually results in a less active 
or even non-functional antibody. Consequently, the VH domains that could function as anti-
tumour VH antibodies might even remain undetected in such single chain Fv or Fab libraries 
because of an incompatible VL partner might prevent binding (Cai et al., 1996).  Therefore, it 
is possible that the VH domain in the scFvM12 is seen not showing its full activity in 
combination with its unnatural VL partner. Simultaneously, the existence of fully functional 
VH domains in Camelids (Hammers-Casterman et al., 1993) provides the additional evidence 
that a functional antibody does not necessarily needs to be associated to a VL domain. 
IV.2.4 Diffusion over co-crystallization 
 
Since, single antibody domains have vast clinical importance, the structural details of the 
antibody-antigen complexes could provide the basis for a protein engineering approach for 
the M12-VH domain in terms of its solubility, affinity and avidity towards its antigen MUC1. 
The crystallization of M12-VH in complex with MUC1 antigen was tried by the diffusion 
method, where the crystal of the M12-VH domain was generated first by in-drop proteolytic 
digestion of the scFvM12 (III.4.4). These crystals were then soaked with peptide to allow 
binding of the peptide through solvent channels, which are inherent part of the protein 
crystals. Diffusion of 21mer biotinylated peptide (APDTRPAPGSTAPPAHGVTSK-ε-
biotin) in to the pre-existing crystals of the M12-VH domain did not result in any 
morphological damage or interference in the ability of the crystals to diffract X-rays. There 
were no resolution losses, widening of the X-rays or decay increases over time. However, 
after processing the data, the presence of bound peptide could not be detected by difference 
Fourier analysis.  
The structure determination of the M12-VH domain showed that the complex 
formation was inhibited due to tight interdomain crystal contacts at the site of the CDR’s and 
therefore, not accessible to peptide binding. The peptide was found in the mother liquor after 
ESI-MS/MS analysis (Figure III-38); therefore, the binding inhibition is due to the 
inaccessibility of the peptide to the VH binding site and not due to a digestion by the 
presence of the protease. Protein-ligand complex crystallization through soaking of the 
protein crystals most often suffers from the accessibility problem of the ligand to the binding 
site of the protein. The low Matthews coefficient (1.98) also suggests the tight packing and 
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less available space for ligand binding. This phenomenon was also reported in other cases 
(Faber et al., 1998). The CDR regions of the M12-VH involved in the hydrogen bonding 
between symmetry related molecules and these bonds are so strong that they did not allow 
the interaction between the peptide antigen and the M12-VH domain even if the peptide has 
the access through the solvent channels. To avoid such problems, co-crystallization would be 
the only alternative. Co-crystallization needs the complexation of the protein and the ligand 
prior to crystallization; therefore, the recombinant M12-VH domain should be used for 
studying the structural details of the antibody-antigen complex. 
IV.3 Structural deviations of the M12-VH domain 
 
The M12-VH domain has the highest sequence (76.11%) and structural similarity with the 
recently solved structure of a camelized human single domain (accession code-1VHP, NMR 
structure).  
In the VH3 family of germline sequences, there is more variation in CDR-H2, because 
of the length variation of a two amino acid residue insertion occurring in a group of human 
sequences (positions 52b and 52c). The CDR-H1 and CDR-H2 loops of the M12-VH domain 
are similar to the type 1 and type 3 canonical structures respectively. Both loops show 
deviations from the average phi/psi angles (Table III-4). The presence of the disallowed 
amino acids enables the formation of additional hydrogen bonds and resulted into change of 
a phi/psi angle. As a result of this additional hydrogen bonding, these CDR's are forming flat 
binding interface instead of the usually observed cleft-like binding pockets. The product of 
three genes (V, D and J), the CDR-H3 exhibits extremely high variability. It is therefore 
considered too hypervariable in structure to assign it to a canonical niche. The CDR-H3 of 
the M12-VH has a deletion at position 100 and is considered to be a rather small loop. The 
M12-VH lacks some of the conserved hydrogen bonds between side chains (Asp-H86 and 
Tyr-H90, Arg-H94 and Asp-H101), side chain to main-chain CO (Arg-H66 and His-H82a, 
Thr-H87 and X84). Main chain NH to side chain (X69 and His-H59, X75 and Asp-H72). 
M12-VH has Gln, while usually histidine is observed at position 82a. In this list, X refers to 
positions without dominant residue preference. 
IV.4 Structural basis of the M12-VH domain 
stability 
 
It is noticeable that the VH domain structure has a strongly distinct network of electrostatic 
interactions. Residue H66 is part of a highly conserved charge cluster within the VH domain 
family. 90.4% of human VH sequences contain Arg at this position and 1.3% Lys.  Residue 
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Arg-H66 interacts strongly with Asp-H86 by forming a salt bridge. This salt bridge is quite 
buried; increasing its stabilizing effect compared to that of a solvent-exposed ion pairs 
(Proba et al., 1998, Figure IV-2). This salt bridge is also present in the M12-VH domain. In 
addition, M12-VH has a Ser at position H52, which is forming a beta-turn and might 
therefore have some influence on folding kinetics.  
 
 
 
 
 
 
 
 
Figure IV-2 Schematic representation of denaturation midpoints of the light-chain 
variable domain (VL) and the heavy-chain variable domain (VH) within the scFv domain 
A48 and its derived mutants (K66R and N52S). Note that VL is chemically identical in all 
cases, whereas the nature of VH is indicated (Wörn et al., 1998). 
 
Wörne et al., (1998) have shown the stabilizing effect of K66R and N52S mutations on an 
scFv domain naturally lacking the conserved disulfide bridge (Figure above). The presence 
of Arg-H66 and Ser-H52 in the VH domain of scFvM12 antibody inherently stabilizes this 
molecule.  
IV.5 The VH/VL interface of the M12-VH domain 
 
To ascertain the difference in the VH/VL interface of the M12-VH domain after its separation 
from the scFvM12 domain, we build a theoretical model of the scFvM12 based on the 
antibody structure and the structure of the M12-VH domain was superimposed on it. The 
crystal structure of the M12-VH domain showed a high degree of similarity with the modeled 
structure for scFvM12 antibody. As predicted, the overall shape of the antigen-binding site is 
in resemblance between model and M12-VH domain with the hydrophobic residues at the 
bottom of the VL interface. Comparison with the modeled scFvM12 structure revealed no 
significant differences for framework residues. The VL interface of the VH domains, when 
part of Fv domains, is formed mainly by beta-strands C' and G and the CDR-H3 loop. Within 
strand C', residues 44, 45 and 47 are those contributing most to the VL interface (Poljak et 
al., 1975; Chothia et al., 1985). There is no principle difference in the conformation of these 
residues when compared to M12-VH structure. The three residues H44, H45 & H47 are 
highly conversed through the human and mouse VH families. Residues 45 & 47 are more 
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conserved than residue 44 in which some variability among VH families is observed. In most 
VH-domains, residue 44 is a glycine (Kabat et al., 1991). No changes concerning the VH-
typical beta-structure were observed in strand C' and strand G. Residues Val-H37 and Arg-
H38 have the same orientations in M12-VH and the scFvM12 model. The Trp-H103 side-
chain is exposed to the solvent. Therefore, it can be anticipated that the M12-VH domain 
does not exhibit any structural difference after its isolation from the VL partner.  
It is interesting to note that on the VL/VH interface, no change was observed in the 
conformation of the interacting residues even after exposure to the solvent. The most 
probable explanation is that to establish the contact between symmetry related molecules 
inside the crystal, the VH/VL interface residues are heavily guarded by intermolecular 
hydrogen bonding. Therefore, the residues escaped the effects of the solvent exposure. 
IV.6 Comparison between the SM3-VH domain 
and the M12-VH domain 
 
Murine SM3-Fab is the first tumour-specific antibody crystallized in complex with the 
MUC1 peptide antigen. The human scFvM12, from which the VH domain has been 
crystallized, is also directed against MUC1. Therefore, the sequence and structure 
comparison can provide information about the components of the VH domain, which might 
contribute towards antigen binding and how this binding can be altered to improve the 
affinity of the VH domain. Compared to M12-VH, SM3-VH antibody has two insertions at 
position at H52 and a deletion at position H99. Interestingly, both antibody domains have  
SM3VH 1 QVQLQESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYAT 
M12VH 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSNSAMSWVRQAPGKGLEWVSSISG--SGGNT 
 
SM3VH 60 HYAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYCTGVGQF--AYWGQGTTVTVSS        
M12VH 60 YSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDWYGM-DVWGQGTTVTVSS  
 
Figure IV-3 Comparison of amino acid of SM3 antibody variable heavy chain with the 
M12-VH domain. Numbering and CDR's (underlined) are defined according to Kabat et al., 
(1991). 
 
deletion at position H100. There is a marked difference in the CDR loop regions between the 
two antibodies especially the CDRH2 and CDRH3 (Table IV-1). SM3 has a cis-peptide bond 
between Gly96H-Gln97H, while there is nothing similar in M12-VH domain. The SM3 
antibody VH domain has Gly44H, Leu45H and Glu47H. Two of the residues are conserved 
but at position 47 unusually has a hydrophilic residue, while the M12-VH domain has all the 
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Table IV-1 Canonical structure assignment according to Al-Lazikani et al. (1997) to the 
variable heavy chain domain of the SM3 (Dokurno et al., 1998), CTM01 (Banfield et al., 
1997) and M12-VH domain. CDR lengths are given in brackets. No canonical forms have 
been assigned for H3 loop. 
 
CDR loop H1 H2 H3 
 
SM3 1(5) 4(17) (6) 
CTM01 1(5) 2(15) (11) 
M12-VH 1(5) 3(16) (7) 
 
conserved residues at these positions (Figure IV-3). Therefore, it is clear that the VL-
interface of M12-VH domain has a more hydrophobic surface, which needed to be modified 
through camelization to reduce the possible insolubility of the single domain antibody. 
The SM3-Fab antibody structure was also reported to possess a number of regions 
with absent electron density (Dokurno et al., 1998). The M12-VH domain also lacks 
interpretable electron density from H40-H43. Depending upon the VH/VL interface 
comparison, it was found that residue H39 is directed slightly inward in M12-VH. Residue 
H37 has a different orientation in the M12-VH while Trp-H103 is more solvent exposed in the 
M12-VH domain. The main-chain conformation is almost similar in both the VH’s (Figure IV-
4). 
 
 
 
 
 
 
 
 
 
 
 
Figure IV-4 Ribbon representation of the structurally aligned SM3-VH (purple) and M12-
VH domain (bluish green). H1, H2 & H3 represents the three CDR loop regions. N: N-
terminal, C: C-terminal. Both of them have 69% amino-acid sequence similarity. The CDR 
regions are labeled. 
 
In order to test if the determined M12-VH domain could bind the antigen in a similar way as 
the SM3 antibody, we performed a detailed analysis in respect to the bound peptide in the 
SM3 structure.  
 
N
C
H3
H2
H1
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Figure IV-5 Superposition of M12-VH domain over SM3-MUC1 complex to extract the 
coordinates of the peptide. Cyan: MUC1 peptide, Purple: M12-VH domain, Green: SM3-VH 
domain. 
 
The SM3-VH was superimposed on the M12-VH structure and the peptide coordinates 
extracted (Figure IV-5).  In order to relieve initial close contacts, two water molecules (7, 8) 
were deleted. 
The comparison between SM3 and M12-VH domain revealed that the residues of the 
SM3-VH domain, which strongly contributes towards the antigen binding have some 
conformationally equivalent residues in M12-VH domain. These conformationally equivalent 
residues might contribute towards the MUC1 binding in the case of the M12-VH domain and 
the SM3-VH domain. In the SM3-Fab, most of the contacts with MUC1 peptide were 
provided by the heavy chain (64%). Significant numbers of interactions are contributed by 
Asn-H31, Tyr-H32 and Trp-H33 of the SM3-VH domain. The conformational equivalent of 
these residues in M12-VH domain are Asn-H31 (for Asn-H31), Arg-H94 (for Tyr-H32) and 
Trp-H96 (for Trp-H33). The conformational equivalency means that all these residues are 
sequentially distant in the SM3-VH and the M12-VH domains but their spatial occupancy is 
almost the same in both cases. In the SM3-Fab-MUC1 complex structure, 66% of the VH/VL 
interaction surface for SM3 comes from residues in the heavy chain, while 33% comes from 
residues of the light chain. 
In the SM3 structure, the CDR-H2 residues involved in antigen binding either through 
van-der-Waals interaction or through hydrogen bonding. The hydrogen bonding is either 
direct or mediated by water molecules. Interestingly, we observed a cluster of water 
molecules around the CDR-H2 residues in M12-VH domain, which could play an important 
role in water mediated antibody-antigen binding. This network is observed only for CDR-H2 
and not for the other CDR-regions. 
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IV.7 Camelization of the M12-VH domain 
 
Minimizing the size of antigen-binding proteins to a single immunoglobulin domain has 
been one of the primary goals of antibody engineering. It was demonstrated previously that 
small antibody domains perform better in-vivo than whole antibodies or Fab's (Yokota et al., 
1992). More often it was observed that the VH domain expression in bacteria is hampered by 
their insolubility and instability (Boss et al., 1984 & Cabilly et al., 1984). The discovery of 
camelid heavy chain antibodies (VHH, Hammers-Castermann et al., 1993) opened up new 
opportunities for the development of soluble and single domain antibodies by incorporating 
the structural features of VHH antibodies into human VH frameworks. Camelization of  
M12VH 1 QVQLQESGGGLVQPGGSLRLSCAASGFTFSNSAMSWVRQAPGKGLEWVSSISGSGGNTYS  
1F2X 1 QVQLVESGGGSVQAGGSLRLSCAASGYTVSTYCMGWFRQAPGKEREGVATI--LGGSTYY 
1HCV 1 DVQLQESGGGLVQAGGSLRLSCAASGRTGSTYDMGWFRQAPGKERESVAAINWDSARTYY  
1JTP 1 DVQLQASGGGSVQAGGSLRLSCAASGYTIGPYCMGWFRQAPGKEREGVAAINMGGGITYY 
1MEL 1 DVQLQASGGGSVQAGGSLRLSCAASGYTIGPYCMGWFRQAPGKEREGVAAINMGGGITYY 
                H1    H2 
M12VH  60 ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDWYGM-------------------        
1F2X  61 GDSVKGRFTISQDNAKNTVYLQMNSLKPEDTAIYYCAGSTVASTGWCSRLRPYDYHYRGQGT  
1HCV   61 ASSVRGRFTISRDNAKKTVYLQMNSLKPEDTAVYTCGAGEGGTW------------------ 
1JTP   61 ADSVKGRFTISQDNAKNTVYLLMNSLEPEDTAIYYCAADSTIYASYYECGHGLSTGGYGY-- 
1MEL   61 ADSVKGRFTISQDNAKNTVYLLMNSLEPEDTAIYYCAADSTIYASYYECGHGLSTGGYGY--  
                              H3 
M12VH 101 DVWGQGTTVTVSS 
1F2X  101 QVTVSSRGRH 
1HCV  101 DSWGQGTQVTVSS 
1JTP  101 DSWGQGTQVTVSSRRYPYDVPDYGSGRA 
1MEL  101 DSWGQGTQVTVSSGRYPYDVPDYGSGRA  
Figure IV-6 Human M12-VH domain sequence comparison with the camelid VHH domain. 
The difference in amino acid sequence is shown in red. The CDR regions are designated 
according to Kabat et al., 1979 i.e. H1 (26-32), H2 (52-56), H3 (95-102). 
 
human VH is promising for the generation of small antigen-binding domains that should be 
useful for therapeutic purposes in humans. The three prominent differences between human 
VH and camelids VHH domains observed are Gly44Gln, Leu45Arg and Trp47Gly. These 
residues are involved in VH/VL interactions in human antibodies. Camelids VHH domains 
have more hydrophilic residues at these positions to make them more soluble. Sequence and 
structural homology of camel VHH and M12-VH shows high degree of similarity (80.65%, 
Figure IV-6). M12-VH belongs to the VH3 family, which is closest to the camel VH gene 
family among both human and murine VH genes family.  
The X-ray structures have shown that in addition to residues H44, H 45 and H47, 
several others at positions scattered throughout the VHH surface also contribute to the VHH 
solubility (Spinelli et al., 1996). On sequence comparison, the residues like Ala-H14, Gly-
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H35, Phe-H37, Ala-H49, Tyr-H59, Thr-H77, Val-H78, Pro-H84, Glu-H108 have been found 
common in all VHH but none of them is present in the M12-VH. These residues are not 
considered for camelization because on one hand the effect of these framework residues on 
the affinity and solubility of the camelid VHH has not been established and on the other hand 
some features, inherent in the human VH, contributes to their solubility (Reiter et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV-7 Ribbon representation of the structurally aligned M12-VH domain (blue) over 
camel VHH domain (bluish green, PDB code – 1HCV). N: N-terminal, C: C-terminal of the 
protein. H1, H2 & H3 represents the three CDR loop regions. The r.m.s. deviation is 1.863. 
The M12-VH domain had 80.65% amino-acid sequence similarity with the camelid VHH 
domain. 
 
The modification in the VL interface is required to abolish non-specific binding of the single 
VH domains and to reduce the tendency for the formation of dimers because of the 
hydrophobic nature of the residues that compose the VH/VL interface. Therefore, the 
camelization of the M12-VH domain is mimicked by the mutations Gly44Gln, Leu45Arg and 
Trp47Gly/His to reduce the most probable problem of solubility and stability in bacterial 
expression and purification. The camelization leads to the expression of the soluble M12-VH 
domain. 
IV.8 Comparison between the M12-VH domain 
and the camelized human VH-P8 antibody 
 
In the PDB database, only 8 structures of single domain heavy chain antibodies are reported. 
Most of these structures are solved for camelid VHH domains either alone or in complex with 
ligand like lysozyme. Only one NMR-solved structure of an isolated camelized (Gly44Gln, 
Leu45Arg and Trp47Gly) human VH antibody is found in the database (PDB code - 1VHP, 
N
C
H3
H2
H1
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Riechmann, L., 1996). The structure of these two antibodies was compared to find out the 
introduction of structural modifications as a result of camelization. Both of these antibodies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV-8 Superposition of the M12-VH structure (yellow β-strands) and the NMR 
structure of the camelized human VH-P8 domain (red beta strands). Nt & Ct are N- and 
C-terminal of the protein, Hypervariable loops (H1, H2, H3) and β-strands (A, A’, B, C, C’, C’’, 
D, E, F, G) are indicated. The VH-P8 lacks the A’ strand. 
 
domains belong to the human germline VH3 family. Both the VH’s have a high sequence 
similarity (74.33%). The r.m.s. Cα deviation between the two structures is 3.281. CDR loops 
have variable length between the two VH's and only the CDR-H1 has sequence similarity 
with a difference of two residues at position 31 and 32. Since the CDR-H2 and CDR-H3 are 
entirely different in sequence, therefore, it is not informative to compare them. The M12-VH 
has ten beta-strands, while the VH-P8 has only 9 beta-stands constituting two beta sheets 
(Figure IV-8). The VH-P8 strands C, D and G are smaller in size in comparison to the M12-
VH domain. VH-P8 has beta-bulge in strands C’ and G while no beta-bulge is detected in the 
M12-VH structure. Non-aligned regions are terminal residues, residue H5 (framework region 
I), H31 & H32 (CDR-H1), H47 to H52a, H56 and H59 (base of CDR-H2), H74 & H77 
(framework region III), H95 to H100 (CDR-H3) and H110 (framework region IV). The 
CDR-H3 loop in the M12-VH is oriented towards the VL interface while in VH-P8 it is 
directed towards the CDR-H1 and CDR-H2 loops. The important difference in CDR-H3 loop 
of the two VH’s is the absence of a conserved salt bridge (Arg-H94 & Asp-H101) in VH-P8 
at the base of CDR-H3 loop. 
The Glu-H44 and Arg-H45 are solvent exposed in the VH-P8 while they are directed 
towards the VL in the M12-VH. The Val-H37 present at the bottom of a hydrophobic pocket 
Nt
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H3
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in the VL associated VH domains while in VH-P8; Val-H37 is buried in the interior as a result 
of distortion in strand C.  The NH group of residue H39 in VH-P8 does not form a hydrogen 
bond with the backbone oxygen atom of residue H89 in strand F, which is normally present 
in the VL associated VH domains. In VH-P8, a commonly observed hydrogen bond between 
residue H46 and Arg-H38 is missing. 
Recently, the structure of a camelized human VH domain (PDB code- 1OL0) has been 
described (Dottorini et al., 2004). The structure has a mutation Val37Phe in addition to 
Gly44Gln, Leu45Arg and Trp47Gly mutations of VH-P8. This mutation has resulted in a 
return of the flip observed for residues H44, H45 and H47 in VH-P8 to their conventional 
orientation as hypothesized by Desmyter et al., (1996). Therefore, the four mutations 
(Val37Phe, Gly44Gln, Leu45Arg and Trp47Gly) are minimally required to reduce the 
structural constraint during camelization of human VH domains. Till now, the effect of these 
mutations on the affinity and avidity of the human VH domains and their immunological 
effects has not been established. The functionality and immunological assessment of native 
and camelized M12-VH domain can contribute in this direction. The native and camelized 
M12-VH domain does not have Val37Phe mutation.  
IV.9 M12-VH domain cloning 
 
The native and camelized M12-VH domain was amplified using the appropriate set of 
primers (see appendix). The forward primer were designed to bind the first framework 
region of the heavy chain while the backward primer annealed to the fourth framework 
region of the heavy chain of the scFvM12 antibody. For the camelization purpose the 
amplified native VH gene segment of the scFvM12 was used as a DNA template. Priming 
takes advantage of sequence conservation of the framework region. The primers had 
restriction sites for the NdeI and XhoI restriction enzymes in the overhangs that were 
incorporated in the amplified product for cloning into the pK3C expression vector. Only few 
degenerate primers were required to clone the majority of the variable region, which is of 
practical importance (Orlandi et al., 1989). However, the disadvantage of this approach is 
that it might introduce amino acid substitutions in the framework region, which can affect 
antibody affinity. 
The annealing temperature used for amplification was slightly raised to avoid non-
specific amplification of the M12-VH genes. The amplified products were tested through 
PCR amplification and automated sequencing. PCR amplification of M12-VH gene segment 
and its sequencing was based on the use of specific primers designed from the M12-VH gene 
  IV-DISCUSSION 
 120
segment of the scFvM12. To avoid DNA polymerase copying errors, colonies were 
randomly screened using the gene specific oligonucleotide probes. 
For soluble antibody expression, five colonies of each construct were sequenced. The protein 
expression was induced after transforming the recombinant plasmid into E. coli BL21 (DE3). 
The expression of the protein was tested through western blot analysis (Figure III-49). The 
protein expression was found to be E. coli strain dependent (Figure III-49). Western blot 
analysis confirmed the presence of M12-VH domain (~12kDa) in the cytoplasm of the 
bacteria was found at variable levels. 
The native and camelized M12-VH domain was expressed in the cytoplasm of E. coli 
BL21 (DE3) strain. Their cytoplasmic expression leads to the formation of inclusion bodies. 
The parameters related to the formation of the inclusion bodies are charge average, turn-
forming residue fraction, cysteine fraction, proline fraction, hydrophilicity and the total 
number of residues (Wilkinson et al., 1991). The first two parameters are strongly correlated 
with inclusion body formation, while the last four parameters show a weak correlation. The 
measures used to circumvent the formation of inclusion bodies include the growth of 
bacterial cultures at lower temperatures (Shirano et al., 1990), the selection of different 
strains (Kenealy et al., 1987) etc. The change of strain to E. coli BL21 (DE3) codon plus 
resulted in the expression of soluble cytoplasmic protein. 
IV.10 Biological implications of single domain 
antibody 
 
It has been envisaged that the reduced size of the VH domains enables them to penetrate 
faster and better into tissues. The bio-distribution and renal clearance is faster (Yokota et al., 
1992). These properties, however, must be tested further by in-vivo studies as recent 
observations indicate a balance between size and tissue (or tumor) localization rate. Using 
recombinant forms of antibody domains it was demonstrated that there is a significant trade 
off in which localization rate (% injected dose localized per gram of tumor) typically 
declines with decreasing size of antibody domain (Adams et al., 1998). VH domains can be 
labeled with radionuclides, fluorescent probes, or other detection markers in the same way 
that antibody domains are being labeled. Fusion proteins can be constructed with VH 
domains (with reporter proteins, fluorescent proteins, toxins, etc.), as well as coupling to 
various biological agents (Reiter & Pastan 1998 and Haard et al., 1998). However, the utility 
of these molecules is dependent on a high yield, stability and solubility and improved affinity 
towards the antigen. The solubility can be improved by camelization and affinity 
improvements can be achieved by the randomization of selected residues followed by 
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selection rounds via the construction of large libraries. Such large libraries were constructed 
for scFv domains of antibodies by recombining large VH and VL repertoires (Griffiths et al., 
1994). The size of the CDR-H3 loop in the library can be enlarged and combined with codon 
based mutagenic oligonucleotides that can be used to avoid stop codons or cysteine residues 
within the CDR. 
IV.11 Conclusion 
 
Although, VH domains are well recognised as part of Fv or Fab fragments, the knowledge 
about the structural aspects of isolated VH domain alone in the absence of their VL partner is 
almost negligible. The probable reason could be their poor solubility as a result of non-
specific interaction through the VL interface (Kortt et al., 1995). Extensive structural 
information is required to optimise VH domains for their use as small recognition units in 
general and in cancer therapy. So far, only the structural details of the isolated camelized 
human VH domain is available (Riechmann, L. 1996 and Dottorini et al., 2003). The first 
detailed three-dimensional structure of non-camelized human VH domain can contribute in 
the following directions: 
1. The structure function relationship between human single domain antibodies and 
its antigen is of profound importance especially in cancer therapy where tumor 
penetration is desirable. The M12-VH domain provides the opportunity to study 
this kind of relationship against MUC1, providing the basis for improvement of 
antibody affinity through display technology like phage or ribosomal display. 
2. The structure will be helpful in the design of small peptide antigens, which can be 
used to raise the cellular immune response against cancerous cells overexpressing 
MUC1. 
3. Although the camelization of VH domains has been proved to increase the 
solubility of camelized VH domains, still there is no consensus regarding the effect 
of camelization on the affinity and avidity of the antibody. The comparative 
functionality study of non-camelized and camelized M12-VH domain can 
contribute in this direction. Also there is no evidence for the influence of 
camelization on the immunogenicity of human VH domains. Camelized M12-VH 
can be used as a basis to study the immunogenic effects of camelization of human 
VH domains. 
4. The structural study of camelized M12-VH domain in complex with the MUC1 
antigen can laid down the foundation for a rational single domain antibody 
design. 
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5. By comparing the structure of the scFvM12 in complex with MUC1 antigen and 
scFvM12 alone could provide the structural basis for the contribution of the two 
domains generated through random combinatorial libraries in antigen recognition. 
Furthermore, the VH/VL interaction could be improved by rational protein design 
to facilitate the formation of multimeric entities. 
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VI APPENDIX 
VI.1 scFvM12 sequence 
 
QVQLQESGGGLVQPGGSLRLSCAASGFTFS         NSAMS        WVRQAPGKGLEWVS     SISGSGGNTYSADSVKG 
   FR1-VH        CDR1-VH   FR2-VH       CDR2-VH 
 
RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR       DWYGMDV      WGQGTTVTVSS         GGGGSGGGGSGGGGS 
    FR3-VH         CDR3-VH   FR4-VH       LINKER 
 
SYVLTQDPAVSVALGQTVRITC               QGDSLRGYYAS    WYQQKPGQAPVLVIY       AKTNRPS         
FR1-VL              CDR1-VL  FR2-VL     CDR2-VL 
        
GIPDRFSGSSSGNTASLTITGAQAEDEADYYC     NSRDNSGTHLEV           FGGGTKLTVLGAAA 
    FR3-VL    CDR3-VL    FR4-VL 
 
EQKLISEEDLNGAA           HHHHHH 
  cMYC-TAG    HIS-TAG 
 
Figure VI-1 scFvM12 antibody amino acid sequence. CDR’s are underlined. 
 
VI.2 DNA sequence of M12-VH domain 
 
                   PstI 
                      | 
         caggtgcagctgcaggagtcggggggaggcttggtacagcctggggggtccctgagactc 
       1 ---------+---------+---------+---------+---------+---------+ 60 
         gtccacgtcgacgtcctcagcccccctccgaaccatgtcggaccccccagggactctgag 
 
         Q  V  Q  L  Q  E  S  G  G  G  L  V  Q  P  G  G  S  L  R  L   - 
  
         tcctgtgcagcctctggattcacctttagcaactctgccatgagctgggtccgccaggct 
      61 ---------+---------+---------+---------+---------+---------+ 120 
         aggacacgtcggagacctaagtggaaatcgttgagacggtactcgacccaggcggtccga 
  
         S  C  A  A  S  G  F  T  F  S  N  S  A  M  S  W  V  R  Q  A   - 
   
         ccagggaaggggctggagtgggtctcaagtatcagtggtagtggcggtaacacatactcc 
     121 ---------+---------+---------+---------+---------+---------+ 180 
         ggtcccttccccgacctcacccagagttcatagtcaccatcaccgccattgtgtatgagg 
   
         P  G  K  G  L  E  W  V  S  S  I  S  G  S  G  G  N  T  Y  S   - 
   
         gctgactccgtgaagggccgattcaccatctccagagacaacgccaagaactcactgtat 
     181 ---------+---------+---------+---------+---------+---------+ 240 
         cgactgaggcacttcccggctaagtggtagaggtctctgttgcggttcttgagtgacata 
   
         A  D  S  V  K  G  R  F  T  I  S  R  D  N  A  K  N  S  L  Y   - 
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                                     EagI 
                                        | 
         ctgcaaatgaacagcctgagagccgaggacacggccgtgtattactgtgcgagagattgg 
     241 ---------+---------+---------+---------+---------+---------+ 300 
         gacgtttacttgtcggactctcggctcctgtgccggcacataatgacacgctctctaacc 
   
         L  Q  M  N  S  L  R  A  E  D  T  A  V  Y  Y  C  A  R  D  W   - 
   
                  AatII   StyI      BstEII       BsmBI 
                      |      |           |           | 
         tacggtatggacgtctggggccaagggaccacggtcaccgtctcctca 
     301 ---------+---------+---------+---------+-------- 348 
         atgccatacctgcagaccccggttccctggtgccagtggcagaggagt 
   
         Y  G  M  D  V  W  G  Q  G  T  T  V  T  V  S  S   - 
Figure VI-2 Linear nucleotide map of M12-VH gene segment used for the cloning of the 
native M12-VH fragment and its camelized versions. 
 
VI.3 Primers 
 
The following primers (MWG) were used for the amplification of the gene of interest. 
Primers A &B also has mutations Gly44Glu and Lys45Arg. The codon mutated for 
camelization with respect to wild type is highlighted. 
A. Native M12-VH domain 
Forward   -  5’- GGG AAT GTC CAT ATG GCC CAG GTG CAG CTG CAG GAG –3’  
Backward - 5’- GGA CTA CCG CTC GAG ACT CGA CAC GGT GAC CGT GGT C -3’  
 
B. Camelization of M12-VH domain (Trp47Gly) 
   Wild type   ggg ctg gag tgg 
    G   L   E   W 
Forward   - 5’– GGTC CGC CAG GCT CCA GGG AAG GAG CGG GAG GGG GTC TCA  
    E   R   E   G 
AG T ATC AGT GGT AGT GG – 3’ 
 
Backward - 5’–CCA CTA CCA CTG ATA CTT GAG ACC CCC TCC CGC TCC TTC CCT GGA 
GCC TGG CGG ACC– 3’ 
 
C. Camelization of M12-VH domain (Trp47His)  
Forward   - 5’– GGTC CGC CAG GCT CCA GGG AAG GAG CGG GAG CAC GTC TCA 
          E   R   E   H 
AGT ATC AGT GGT AGT GG – 3’ 
 
Backward -  5’–CCA CTA CCA CTG ATA CTT GAG ACG TGC TCC CGC TCC TTC CCT GGA 
GCC TGG CGG ACC– 3’ 
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VI.4 M12-VH domain (1.8Å) 
 
The structure of the M12-VH domain at resolution 1.8Å was solved by Hoffmann, K. M. V. 
(2001, Bionalytics Group, RWTH Aachen, Germany).  The data was collected up to 1.8Å on 
Rigaku X-ray generator (λ-1.542Å) at 100K. The collected dataset contained the following 
statistics (Table VI-1). 
Table VI-1 Data collection statistics for M12-VH domain (1.8Å). 
 
Parameters Values 
Space group C2 
Unit-cell length (Å) a = 72.011, b = 
38.354, 
c = 37.573 
Unit-cell angles (°) α = γ = 90, β = 
109.746 
Mathew’s coefficients (Å3 Da-1) 1.98 
Solvent content (%) 37.8 
Mosaicity  0.8 
Unit cell volume (Å3) 103773.240 
Number of molecules in the 
asymmetric unit 
1 
Observed reflections 46010 
Unique reflections 8576 
Wavelength (Å) 1.542 
Maximum resolution (Å) 1.8 
Highest resolution shell (Å) 1.86 - 1.80 
Observed completeness 
         overall 
         high-resolution shell 
 
(94.4%) 
(87.8%) 
Rmerge 
        overall  
        high-resolution shell 
 
(0.031) 
(0.141) 
 
Table VI-2 Data statistics breakdown for the M12-VH domain (1.8Å) dataset with 
resolution. The values correspond to the X-ray wavelength (1.542Å). *Rmerge is defined as 
100Σn|<I>-In|/ΣhklΣnIn, which is summed over all reflections, where <I> is the mean intensity of 
the reflection hkl and In is the intensity of the nth observation of a reflection hkl.  *I/σ is defined 
as <I> divided by the average error on I. 
 
Resolution 
range (Å)  
Chi2 Rmerge 
(%)* 
I/σ* Completeness 
(%) 
100.00 - 3.88 0.887 1.9 37.74 97.9 
3.88 - 3.08 0.997 2.2 37.70 97.6 
3.08 - 2.69 1.002 2.8 31.94 96.9 
2.69 - 2.44 0.915 3.6 23.91 96.1 
2.44 - 2.27 0.936 4.3 21.07 95.1 
2.27 - 2.13 0.840 4.8 18.15 94.2 
2.13 - 2.03 0.900 6.5 14.62 93.5 
2.03 - 1.94 0.983 8.0 12.31 92.4 
1.94 - 1.86 1.020 10.9 9.06 92.0 
1.86 - 1.80 1.020 13.3 6.74 87.8 
All reflections 0.948 3.1 27.38 94.4 
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The overall quality of the high-resolution dataset was evaluated by using the standard data 
quality indicators calculated per resolution shell (Table VI-2). The chi2 is close to 1 for all 
the resolution shells, therefore, the statistical distribution of the reflections is homogenous in 
the resolution shells. The intensity and the Rmerge value of the data were found to be good in 
the high-resolution shell. 
The phase information for the M12-VH domain was determined by using the 
theoretical search model 1H0U (Hougs et al., 1999). The sequence of the theoretical search 
model 1H0U was appropriately trimmed to increase the homology with the target M12-VH 
fragment. The search model has 89.655% sequence identity with the target sequence as 
shown in figure. The orthogonal co-ordinates of the model were converted into fractional co-
ordinates by using the pearl script. 
                10        20        30        40        50        60 
M12-VH  QVQLQESGGGLVQPGGSLRLSCAASGFTFSNSAMSWVRQAPGKGLEWVSSISGSGGNTYS 
        .::: :::::::::::::::::::::::::. :::::::::::::::::.::::::.::  
1HOU-VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYY 
                10        20        30        40        50        60 
                70        80        90       100       110       120 
M12-VH  ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDWYGMDVWGQGTTVTVSSGGGG 
        ::::::::::::::.::.:::::::::::::::::::.  ::::::::::::::::     
1HOU-VH ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKG-YGMDVWGQGTTVTVSS     
                70        80        90        100       110          
Figure VI-3 Sequence similarity between M12-VH and 1H0U-VH domains. 
 
Molecular replacement was performed with AMoRe (Navaza, J., 1994) using reflections from 
20.0-3.0Å. As a result of the rotation search, a single clear solution (α =362.52°, β = 0.00°, γ 
= 0.00°) having the highest correlation coefficient 21.5% and Rfac 52.2% was obtained. The 
correct solution generated as a result of rotation function is translated and the translation 
function found to have the coefficients as Tx = 0.3409, Ty =0.0000, Tz =0.2708 with 
improvement of correlation coefficient of 40.0% and Rfac 46.3%. This translated solution was 
fitted to the search model, which resulted in α =150.0°, β = 49.28°, γ = 57.49° and Tx = 
0.3377, Ty = 0.0000, Tz = 0.2746 with further improvement of correlation coefficient 54.1% 
and Rfac dropped to 41.1%. Rigid body refinement led to a final R-factor 40.0% and a 
correlation coefficient of 55.5%.  
The model was built manually by using the program ‘O’ (Jones et al., 1991). The 
initial model has Rcryst/Rfree factor 47.61(%)/46.65(%). The partial model was refined with in 
the resolution range 8.0-2.0Å. The residues 40-43, 52-56, 93-107 and 112-113 with poor 
electron density were removed. 10% of the reflections were kept for calculating the Rfree 
factor. Cycles of manual model building in ‘O’ and refinement through CNS resulted in 
model having the Rcryst and Rfree values 23.54 and 28.69.  The refinement statistics is given in 
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Table VI-3. The refined model has 683 atoms and 90 residues. Finally 80 water molecules 
were added to the structure. 
Table VI-3 Summary of structure refinement statistics for M12-VH domain (1.8Å). 
 
Refinement resolution (Å) 8.0 – 2.0 
Number of unique reflections  5609 
After simulated annealing 
Rcryst (%) 
Rfree (%) 
 
23.54 
28.69 
Number of unique reflections 
used for Rfree 
651 
Final Rcryst (all data; %) 
Final Rfree (%) 
23.34 
28.60 
I>2σ  
r.m.s.d.  bond length (Å) 0.00548 
r.m.s.d.  bond angles (°) 1.30554 
r.m.s.d.  torsion angle (°) 1.899 
 
In overall appearance, the M12-VH has main-chain resemblance to other human VH 
fragments. The residue numbering scheme and CDR definitions follow the standard Kabat 
conventions (Kabat et al., 1991). A luzzati plot suggests a mean positional error of 0.24Å 
(Luzzati, P. V., 1952) while the σA error estimate is 0.293 Å (Read, R. J., 1986). The model 
exhibits good stereogeometry that is consistent with 1.8Å resolution data and it meets or 
exceeds all main chain and side chain tests of PROCHECK (Laskowski et al., 1993). The VH 
molecule displayed the well-characterized immunoglobulin fold, in which VH consists of two 
twisted, anitparallel β-sheets packed tightly against each other. 
VI.5 Intermolecular crystal contacts for M12-VH 
domain (1.5Å) 
 
5Gln-31Asn, 6Glu-31Asn, 7Ser- 28Thr, 7Ser-31Asn, 8Gly-28Thr, 10Gly-39Gln, 10Gly-45Leu, 
11Leu-39Gln, 11Leu-45Leu, 11Leu-91Tyr, 11Leu–102Val, 14Pro-14Pro, 14Pro-15Gly, 15Gly-
14Pro, 25Ser-96Trp, 28Thr–7Ser, 28Thr–42Gly, 30Ser-43Lys, 31Asn-6Glu, 31Asn-5Gln, 31Asn-
7Ser, 39Gln-10Gly, 39Gln-11Leu, 42Gly-28Thr, 43Lys-30Ser, 43Lys-76Asn, 45Leu-10Gly, 45Leu-
11Leu, 45Leu-110Thr, 53Ser-64Lys, 53Ser-65Gly, 54Gly-59Ser, 54Gly-64Lys, 55Gly-59Ser, 55Gly-
64Lys, 56Asn-58Tyr, 56Asn-57Thr, 56Asn-58Tyr, 57Thr-56Asn, 57Thr-57Thr, 58Tyr-55Gly, 
58Tyr-56Asn, 59Ser-54Gly, 59Ser-55Gly, 64Lys-53Ser, 64Lys-55Gly, 65Gly-71Arg, 68Thr-68Thr, 
68Thr-70Ser, 70Ser-68Thr, 71Arg-65Gly, 74Ala -84Ala, 75Lys-101Asp, 75Lys-113Ser, 76Asn-
43Lys, 83Arg-83Arg, 83Arg-85Glu, 84Ala-74Ala, 85Glu-83Arg, 87Thr- 99Met, 88Ala- 99Met, 
91Tyr-11Leu, 96Trp-25Ser, 99Met-110Thr, 99Met-87Thr, 99Met- 88Ala, 101Asp-75Lys, 101Asp–
113Ser, 102Val-11Leu, 102Val-112Ser, 102Val-113Ser,  103Trp-113Ser, 110Thr-45Leu, 110Thr-
99Met, 112Ser-102Val, 112Ser-101Asp, 113Ser-102Val, 113Ser-103Trp 
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VI.6 Hydrogen bonding pattern of M12-VH 
domain (1.5Å) 
 
Table VI-4 Intra-molecular hydrogen bonding in M12-VH domain (1.5Å). The N and C 
alphabets indicate the amino Nitrogen and Carbonyl oxygen atoms of amino acids. The OD, 
OE, OG indicates the delta, epsilon and gamma carbonyl oxygen atom of side chain of amino 
acids. The numbers in brackets indicate the bond distance. The residues are numbered 
according to Kabat  et al. (1977). 
 
Main chain to 
Main Chain 
Main chain to Side 
Chain 
Side chain to Main 
chain 
Side chain to Side 
Chain 
3:N 25:O (2.87) 
25:N 3:O (2.97) 
5:N 23:O (2.97) 
23:N 5:O (2.97) 
7:N 21:O (2.83) 
21:N 7:O (2.85) 
10:N 108:O (2.91) 
110:N 10:O (2.99) 
12:N 110:O (2.90) 
112:N 12:O (2.74) 
16:N 13:O (2.92) 
15:N 82C:O(2.73) 
82C:N 16:O (2.98) 
18:N 82:O (2.90) 
82:N 18:O (2.75) 
20:N 80:O (2.79) 
80:N 20:O (2.93) 
22:N 78:O (2.74) 
78:N 22:O (2.88) 
24:N 76:O (3.00) 
32:N 29:O (2.99) 
34:N 51:O (2.96) 
51:N 34:O (2.87) 
35:N 93:O (2.88) 
93:N 35:O (2.80) 
36:N 49:O (2.85) 
48:N 36:O (2.84) 
37:N 91:O (2.91) 
91:N 37:O (2.83) 
38:N 46:O (2.86) 
46:N 38:O (2.77) 
39:N 89:O (2.79) 
89:N 39:O (2.91) 
43:N 40:O (2.89) 
60:N 48:O (2.87) 
50:N 58:O (2.85) 
58:N 50:O (2.94) 
52:N 56:O (2.94) 
54:N 52:O(2.96) 
66:N 63:O (2.96) 
68:N 81:O (2.81) 
81:N 68:O (2.86) 
79:N 70:O (2.80) 
54:N 52:O (2.97) 
64:N 60:O (2.89) 
72:N 77:O (2.79) 
76:N 72:O (2.97) 
86:N 83:O (2.86) 
6:N 6:OE1 (2.72) 
106:N 6:OE1 (2.83) 
92:N 6:OE2 (2.81) 
9:N       107:OG1 (2.97) 
98:N 35:OG (2.79) 
74:N 72:OD1 (2.98) 
83:N 86:OD2 (2.83) 
85:N 85:OE1 (2.82) 
111:N 87:OG1 (2.90) 
95:N      95:OD1 (2.72) 
99:N      95: OD2 (2.88) 
71:NH2   29:O (2.69) 
32:OG    33:O (2.98)  
32:OG    94:O (2.92) 
71:NH1   32:O (2.89) 
71:NH2    32:O (2.95) 
35:OG    95:O (2.75) 
43:N    41:O (2.94) 
49:OG    58:O (2.66) 
50:OG      96:O(2.50) 
71:NH1    52:O (2.88) 
66:NH1    82B:O (2.87) 
66:NH2    62:O (2.91) 
73:ND2    52A:O (2.85) 
77:OG      75:O(2.75) 
82B:OG   82B:O (2.96) 
90:OH    86:O (2.62) 
93:N1    101:O (2.91) 
112:OG   112:O (2.94) 
 
7:OG       21:OG (2.86) 
17:OG     2A:OD1(3.00) 
38:NE      46:OE1 (2.83) 
38:NH1    86:OD1(2.93) 
38:NH1    90:OH (2.86) 
38:NH2    46:OE1 (2.97) 
46:OE2     62:OG (2.73) 
47:OE2     50:OG (2.79) 
64:NZ     61:OD1(2.94) 
66:NH1    86:OD2(2.75) 
71:NE     73:OD1(2.74) 
103:NE1  101:OD1(2.81) 
82B:OG   82B:OG (2.92) 
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88:N 109:O (2.98) 
90:N     107:O (2.80) 
107:N    90:O (2.94) 
94:N     101:O (2.95) 
109:N 88:O (2.94) 
90:N 107:O (2.80) 
107:N 90:O (2.89) 
94:N 95:O (2.63) 
96:N 95:O (2.22) 
 
VI.7 Structural studies of macromolecules 
 
VI.7.1 Overview 
 
The knowledge of accurate molecular structure is a prerequisite for the study of structure-
function relationship, which provides the rational basis for the development of effective 
therapeutic agents and drugs. There are number of experimental and theoretical methods that 
can provide information about a macromolecular assembly structure. The experimental 
methods used for structural characterization of macromolecular assemblies are X-ray 
crystallography, nuclear magnetic resonance (NMR) spectroscopy, electron crystallography, 
electron tomography, immunoelectron microscopy, fluorescence resonance energy transfer 
(FRET), mass spectroscopy and protein arrays (Sali et al., 2003). Out of the various 
methods, X-ray crystallography is the most powerful method for structure determination 
because it is capable of providing an atomic structure of the whole macromolecular assembly 
(Ban et al., 2000). When suitable crystal and high-resolution crystallographic data are 
obtained, there is little need for other methods of structure determination.   
Recently, the application of NMR spectroscopy has expanded to structure 
determination of increasingly large subunits and even their complexes (Fiaux et al., 2002). 
The technique is still restricted for small molecular weight proteins (up to 30kDa) and very 
time consuming. The main advantage with NMR spectroscopy is its utility for dynamic 
studies and can provide useful information about the protein in solution. In contrast to NMR 
spectroscopy, no size limitation exists for the molecule or complex to be studied in X-ray 
crystallography. Crystallography can reliably provide the answer to many structure related 
questions, from global folds to atomic details of bonding.  
The high accuracy of crystallographic structure requires the growth of good crystals 
of a macromolecule either alone or in complex with its ligand. Protein crystals differ from 
the inorganic crystals in terms of size and solvent content. The high solvent content of the 
protein crystals makes them fragile to handle. 
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VI.7.2 Methodology 
 
The techniques used for growing the crystals are vapor diffusion, batch, microbatch, 
microdialysis, free interface diffusion, macro and microseeding. Out of the various 
techniques, vapor diffusion and microbatch are the most commonly used methods because 
they are easy to perform, require a small amount of sample, and allow sufficient flexibility 
during screening and optimization.  
The principle involved in the vapor diffusion is that the initial concentration of the 
precipitating agent in the drop is lower than the well buffer and as an equilibration is reached 
slowly, the respective concentration of the precipitating agent increases resulting a 
supersaturation stage. Supersaturation is a metastable state. A supersaturated solution will 
give eventually rise to nuclei some of which will grow into larger crystals. Supersaturation 
must be slowly approached to minimize nucleation, so that a small number of larger crystals 
are obtained. Solutions must be clean to avoid the chance of heterogeneous nucleation. 
Crystallization is a multi-parameter problem, which is not entirely under rational control. 
Trial-and-error variation of a multitude of biochemical and biophysical parameters can be 
used to decrease the solubility of the protein, so that the solution becomes supersaturated. 
Also the crystallization technique itself may be a parameter.  
Vapor diffusion can be achieved either by using the sitting or hanging drop 
methodology. In sitting drop technique (Figure VI-4A) one places a small (1 to 15µl, in high 
throughput robotic systems 0.1-0.2µl) droplet of the sample mixed with an equal volume of 
precipitating agent on a platform in vapor equilibration with the well buffer. The advantage 
of the sitting drop technique includes speed and simplicity. The disadvantages are that 
crystals can sometimes adhere to the sitting drop surface making their collection difficult.  
 
 
 
 
 
 
Figure VI-4 Sitting drop (A) and hanging drop (B) crystallization techniques 
 
This disadvantage can turn into an advantage where occasionally the surface of the sitting 
drop can assist in nucleation. The sitting drop is an excellent method for screening and 
optimization. 
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In the hanging drop technique (Figure VI-4B); the small (1 to 10µl) droplet of the 
sample mixed with an equal volume of reservoir buffer solution was kept on a siliconized 
glass cover slide. Then, the slide gently inverted over the reservoir. The advantages of the 
hanging drop technique include the ability to view the drop through glass without the optical 
interference from plastic, reduced chance of crystals sticking to the hardware, and easy 
access to the drop. The disadvantage is that a little extra time is required for setting up the 
hanging drops.  
Once good crystals are grown, they are checked for their optical and biochemical 
quality. Some protein crystals can be kept for years and will still diffract; others do not last. 
It may only be possible to keep the crystals in the mother liquor in which they grew. If 
possible it is preferable to harvest the crystals in a stabilization buffer, as this will allow 
easier handling when doing heavy metal soaks. It is usually not possible to use fresh mother 
liquor for harvesting as under the equilibrium conditions the crystals will dissolve or get 
damaged. Increasing the concentration of precipitant in the mother liquor by several percent 
can circumvent this problem. The best harvesting solution will be found by trial-and-error. 
VI.7.3 Data collection 
 
For data collection, the crystals are either mounted in capillary or flash cooled at 100K. 
Before mounting, the crystal is washed with fresh stabilization buffer to remove any 
remaining protein solution. Stabilization buffer (or alternatively mother liquor) and a crystal 
are drawn into a capillary tube by capillary action along with very small amount of reservoir 
solution to keep the crystal moist. This may be quite difficult in case of highly viscous 
solutions. The capillary tube will usually be a mounting tube. The data from a crystal 
mounted in capillary is collected at room temperature and therefore the crystal is susceptible 
to radiation damage on one side and results in enhanced background due to the presence of 
tiny amount of mother liquor around the crystal. To avoid the radiation damage of the 
crystal, the capillary mounting is now less common. In the flash cooling method, ice 
formation can be largely suppressed by the use of a cryo-protectant (e.g. Glycerol, PEG, 
MPD etc.), in which the crystal is dipped immediately before mounting. The crystal is held 
by surface tension in a thin film of containing-containing solution formed within a small 
loop made from mohair or rayon fibers. If a loop of the correct size is used there will be little 
mechanical stress and a large surface area will be exposed allowing high cooling rates. 
Getting the crystal in the loop is tricky and is usually done under the microscope. The crystal 
is gently pushed to the surface and then scooped up and pulled through the meniscus. The 
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loop is then rapidly mounted on a goniometer in the beam of a liquid nitrogen gas delivery 
system. The flash cooled crystal is stored in liquid nitrogen till the time of data collection. 
When the crystal exposed to X-rays, most of the x-rays travel straight through it. 
Some, however, interact with the electron cloud and undergo diffraction as a result of 
constructive interference. It is often observed that the microscopic goodness of the crystals is 
not enough rather the crystal should be well ordered internally to get the strong x-ray 
diffraction. The diffraction of x-ray beam depends upon the molecules arranged in a regular 
and repeating array. This repeating arrangement of molecules constitutes the unit cell inside 
the crystal. The unit cell consists of the asymmetric unit defined by the symmetrical 
arrangement of the protein molecule. The diffracted X-rays produce a characteristic pattern 
on a detector as a result of the symmetrical arrangement of the protein molecule inside the 
crystal. Diffraction of X-rays from the crystal can be regarded as the reflection of the beam 
by sets of parallel planes called lattice planes. If θ is the angle between the primary X-ray 
beam and the lattice plane with interplanar spacing d (Figure VI-5), then the path difference 
between the two waves scattered in A and C, respectively, is BC+CD = 2d sinθ. If this path 
difference is a multiple  
 
Figure VI-5 Schematic representation of Bragg’s law for x-ray diffraction. Blue dotted 
lines indicate the plane of atoms in the crystal. Arrow indicates the x-ray beam and its 
diffraction after interacting with the electron cloud of the atom. D: distance between the 
planes, θ: reflection angle. 
 
‘n’ of the wavelength (λ), then we get constructive interference between the two waves. 
Here, n is the order of diffraction. Consequently, the condition for an X-ray reflection is  
      2d sinθ = n λ     
which is known as Bragg's law. The angle θ for which the equation holds is called the 
Bragg angle. For a given n and λ and any other angle of incidence, waves emerging from 
successive planes are out of phase and interfere destructively. 
When the X-rays diffract according to Bragg’s law, they are recorded as distinct diffraction 
spot. A diffraction image contains many reflections, which can easily overlap. The crystal is 
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constantly rotated by a small angle as well as oscillating simultaneously during data 
collection on each image. It is therefore necessary to collect many images to measure all 
unique reflections of a protein crystal. 
VI.7.4 Phase problem and related methodology 
 
Since the X-rays are considered as waves possess amplitude and phases. For structure 
determination, the knowledge of three parameters, namely, the amplitude, the wavelength 
and the phases are required. If both the amplitude and the phases are known, the electron 
density, which gave rise to the diffracted waves, can be reconstituted by a Fourier synthesis. 
However, in a crystallographic diffraction experiment only the amplitude is recorded. The 
amplitude can be obtained from the intensity of the diffraction spot but during diffraction 
data collection, the phase information is lost. This is called as the phase problem in 
crystallography. Therefore, instead of being able to obtain a direct image of the structure in a 
crystal, it is necessary to measure the direction and intensity (or amplitude squared) of each 
diffracted X-ray beam, and then reconstitute its phase.  
The phase problem can be solved either ab-initio or by using the phase information 
from a solved structure. 
VI.7.5 Ab-initio phase determination 
 
Phases are determined ab-initio in two ways- 
A. either the crystals are "derivatised" by introducing heavy metal atoms. If only a few 
metal ions are present in the crystal, the "heavy metal structure" can be determined by a 
Patterson analysis. If the crystal essentially stays unperturbed ("isomorphous"), the technique 
of multiple isomorphous replacement (MIR, Crick et al., 1956) can exploit the heavy 
metal structure to determine phases for the protein. 
B. Or crystals are labeled with anomalously scattering atoms like heavy metal atoms. If 
only a few anomalous scatterers are present in the crystal, the "anomalous scatterer structure" 
can be determined by a Patterson analysis. The small variation in the real and imaginary 
components of the scattering factor (f' and f") of an anomalously scattering atom, when the 
wavelength of the incident beam approaches one of its absorption edges, can be exploited to 
determine the phases of the native structure and this approach is called as multiwavelength 
anomalous diffraction (MAD, Lye et al., 1980). Naturally a "tunable" X-ray source such as 
a synchrotron is needed for this experiment. 
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VI.7.6 Molecular replacement 
 
The initial estimate of phases can be extracted from the structure factor of a known protein. 
Therefore, the structure of the new protein can be determined from a single native data set. 
The know protein is called as the phasing model and the method which entails calculating 
the phases by placing a model of the known protein in the unit cell of the new protein, is 
called the molecular replacement (Rossmann, M.G., 1972). In molecular replacement, the 
rotation and translation functions are executed to fit the target over search model for 
determining the patterson map. The Patterson map provides the phase information. The 
translocated solutions were subjected to rigid body refinement and then reoriented on the 
model structure to find the correctness of the molecular replacement solution. The resulting 
solution is converted in to a pdb coordinates. The phase information generated as a result of 
molecular replacement can be improved by using the PHASES program (Furey et al., 1997). 
VI.7.7 Model building and refinement 
 
Initially structure factor amplitude data |F| have been measured. The phase problem has been 
solved either by Molecular Replacement (MR), Isomorphous Replacement (MIR) or 
Multiwavelength Anomalous Diffraction (MAD), so that initial "observed" phases are 
available. An electron density map can now be calculated by a Fourier synthesis. The 
electron density map provides the template for building the three dimensional protein 
structures. The quality of the map depends on the resolution of the diffraction data. In 
general, phases derived from MIR produce electron density map, which is not yet of 
sufficient quality to uniquely identify and position the whole of the amino acid sequence 
because the phases are not accurate enough, and do not extend to the full resolution of the 
amplitude data. Therefore, the quality of the electron density map needs to be improved to 
build the protein model. Density modification consists of alternating steps of electron density 
map modification proper (real space) and phase combination (reciprocal space), where the 
fast Fourier transform is used to convert from real space to reciprocal space and vice versa. 
Once the quality of the phases has become high enough to calculate an interpretable electron 
density map, it will be possible to build a partial model in the electron density. In the case of 
isomorphous replacement (MIR) the initial model will usually comprise main chain atoms 
only, later to include main chain and side chain atoms. In the case of molecular replacement 
(MR), the initial model usually comprises both main chain and side chain atoms, and the 
correct sequence can be built into, to replace that of the model. Any model is completed and 
improved by removing positional errors by alternating cycles of electron density modeling 
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with a computer graphics program (manual) and refinement with a refinement program 
(automatic), while extending the resolution to the full extent of the native amplitude data.  
In refinement, the parameters of the model are altered to improve the agreement 
between amplitudes calculated from the model and the amplitudes obtained by measurement. 
Refinement is the minimization of a function, which reflects the discrepancy between these 
two. The final model coordinates will contain random and systematic errors, which represent 
the history of their generation. The problem is to determine and correct the errors during the 
process of modeling and refinement. Once the residual errors have become acceptable and 
the modeling and refinement process has converged, the crystallographic, stereochemical 
and structural parameters of the model needs to be validated. 
VI.7.8 Structure validation and submission 
 
The crystallographic parameters are checked by the structure factor amplitudes calculated 
from the model and measured against the observed amplitudes. Although the conventional 
R-factor [R-factor = Σ (Fo-Fc)/ ΣFo; Fo and Fc are the observed and calculated structure factor 
amplitudes] will be helpful, the Rfree factor [Rfree factor = Σfree (Fo-Fc)/ ΣfreeFo, a small subset 
of reflection (5-10%) kept aside to calculate R-factor] calculated for the small wedge of data 
kept out of the refinement, will be a much better statistical criterion to validate the 
coordinates. Either a Luzzati plot [plot of R-factor against 1/d (where d=resolution)] or the 
SigmaA [a plot of ln σA against (sinθ/λ)2; σA- coordinate error] method may estimate the 
overall coordinate precision. Deviations for the main chain torsion angles from 
Ramachandran plots give a good indication for the stereochemical quality of the model.  
Checking structural parameters (e.g. Hydrogen bonds) will aid in the production of as 
good a coordinate data set as structural knowledge will permit. These parameters test 
features, which may not yet be obvious from the current electron density (e.g. incorrectly 
folded structure), or features, which cannot be determined from electron density maps (e.g. 
the position of the N and O in the side chain of Asn). They may point to incorrect areas in 
the model. They may aid in getting His/Gln/Asn side chain atoms in the correct orientation. 
They will help in positioning water molecules in the most appropriate place.  
Once the model is thoroughly checked and found acceptable it has to be submitted to 
the international protein structure repository called Protein Data base (PDB, www.rcsb.org). 
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VI.7.9 Vector maps 
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VI.8 List of abbreviations 
 
%  percentage 
λ  wavelength 
σ  sigma 
Å  angstrom 
A  alanine (Ala) 
Ab  antibody 
Ampr  ampicillin resistance 
AP  alkaline phosphatase 
asu  asymmetric unit 
β  beta 
BCA  bicinchoninic acid 
BCIP  5-bromo-4-chloro-3-indolyl phosphate 
bp  base pair 
BSA  bovine serum albumin 
C  cysteine (Cys) 
CaCl2  calcium Chloride 
cDNA  complementary deoxyribonucleic acid  
CTL  cytotoxic T-Lymphocytes  
CV  column volume 
D  aspartic acid (Asp) 
dNTP  deoxynucleotide triphosphate 
DTT  dithiothreitol 
E  glutamic acid (Glu) 
E. coli  escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
F  phenylalanine (Phe) 
FACS  fluorescence-activated Cell Sorter 
FC  calculated Structure factor  
FDA  food and drug administration  
F0   observed structure factor 
FPLC   fast flow liquid chromatography 
Fv  variable fragment of antibody consists of VH and VL without linker 
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G  glycine (Gly) 
GAM  goat anti-mouse antibodies 
H  histidine (His)  
H1, H2, H3 variable heavy chain CDR loops 
HAMA human anti-murine-antibody immune response  
HEPES N- [2-hydroxyethyl]-piperazine-N0- [2-ethanesulphonic acid] 
His  histidine 
I  isoleucine (Ile) 
IEF  iso-electric focussing 
ICAM  intercellular Adhesion Molecule 
IgG  immunoglobulin type gamma  
IgM  immunoglobulin type mu 
Ig  immunoglobulin 
IL-2  interleukin -2 
IMAC  immobilized metal ion affinity chromatography 
IPTG  isopropylthiogalactopyranoside 
K  lysine (Lys) 
KCl  potassium Chloride 
(K) Da  (kilo) dalton 
Kg  kilogram 
L  leucine (Leu) 
LB  lauria bertini medium 
LiSo4  lithium Sulphate 
M  molar  
M  methionine (Met) 
mAb  monoclonal antibody 
MALDI-TOF matrix assisted laser desorption/ionization- time of flight 
MES  2-[N-morpholino]-ethanesulphonic acid  
MgSo4  magnesium Sulphate  
min  minute(s) 
ml  millilitre 
mM  mili molar 
MME  monomethylether 
MnCl2  manganese Chloride  
  VI-APPENDIX 
 158
MOPS  3-morpholino propane  
ESI-MS/MS  electrospray mass spectrometry  
MW  molecular weight 
MWCO molecular weight cut-off 
µL  microlitre  
N  asparagine (Asn) 
NaCl  sodium Chloride 
NBT  nitro blue tetrazolium 
Ni-NTA nickel charged nitriloacetic acid resin 
nm  nanometer 
NMR  nuclear magnetic resonance 
O.D.  optical density 
P  proline (Pro)   
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PBST  phosphate buffered saline containing 0.05% (v/v) Tween20 
PCR  polymerase chain reaction 
PDB  protein Data Bank 
PEG  polyethyleneglycol 
pI  isoelectric point 
PMSF  phenylmethylsulfonylfluoride 
Q  glutamine (Gln) 
R  arginine (Arg) 
r.p.m.  rotation per minute 
r.m.s.  root mean square  
RT  room temperature 
S  serine (Ser) 
scFv single chain variable fragment consists of VH and VL fragment of 
antibody  
SDS  sodium dodecylsulfate 
SDS-PAGE sodium dodecylsulphate polyacrylamide gel electrophoresis 
So42-  sulphate ions  
T  threonine (Thr)  
Taq  thermus aquaticus 
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TEMED  N, N, N’, N’ tetarmethylethylenediamine 
TR  tandem repeat 
Tris  tris- [hydroxymethyl]-aminoethane 
U  unit 
USA  united States of America 
UV  ultraviolet 
V  volt 
V  valine (Val) 
V-type  variable domain type 
VH  variable heavy chain fragment 
VHH  camelid variable heavy chain  
VL  variable light chain fragment 
VNTR  variable number tandem repeat 
v/v  volume per volume 
W  tryptophan (Trp) 
w/v  weight per volume 
Y  tyrosine (Tyr) 
ZnCl2   zinc chloride 
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